Becton, Dickinson and (BDX) 10-K 27 Nov 19 2019 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Sep. 30, 2019	Oct. 31, 2019	Mar. 31, 2019
Entity Information [Line Items]
Document type	10-K
Document Annual Report	true
Document period end date	Sep. 30, 2019
Document Transition Report	false
Entity File Number	001-4802
Entity registrant name	BECTON, DICKINSON AND COMPANY
Entity central index key	0000010795
Current fiscal year end date	--09-30
Document fiscal year focus	2019
Document fiscal period focus	FY
Amendment flag	false
Entity Incorporation, State or Country Code	NJ
Entity Tax Identification Number	22-0760120
Entity Address, Address Line One	1 Becton Drive,
Entity Address, Postal Zip Code	07417-1880
Entity Address, City or Town	Franklin Lakes,
Entity Address, State or Province	NJ
City Area Code	201
Local Phone Number	847-6800
Entity well-known seasoned issuer	Yes
Entity voluntary filers	No
Entity Current Reporting Status	Yes
Entity current reporting status	Yes
Entity filer category	Large Accelerated Filer
Entity small business	false
Entity emerging growth company	false
Entity shell company	false
Entity public float			$ 67,278,853,280
Entity common stock, shares outstanding (shares)		270,459,892
Common Stock Issued at Par Value | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	Common stock, par value $1.00
Trading Symbol	BDX
Security Exchange Name	NYSE
Depositary shares [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	Depositary Shares, each representing 1/20th of a share of 6.125% Cumulative Preferred Stock Series A
Trading Symbol	BDXA
Security Exchange Name	NYSE
1.000% Notes due December 15, 2022 | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.000% Notes due December 15, 2022
Trading Symbol	BDX22A
Security Exchange Name	NYSE
1.900% Notes due December 15, 2026 | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.900% Notes due December 15, 2026
Trading Symbol	BDX26
Security Exchange Name	NYSE
1.401% Notes due May 24, 2023 | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.401% Notes due May 24, 2023
Trading Symbol	BDX23A
Security Exchange Name	NYSE
Notes 3.020% due May 24, 2025 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	3.020% Notes due May 24, 2025
Trading Symbol	BDX25
Security Exchange Name	NYSE
0.174% Notes due June 4, 2021 | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	0.174% Notes due June 4, 2021
Trading Symbol	BDX/21
Security Exchange Name	NYSE
0.632% Notes due June 4, 2023 | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	0.632% Notes due June 4, 2023
Trading Symbol	BDX/23A
Security Exchange Name	NYSE
1.208% Notes due June 4, 2026 | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.208% Notes due June 4, 2026
Trading Symbol	BDX/26A
Security Exchange Name	NYSE

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Revenues	$ 17,290	$ 15,983	$ 12,093
Cost of products sold	9,002	8,714	6,128
Selling and administrative expense	4,332	4,016	2,909
Research and development expense	1,062	1,004	770
Acquisitions and other restructurings	480	740	354
Other operating expense, net	654	0	410
Total Operating Costs and Expenses	15,530	14,474	10,571
Operating Income	1,760	1,509	1,522
Interest expense	(639)	(706)	(521)
Interest income	12	65	76
Other income (expense), net	43	305	(101)
Income Before Income Taxes	1,176	1,173	976
Income tax (benefit) provision	(57)	862	(124)
Net Income	1,233	311	1,100
Preferred stock dividends	(152)	(152)	(70)
Net income applicable to common shareholders	$ 1,082	$ 159	$ 1,030
Basic Earnings per Share
Basic Earnings per Share (USD per share)	$ 4.01	$ 0.62	$ 4.70
Diluted Earnings per Share
Diluted Earnings per Share (USD per share)	$ 3.94	$ 0.60	$ 4.60

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Statement of Comprehensive Income [Abstract]
Net Income	$ 1,233	$ 311	$ 1,100
Other Comprehensive (Loss) Income, Net of Tax
Foreign currency translation adjustments	(93)	(161)	11
Defined benefit pension and postretirement plans	(275)	(26)	179
Cash flow hedges	(6)	1	17
Other Comprehensive (Loss) Income, Net of Tax	(374)	(186)	206
Comprehensive Income	$ 859	$ 125	$ 1,306

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2019	Sep. 30, 2018
Current Assets
Cash and equivalents	$ 536	$ 1,140
Restricted cash	54	96
Short-term investments	30	17
Trade receivables, net	2,345	2,319
Inventories	2,579	2,451
Assets held for sale	0	137
Prepaid expenses and other	1,119	1,251
Total Current Assets	6,664	7,411
Property, Plant and Equipment, Net	5,659	5,375
Goodwill	23,376	23,600
Developed Technology, Net	11,054	12,184
Customer Relationships, Net	3,424	3,723
Other Intangibles, Net	500	534
Other Assets	1,088	1,078
Total Assets	51,765	53,904
Current Liabilities
Short-term debt	1,309	2,601
Accounts payable	1,092	1,106
Accrued expenses	2,127	2,255
Salaries, wages and related items	987	910
Income taxes	140	343
Total Current Liabilities	5,655	7,216
Long-Term Debt	18,081	18,894
Long-Term Employee Benefit Obligations	1,272	1,056
Deferred Income Taxes and Other	5,676	5,743
Commitments and Contingencies (See Note 5)
Shareholders’ Equity
Preferred stock	2	2
Common stock — $1 par value: authorized — 640,000,000 shares; issued — 346,687,160 shares in 2019 and 2018.	347	347
Capital in excess of par value	16,270	16,179
Retained earnings	12,913	12,596
Deferred compensation	23	22
Common stock in treasury — at cost — 76,259,835 shares in 2019 and 78,462,971 shares in 2018.	(6,190)	(6,243)
Accumulated other comprehensive loss	(2,283)	(1,909)
Total Shareholders’ Equity	21,081	20,994
Total Liabilities and Shareholders’ Equity	$ 51,765	$ 53,904

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2019	Sep. 30, 2018
Statement of Financial Position [Abstract]
Common stock, par value (USD per share)	$ 1	$ 1
Common stock, shares authorized (shares)	640,000,000	640,000,000
Common stock, shares issued (shares)	346,687,160	346,687,160
Common stock in treasury, shares (shares)	76,259,835	78,462,971

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Operating Activities
Net Income	$ 1,233	$ 311	$ 1,100
Adjustments to net income to derive net cash provided by operating activities:
Depreciation and amortization	2,253	1,978	1,088
Share-based compensation	261	322	174
Deferred income taxes	(381)	(240)	(236)
Change in operating assets and liabilities:
Trade receivables, net	(51)	(170)	(93)
Inventories	(149)	246	(46)
Prepaid expenses and other	299	(46)	(366)
Accounts payable, income taxes and other liabilities	(470)	867	134
Pension obligation	(123)	(263)	84
Excess tax benefits from payments under share-based compensation plans	55	78	77
Lease contract modification-related charge	0	0	748
Gain on sale of Vyaire interest	0	(303)	0
Gain on sale of business	(336)	0	0
Product liability-related charges	914	0	0
Other, net	(177)	85	(114)
Net Cash Provided by Operating Activities	3,330	2,865	2,550
Investing Activities
Capital expenditures	(957)	(895)	(727)
Acquisitions of businesses, net of cash acquired	0	(15,155)	(174)
Proceeds from divestitures, net	477	534	165
Other, net	(261)	(217)	(148)
Net Cash Used for Investing Activities	(741)	(15,733)	(883)
Financing Activities
Change in credit facility borrowings	485	0	(200)
Proceeds from long-term debt and term loans	2,224	5,086	11,462
Payments of debt and term loans	(4,744)	(3,996)	(3,980)
Proceeds from issuance of equity securities	0	0	4,827
Repurchase of common stock	0	0	(220)
Dividends paid	(984)	(927)	(677)
Other, net	(205)	(220)	(234)
Net Cash (Used for) Provided by Financing Activities	(3,223)	(58)	10,977
Effect of exchange rate changes on cash and equivalents and restricted cash	(12)	(17)	(6)
Net (Decrease) Increase in Cash and Equivalents and Restricted Cash	(646)	(12,943)	12,638
Opening Cash and Equivalents and Restricted Cash	1,236	14,179	1,541
Closing Cash and Equivalents and Restricted Cash	590	1,236	14,179
Non-Cash Investing Activities
Noncash consideration-fair value of shares issued	0	8,004	0
Noncash consideration-fair value of stock options and other equity awards	$ 0	$ 613	$ 0

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying Consolidated Financial Statements and Notes to Consolidated Financial Statements of Becton, Dickinson and Company (the “Company” or "BD") have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). Within the financial statements and tables presented, certain columns and rows may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. Our fiscal year ends on September 30. Principles of Consolidation The consolidated financial statements include the Company’s accounts and those of its majority-owned subsidiaries after the elimination of intercompany transactions. The Company has no material interests in variable interest entities. Cash Equivalents Cash equivalents consist of all highly liquid investments with a maturity of three months or less at time of purchase. Restricted Cash Restricted cash consists of cash restricted from withdrawal and usage and largely represents funds that are restricted for certain product liability matters assumed in the acquisition of C.R. Bard, Inc. ("Bard") which is further discussed in Note 10 . Trade Receivables The Company grants credit to customers in the normal course of business and the resulting trade receivables are stated at their net realizable value. The allowance for doubtful accounts represents the Company’s estimate of probable credit losses relating to trade receivables and is determined based on historical experience and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectible. Inventories Inventories are stated at the lower of approximate cost determined on the first-in, first-out basis or market. Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are principally provided on the straight-line basis over estimated useful lives, which range from 20 to 45 years for buildings, four to 13 years for machinery and equipment and one to 20 years for leasehold improvements. Depreciation and amortization expense was $633 million , $600 million and $406 million in fiscal years 2019 , 2018 and 2017 , respectively. Goodwill and Other Intangible Assets The Company’s unamortized intangible assets include goodwill which arise from acquisitions. The Company currently reviews goodwill for impairment using quantitative models. Goodwill is reviewed at least annually for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. The Company’s reporting units generally represent one level below reporting segments. Potential impairment of goodwill is generally identified by comparing the fair value of a reporting unit, estimated using an income approach, with its carrying value. The annual impairment review performed on July 1, 2019 indicated that all identified reporting units’ fair values exceeded their respective carrying values. Amortized intangible assets include developed technology assets which arise from acquisitions. These assets represent acquired intellectual property that is already technologically feasible upon the acquisition date or acquired in-process research and development assets that are completed subsequent to acquisition. Developed technology assets are generally amortized over periods ranging from 15 to 20 years, using the straight-line method. Customer relationship assets are generally amortized over periods ranging from 10 to 15 years, using the straight-line method. Other intangibles with finite useful lives, which include patents, are amortized over periods principally ranging from one to 40 years, using the straight-line method. Finite-lived intangible assets, including developed technology assets, are periodically reviewed when impairment indicators are present to assess recoverability from future operations using undiscounted cash flows. The carrying values of these finite-lived assets are compared to the undiscounted cash flows they are expected to generate and an impairment loss is recognized in operating results to the extent any finite-lived intangible asset’s carrying value exceeds its calculated fair value. Foreign Currency Translation Generally, foreign subsidiaries’ functional currency is the local currency of operations and the net assets of foreign operations are translated into U.S. dollars using current exchange rates. The U.S. dollar results that arise from such translation, as well as exchange gains and losses on intercompany balances of a long-term investment nature, are included in the foreign currency translation adjustments in Accumulated other comprehensive income (loss). Revenue Recognition The Company recognizes revenue from product sales when the customer obtains control of the product, which is generally upon shipment or delivery, depending on the delivery terms specified in the sales agreement. Revenues associated with certain instruments and equipment for which installation is complex, and therefore significantly affects the customer’s ability to use and benefit from the product, are recognized upon customer acceptance of these installed products. Revenue for certain service arrangements, including extended warranty and software maintenance contracts, is recognized ratably over the contract term. When arrangements include multiple performance obligations, the total transaction price of the contract is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. Variable consideration such as rebates, sales discounts and sales returns are estimated and treated as a reduction of revenue in the same period the related revenue is recognized. These estimates are based on contractual terms, historical practices, and current trends, and are adjusted as new information becomes available. Revenues exclude any taxes that the Company collects from customers and remits to tax authorities. Equipment lease transactions with customers are evaluated and classified as either operating or sales-type leases. Generally, these arrangements are accounted for as operating leases and therefore, revenue is recognized at the contracted rate over the rental period defined within the customer agreement. Additional disclosures regarding the Company's accounting for revenue recognition are provided in Note 6. Shipping and Handling Costs The Company considers its shipping and handling costs to be contract fulfillment costs and records them within Selling and administrative expense. Shipping expense was $511 million , $479 million and $365 million in 2019 , 2018 and 2017 , respectively. Derivative Financial Instruments All derivatives are recorded in the balance sheet at fair value and changes in fair value are recognized currently in earnings unless specific hedge accounting criteria are met. Any deferred gains or losses associated with derivative instruments are recognized in income in the period in which the underlying hedged transaction is recognized. Additional disclosures regarding the Company's accounting for derivative instruments are provided in Note 14 . Income Taxes The Company has reviewed its needs in the United States for possible repatriation of undistributed earnings of its foreign subsidiaries and continues to invest foreign subsidiaries earnings outside of the United States to fund foreign investments or meet foreign working capital and property, plant and equipment expenditure needs. As a result, after reevaluation of the permanent reinvestment assertion, the Company is permanently reinvested with respect to all of its historical foreign earnings as of September 30, 2019. Deferred taxes are not provided on undistributed earnings of foreign subsidiaries that are indefinitely reinvested. The determination of the amount of the unrecognized deferred tax liability related to the undistributed earnings is not practicable because of the complexities associated with its hypothetical calculation. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of tax jurisdictions. In evaluating the exposure associated with various tax filing positions, the Company records accruals for uncertain tax positions, based on the technical support for the positions, past audit experience with similar situations, and the potential interest and penalties related to the matters. The Company maintains valuation allowances where it is more likely than not that all or a portion of a deferred tax asset will not be realized. Changes in valuation allowances are included in the tax provision in the period of change. In determining whether a valuation allowance is warranted, management evaluates factors such as prior earnings history, expected future earnings, carryback and carryforward periods and tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset. Additional disclosures regarding the Company's accounting for income taxes are provided in Note 17 . Earnings per Share Basic earnings per share are computed by dividing income available to common stockholders by the weighted average number of common shares outstanding. Diluted earnings per share reflect the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. In computing diluted earnings per share, only potential common shares that are dilutive (i.e., those that reduce earnings per share or increase loss per share) are included in the calculation. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions. These estimates or assumptions affect reported assets, liabilities, revenues and expenses as reflected in the consolidated financial statements. Actual results could differ from these estimates.

Accounting Changes

Accounting Changes	12 Months Ended
	Sep. 30, 2019
Accounting Changes and Error Corrections [Abstract]
Accounting Changes	Accounting Changes New Accounting Principles Adopted On October 1, 2018, the Company adopted Accounting Standards Codification Topic 606, "Revenue from Contracts with Customers" ("ASC 606") using the modified retrospective method. Under ASC 606, revenue is recognized upon the transfer of control of goods or services to customers and reflects the amount of consideration to which a reporting entity expects to be entitled in exchange for those goods or services. The Company assessed the impact of this new standard on its consolidated financial statements based upon a review of contracts that were not completed as of October 1, 2018. Amounts presented in the Company's financial statements for the prior-year periods have not been revised and are reflective of the revenue recognition requirements which were in effect for those periods. This accounting standard adoption, which is further discussed in Note 6, did not materially impact any line items of the Company's consolidated income statements and balance sheet. On October 1, 2018, the Company retrospectively adopted an accounting standard update which requires all components of net periodic pension and postretirement benefit costs to be disaggregated from the service cost component and to be presented on the income statement outside a subtotal of income from operations, if one is presented. Upon the Company's adoption of the accounting standard update, which did not have a material impact on its consolidated financial statements, all components of the Company’s net periodic pension and postretirement benefit costs, aside from service cost, are recorded to Other income (expense), net on its consolidated income statements for all periods presented. Revisions of prior-year amounts were estimated based upon previously disclosed amounts. On October 1, 2018, the Company adopted an accounting standard update which requires that the income tax effects of intercompany sales or transfers of assets, except those involving inventory, be recognized in the income statement as income tax expense (or benefit) in the period that the sale or transfer occurs. The Company adopted this accounting standard update, which did not have a material impact on its consolidated financial statements, using the modified retrospective method. In the second quarter of its fiscal year 2018, the Company prospectively adopted an accounting standard update relating to the stranded income tax effects on items within Accumulated other comprehensive income (loss) resulting from the enactment of new U.S. tax legislation, which legislation is further discussed in Note 17. Additional disclosures regarding this accounting standard adoption are provided in Note 3. On October 1, 2016, the Company prospectively adopted amended requirements relating to the timing of recognition and classification of share-based compensation award-related income tax effects. Upon adoption of the requirements in 2017, the Company has recorded tax benefits relating to share-based compensation awards within Income tax (benefit) provision on its consolidated statement of income. These tax benefits had been previously recorded within Capital in excess of par value on the Company's consolidated balance sheet. Also upon adoption of the amended guidance in 2017, the Company has classified excess tax benefits on its consolidated statement of cash flows within Net Cash Provided by Operating Activities , rather than Net Cash (Used for) Provided by Financing Activities . New Accounting Principles Not Yet Adopted In February 2016, the Financial Accounting Standards Board ("FASB") issued a new lease accounting standard which requires lessees to recognize lease assets and lease liabilities on the balance sheet. The new standard also requires expanded disclosures regarding leasing arrangements. The Company will adopt the standard on October 1, 2019 and expects to elect certain practical expedients permitted under the transition guidance, including a transition method which allows application of the new standard at its adoption date, rather than at the earliest comparative period presented in the financial statements. The Company has also elected a practical expedient which allows entities to account for the lease and non-lease components in an arrangement as a single lease component. Upon adoption of the standard, the Company's operating leases will be recognized as right-of-use assets and corresponding lease liabilities on its consolidated balance sheet. The Company's measurement of these assets and liabilities will be finalized during the first quarter of fiscal year 2020. The Company does not expect the adoption of this standard to materially impact its consolidated financial statements. In June 2016, the FASB issued a new accounting standard which requires earlier recognition of credit losses on loans and other financial instruments held by entities, including trade receivables. The new standard requires entities to measure all expected credit losses for financial assets held at each reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company is currently evaluating the impact that this new accounting standard will have on its consolidated financial statements upon its adoption on October 1, 2020.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Sep. 30, 2019
Stockholders' Equity Note [Abstract]
Shareholders' Equity	Shareholders’ Equity Changes in certain components of shareholders’ equity were as follows: Common Stock Issued at Par Value Capital in Excess of Par Value Retained Earnings Deferred Compensation Treasury Stock (Millions of dollars) Shares (in thousands) Amount Balance at September 30, 2016 $ 333 $ 4,693 $ 12,727 $ 22 (119,371 ) $ (8,212 ) Net income — — 1,100 — — — Cash dividends: Common ($2.92 per share) — — (645 ) — — — Preferred — — (70 ) — — — Common stock issued for: Public equity offerings (a) 14 4,810 — — — — Share-based compensation and other plans, net — (65 ) (1 ) (3 ) 1,908 6 Share-based compensation — 180 — — — — Common stock held in trusts, net (b) — — — — 7 — Repurchase of common stock (c) — — — — (1,289 ) (220 ) Balance at September 30, 2017 $ 347 $ 9,619 $ 13,111 $ 19 (118,745 ) $ (8,427 ) Net income — — 311 — — — Cash dividends: Common ($3.00 per share) — — (775 ) — — — Preferred — — (152 ) — — — Common stock issued for: Acquisition (see Note 10) — 6,478 — — 37,306 2,121 Share-based compensation and other plans, net — (246 ) (2 ) 3 2,982 62 Share-based compensation — 328 — — — — Common stock held in trusts, net (b) — — — — (6 ) — Effect of change in accounting principle (see Note 2 and further discussion below) — — 103 — — — Balance at September 30, 2018 $ 347 $ 16,179 $ 12,596 $ 22 (78,463 ) $ (6,243 ) Net income — — 1,233 — — — Cash dividends: Common ($3.08 per share) — — (832 ) — — — Preferred — — (152 ) — — — Common stock issued for share-based compensation and other plans, net — (170 ) (1 ) 1 2,155 53 Share-based compensation — 261 — — — — Common stock held in trusts, net (b) — — — — 48 — Effect of change in accounting principle (see Note 2) — — 68 — — — Balance at September 30, 2019 $ 347 $ 16,270 $ 12,913 $ 23 (76,260 ) $ (6,190 ) (a) In May 2017 and in connection with the Company's acquisition of Bard, which is further discussed in Note 10 , the Company completed registered public offerings of equity securities including 14.025 million shares of the Company's common stock and 2.475 million shares of the Company's mandatory convertible preferred stock (ownership is held in the form of depositary shares, each representing a 1/20th interest in a share of preferred stock) for total net proceeds of $4.8 billion . If and when declared, dividends on the mandatory convertible preferred stock are payable on a cumulative basis at an annual rate of 6.125% on the liquidation preference of $1,000 per preferred share ( $50 per depositary share). The shares of preferred stock are convertible to a minimum of 11.7 million and up to a maximum of 14.0 million shares of Company common stock at an exchange ratio that is based on the market price of the Company’s common stock at the date of conversion, and no later than the mandatory conversion date of May 1, 2020. (b) Common stock held in trusts represents rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan. (c) Using proceeds received from the divestiture of the Respiratory Solutions business in the first quarter of fiscal year 2017, the Company repurchased shares of its common stock under an accelerated share repurchase agreement. The components and changes of Accumulated other comprehensive income (loss) were as follows: (Millions of dollars) Total Foreign Currency Translation Benefit Plans Cash Flow Hedges Balance at September 30, 2016 $ (1,929 ) $ (1,011 ) $ (883 ) $ (35 ) Other comprehensive income before reclassifications, net of taxes 140 11 121 8 Amounts reclassified into income, net of 66 — 58 8 Balance at September 30, 2017 $ (1,723 ) $ (1,001 ) $ (703 ) $ (18 ) Other comprehensive (loss) income before reclassifications, net of taxes (142 ) (161 ) 19 — Amounts reclassified into income, net of 57 — 52 5 Tax effects reclassified to retained earnings (103 ) — (99 ) (4 ) Balance at September 30, 2018 $ (1,909 ) $ (1,162 ) $ (729 ) $ (17 ) Other comprehensive loss before reclassifications, net of taxes (427 ) (93 ) (325 ) (9 ) Amounts reclassified into income, net of taxes 52 — 49 3 Balance at September 30, 2019 $ (2,283 ) $ (1,256 ) $ (1,005 ) $ (23 ) The amount of foreign currency translation recognized in other comprehensive income during the years ended September 30, 2019, 2018 and 2017 included net gains (losses) relating to net investment hedges, as further discussed in Note 14 . The amounts recognized in other comprehensive income relating to cash flow hedges in 2019 and 2017 related to forward starting interest rate swaps. Additional disclosures regarding the Company's cash flow hedge activities are provided in Note 14 . During the second quarter of 2018, as permitted under U.S. GAAP guidance, the Company reclassified stranded income tax effects on items within Accumulated other comprehensive income (loss) resulting from the enactment of new U.S. tax legislation, which legislation is further discussed in Note 17 , to Retained earnings . The reclassified tax effects related to prior service credits and net actuarial losses relating to benefit plans, as well as to terminated cash flow hedges. The tax effects relating to these items are generally recognized as such amounts are amortized into earnings. The tax impacts for amounts recognized in other comprehensive income before reclassifications were as follows: (Millions of dollars) 2019 2018 2017 Benefit Plans Income tax benefit (provision) for net (losses) gains recorded in other comprehensive income $ 91 $ (19 ) $ (60 ) The tax impacts for cash flow hedges recognized in other comprehensive income before reclassifications in 2019 and 2017 were immaterial to the Company's consolidated financial results. Reclassifications out of Accumulated other comprehensive income (loss) and the related tax impacts relating to benefit plans and cash flow hedges in 2019 , 2018 and 2017

Earnings per Share

Earnings per Share	12 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Earnings per Share	Earnings per Share The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) for the years ended September 30 were as follows: 2019 2018 2017 Average common shares outstanding 269,943 258,354 218,943 Dilutive share equivalents from share-based plans (a) 4,832 6,267 4,645 Average common and common equivalent shares outstanding — assuming dilution 274,775 264,621 223,588 (a) For the years ended September 30, 2019 , 2018 and 2017 , dilutive share equivalents associated with mandatory convertible preferred stock of 12 million , 12 million and 5 million , respectively, were excluded from the diluted shares outstanding calculation because the result would have been antidilutive. The issuance of the convertible preferred stock is further discussed in Note 3 . For the years ended September 30, 2019 , 2018 and 2017 , there were no options to purchase shares of common stock which were excluded from the diluted earnings per share calculation.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments Rental expense for all operating leases amounted to $169 million in 2019 , $149 million in 2018 and $110 million in 2017 . Future minimum rental commitments on non-cancelable leases are as follows: (Millions of dollars) Future minimum rental commitments on non-cancelable leases 2020 $ 122 2021 103 2022 83 2023 57 2024 56 Thereafter 123 As of September 30, 2019 , the Company has certain future purchase commitments aggregating to approximately $1.364 billion , which will be expended over the next several years. Contingencies Given the uncertain nature of litigation generally, the Company is not able, in all cases, to estimate the amount or range of loss that could result from an unfavorable outcome of the litigation to which the Company is a party. In accordance with U.S. GAAP, the Company establishes accruals to the extent probable future losses are estimable (in the case of environmental matters, without considering possible third-party recoveries). With respect to putative class action lawsuits in the United States and certain of the Canadian lawsuits described below relating to product liability matters, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class. With respect to the civil investigative demand served by the Department of Justice, as discussed below, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved. In view of the uncertainties discussed below, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations and consolidated cash flows. Product Liability Matters The Company believes that certain settlements and judgments, as well as legal defense costs, relating to product liability matters are or may be covered in whole or in part under its product liability insurance policies with a limited number of insurance carriers, or, in some circumstances, indemnification obligations to the Company from other parties, which if disputed, the Company intends to vigorously contest. Amounts recovered under the Company’s product liability insurance policies or indemnification arrangements may be less than the stated coverage limits or less than otherwise expected and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers or other parties will pay claims or that coverage or indemnity will be otherwise available. Hernia Product Claims As of September 30, 2019 , the Company is defending approximately 12,040 product liability claims involving the Company’s line of hernia repair devices (collectively, the “Hernia Product Claims”). The majority of those claims are currently pending in a coordinated proceeding in Rhode Island State Court, but claims are also pending in other state and/or federal court jurisdictions. In addition, those claims include multiple putative class actions in Canada. Generally, the Hernia Product Claims seek damages for personal injury allegedly resulting from use of the products. From time to time, the Company engages in resolution discussions with plaintiffs’ law firms regarding certain of the Hernia Product Claims, but the Company also intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. Trials are scheduled throughout 2020 in various state and/or federal courts. The Company expects additional trials of Hernia Product Claims to take place over the next 12 months. In August 2018, a new hernia multi-district litigation (“MDL”) was ordered to be established in the Southern District of Ohio. The Company cannot give any assurances that the resolution of the Hernia Product Claims that have not settled, including asserted and unasserted claims and the putative class action lawsuits, will not have a material adverse effect on the Company’s business, results of operations, financial condition and/or liquidity. Women’s Health Product Claims As of September 30, 2019 , the Company is defending approximately 885 product liability claims involving the Company’s line of pelvic mesh devices. The majority of those claims are currently pending in various federal court jurisdictions, and a coordinated proceeding in New Jersey State Court, but claims are also pending in other state court jurisdictions. In addition, those claims include putative class actions filed in the United States. Not included in the figures above are approximately 1,010 filed and unfiled claims that have been asserted or threatened against the Company but lack sufficient information to determine whether a pelvic mesh device of the Company is actually at issue. The claims identified above also include products manufactured by both the Company and two subsidiaries of Medtronic plc (as successor in interest to Covidien plc) (“Medtronic”), each a supplier of the Company. Medtronic has an obligation to defend and indemnify the Company with respect to any product defect liability relating to products its subsidiaries had manufactured. As described below, in July 2015 the Company reached an agreement with Medtronic (which was amended in June 2017) regarding certain aspects of Medtronic’s indemnification obligation. The foregoing lawsuits, unfiled claims, putative class actions, and other claims, together with claims that have settled or are the subject of agreements or agreements in principle to settle, are referred to collectively as the “Women’s Health Product Claims.” The Women’s Health Product Claims generally seek damages for personal injury allegedly resulting from use of the products. As of September 30, 2019 , the Company has reached agreements or agreements in principle with various plaintiffs’ law firms to settle their respective inventories of cases totaling approximately 15,160 of the Women’s Health Product Claims. The Company believes that these Women’s Health Product Claims are not the subject of Medtronic’s indemnification obligation. These settlement agreements and agreements in principle include unfiled and previously unknown claims held by various plaintiffs’ law firms, which are not included in the approximate number of lawsuits set forth in the first paragraph of this section. Each agreement is subject to certain conditions, including requirements for participation in the proposed settlements by a certain minimum number of plaintiffs. The Company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Women’s Health Product Claims, which may include additional inventory settlements. Starting in 2014 in the MDL, the court entered certain pre-trial orders requiring trial work up and remand of a significant number of Women’s Health Product Claims, including an order entered in the MDL on January 30, 2018, that requires the work up and remand of all remaining unsettled cases (the “WHP Pre-Trial Orders”). The WHP Pre-Trial Orders may result in material additional costs or trial verdicts in future periods in defending Women’s Health Product Claims. Trials are anticipated throughout 2020 in state and federal courts. A trial in the New Jersey coordinated proceeding began in March 2018, and in April 2018 a jury entered a verdict against the Company in the total amount of $68 million ( $33 million compensatory; $35 million punitive). The Company is in the process of appealing that verdict. A consolidated trial involving three plaintiffs is scheduled to begin in January 2020 in the New Jersey coordinated proceeding. The Company expects additional trials of Women’s Health Product Claims to take place over the next 12 months, which may potentially include consolidated trials. In July 2015, as part of the agreement with Medtronic noted above, Medtronic agreed to take responsibility for pursuing settlement of certain of the Women’s Health Product Claims that relate to products distributed by the Company under supply agreements with Medtronic, and the Company has paid Medtronic $121 million towards these potential settlements. In June 2017, the Company amended the agreement with Medtronic to transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on terms similar to the July 2015 agreement, including with respect to the obligation to make payments to Medtronic towards these potential settlements. In August 2019, the Company paid Medtronic an additional $20 million toward additional settlements. The Company also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms. The agreements do not resolve the dispute between the Company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any. During the course of engaging in settlement discussions with plaintiffs’ law firms, the Company has learned, and may in future periods learn, additional information regarding these and other unfiled claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company. Filter Product Claims As of September 30, 2019 , the Company is defending approximately 4,485 product liability claims involving the Company’s line of inferior vena cava filters (collectively, the “Filter Product Claims”). The majority of those claims are currently pending in an MDL in the United States District Court for the District of Arizona, but those MDL claims are in the process of bring remanded to various federal jurisdictions. Filter Product Claims are also pending in various state court jurisdictions, including a coordinated proceeding in Arizona State Court. In addition, those claims include putative class actions filed in the United States and Canada. The Filter Product Claims generally seek damages for personal injury allegedly resulting from use of the products. The Company has limited information regarding the nature and quantity of certain of the Filter Product Claims. The Company continues to receive claims and lawsuits and may in future periods learn additional information regarding other unfiled or unknown claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company. On May 31, 2019, the MDL Court ceased accepting direct filings or transfers into the Filter Product Claims MDL and, as noted above, remands for non-settled cases have begun and are expected to continue over the next three to six months. Federal and state court trials are scheduled throughout 2020. As of September 30, 2019 , the Company entered into settlement agreements and/or settlement agreements in principle for approximately 4,200 cases. On March 30, 2018, a jury in the first MDL trial found the Company liable for negligent failure to warn and entered a verdict in favor of plaintiffs. The jury found the Company was not liable for (a) strict liability design defect; (b) strict liability failure to warn; and (c) negligent design. The Company has appealed that verdict. On June 1, 2018, a jury in the second MDL trial unanimously found in favor of the Company on all claims. On August 17, 2018, the Court entered summary judgment in favor of the Company on all claims in the third MDL trial. On October 5, 2018, a jury in the fourth MDL trial unanimously found in favor of the Company on all claims. The Company expects additional trials of Filter Product Claims may take place over the next 12 months. In most product liability litigations (like those described above), plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the Company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions and, consequently, is unable to fully evaluate the claims. The Company expects that it will receive and review additional information regarding any remaining unsettled product liability matters. In January 2017, the Company reached an agreement to resolve litigation filed in the Southern District of New York by its insurance carriers in connection with Women’s Health Product Claims and Filter Product Claims. The agreement requires the insurance carriers to reimburse the Company for certain future costs incurred in connection with Filter Product Claims up to an agreed amount. For certain product liability claims or lawsuits, the Company does not maintain or has limited remaining insurance coverage. Other Legal Matters Since early 2013, the Company has received subpoenas or Civil Investigative Demands from a number of State Attorneys General seeking information related to the sales and marketing of certain of the Company’s products that are the subject of the Hernia Product Claims and the Women’s Health Product Claims. The Company is cooperating with these requests. Although the Company has had, and continues to have, discussions with the State Attorneys General with respect to overall potential resolution of this matter, there can be no assurance that a resolution will be reached or what the terms of any such resolution may be. In July 2017, a civil investigative demand was served by the Department of Justice seeking documents and information relating to an investigation into possible violations of the False Claims Act in connection with the sales and marketing of FloChec ® and QuantaFlo TM devices. The Company is cooperating with these requests. Since it is not feasible to predict the outcome of these matters, the Company cannot give any assurances that the resolution of these matters will not have a material adverse effect on the Company’s business, results of operations, financial condition and/or liquidity. The Company is a potentially responsible party to a number of federal administrative proceedings in the United States brought under the Comprehensive Environment Response, Compensation and Liability Act, also known as “Superfund,” and similar state laws. The affected sites are in varying stages of development. In some instances, the remedy has been completed, while in others, environmental studies are underway or commencing. For several sites, there are other potentially responsible parties that may be jointly or severally liable to pay all or part of cleanup costs. While it is not feasible to predict the outcome of these proceedings, based upon the Company’s experience, current information and applicable law, the Company does not expect these proceedings to have a material adverse effect on its financial condition and/or liquidity. However, one or more of the proceedings could be material to the Company’s business and/or results of operations. The Company is also involved both as a plaintiff and a defendant in other legal proceedings and claims that arise in the ordinary course of business. The Company believes that it has meritorious defenses to these suits pending against the Company and is engaged in a vigorous defense of each of these matters. Litigation Reserves The Company regularly monitors and evaluates the status of product liability and other legal matters, and may, from time-to-time, engage in settlement and mediation discussions taking into consideration developments in the matters and the risks and uncertainties surrounding litigation. These discussions could result in settlements of one or more of these claims at any time. During fiscal year 2019, the Company recorded pre-tax charges to Other operating expense, net , of approximately $914 million related to certain of the product liability matters discussed above under the heading “Product Liability Matters,” including the related legal defense costs. The Company recorded these charges based on additional information obtained during the year, including but not limited to: the nature and quantity of unfiled and filed claims and the continued rate of claims being filed in certain product liability matters; the status of certain settlement discussions with plaintiffs’ counsel; the allegations and documentation supporting or refuting such allegations; publicly available information regarding similar medical device mass tort settlements; historical information regarding other product liability settlements involving the Company; and the stage of litigation. Accruals for the Company's product liability claims which are specifically discussed above, as well as the related legal defense costs, amounted to approximately $2.5 billion at September 30, 2019 and $2.0 billion at September 30, 2018 . These accruals, which are generally long-term in nature, are largely recorded within Deferred Income Taxes and Other on the Company's consolidated balance sheets. As of September 30, 2019 and 2018 , the Company had $53 million and $94 million , respectively, in qualified settlement funds (“QSFs”), subject to certain settlement conditions, for certain product liability matters. Payments to QSFs are recorded as a component of Restricted cash . The Company's expected recoveries related to product liability claims and related legal defense costs were approximately $150 million and $343 million at September 30, 2019 and 2018 , respectively. A substantial amount of these expected recoveries at September 30, 2019 and 2018 related to the Company’s agreements with Medtronic related to certain Women’s Health Product Claims. During fiscal year 2019 , Medtronic provided the Company with releases from liability for certain claims that were the subject of the agreement discussed further above. Accordingly, adjustments to reduce accruals for the Company's product liability claims, as well as the balance recorded for expected recoveries related to product liability claims, were recorded during fiscal year 2019 . The terms of the Company’s agreements with Medtronic are substantially consistent with the assumptions underlying, and the manner in which, the Company has recorded expected recoveries related to the indemnification obligation. The expected recoveries at September 30, 2019 related to the indemnification obligation are not in dispute with respect to claims that Medtronic settles pursuant to the agreements. As described above, the agreements do not resolve the dispute between the Company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any, and the Company also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms.

Revenues

Revenues	12 Months Ended
	Sep. 30, 2019
Revenue from Contract with Customer [Abstract]
Revenue	Revenues As previously discussed in Note 2 , the Company adopted ASC 606 using the modified retrospective method. The Company sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products which are distributed through independent distribution channels and directly by BD through sales representatives. End-users of the Company's products include healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. Timing of Revenue Recognition The Company's revenues are primarily recognized when the customer obtains control of the product sold, which is generally upon shipment or delivery, depending on the delivery terms specified in the sales agreement. Revenues associated with certain instruments and equipment for which installation is complex, and therefore significantly affects the customer’s ability to use and benefit from the product, are recognized when customer acceptance of these installed products has been confirmed. For certain service arrangements, including extended warranty and software maintenance contracts, revenue is recognized ratably over the contract term. The majority of revenues relating to extended warranty contracts associated with certain instruments and equipment is generally recognized within a few years whereas deferred revenue relating to software maintenance contracts is generally recognized over a longer period. Measurement of Revenues The Company acts as the principal in substantially all of its customer arrangements and as such, generally records revenues on a gross basis. Revenues exclude any taxes that the Company collects from customers and remits to tax authorities. The Company considers its shipping and handling costs to be costs of contract fulfillment and has made the accounting policy election to record these costs within Selling and administrative expense . Payment terms extended to the Company's customers are based upon commercially reasonable terms for the markets in which the Company's products are sold. Because the Company generally expects to receive payment within one year or less from when control of a product is transferred to the customer, the Company does not generally adjust its revenues for the effects of a financing component. The Company’s estimate of probable credit losses relating to trade receivables is determined based on historical experience and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectible. Such amounts are not material to the Company's consolidated financial results. The Company's gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration include rebates, sales discounts and sales returns. Because these deductions represent estimates of the related obligations, judgment is required when determining the impact of these revenue deductions on gross revenues for a reporting period. Rebates provided by the Company are based upon prices determined under the Company's agreements with its end-user customers. Additional factors considered in the estimate of the Company's rebate liability include the quantification of inventory that is either in stock at or in transit to the Company's distributors, as well as the estimated lag time between the sale of product and the payment of corresponding rebates. The impact of other forms of variable consideration, including sales discounts and sales returns, is not material to the Company's revenues. Additional disclosures relating to sales discounts and sales returns are provided in Note 19. The Company's agreements with customers within certain organizational units including Medication Management Solutions, Diagnostic Systems and Biosciences, contain multiple performance obligations including both products and certain services noted above. The transaction price for these agreements is allocated to each performance obligation based upon its relative standalone selling price. Standalone selling price is the amount at which the Company would sell a promised good or service separately to a customer. The Company generally estimates standalone selling prices using its list prices and a consideration of typical discounts offered to customers. Effects of Revenue Arrangements on Consolidated Balance Sheet Due to the nature of the majority of the Company's products and services, the Company typically does not incur costs to fulfill a contract in advance of providing the customer with goods or services. Capitalized contract costs associated with the costs to fulfill contracts for certain products in the Medication Management Solutions organizational unit are immaterial to the Company's consolidated balance sheets. The Company's costs to obtain contracts are comprised of sales commissions which are paid to the Company's employees or third party agents. The majority of the sales commissions incurred by the Company relate to revenue that is recognized over a period that is less than one year and as such, the Company has elected a practical expedient provided under ASC 606 to record the majority of its expense associated with sales commissions as it is incurred. Commissions relating to revenues recognized over a period longer than one year are recorded as assets which are amortized over the period over which the revenues underlying the commissions are recognized. Capitalized contract costs related to such commissions are immaterial to the Company's consolidated balance sheets. The Company records contract liabilities for unearned revenue that is allocable to performance obligations, such as extended warranty and software maintenance contracts, which are performed over time as discussed further above. These contract liabilities are immaterial to the Company's consolidated financial results. The Company's liability for product warranties provided under its agreements with customers is not material to its consolidated balance sheets. Remaining Performance Obligations The Company's obligations relative to service contracts, which are further discussed above, and pending installations of equipment, primarily in the Company's Medication Management Solutions unit, represent unsatisfied performance obligations of the Company. The revenues under existing contracts with original expected durations of more than one year, which are attributable to products and/or services that have not yet been installed or provided, are estimated to be approximately $1.8 billion at September 30, 2019 . The Company expects to recognize the majority of this revenue over the next three years . Within the Company's Medication Management Solutions, Medication Delivery Solutions, Diagnostic Systems, and Biosciences units, some contracts also contain minimum purchase commitments of reagents or other consumables and the future sales of these consumables represent additional unsatisfied performance obligations of the Company. The revenue attributable to the unsatisfied minimum purchase commitment-related performance obligations, for contracts with original expected durations of more than one year, is estimated to be approximately $2.8 billion at September 30, 2019 . This revenue will be recognized over the customer relationship period. Disaggregation of Revenues A disaggregation of the Company's revenues by segment, organizational unit and geographic region is provided in Note 7 .

Segment Data

Segment Data	12 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Segment Data	Segment Data The Company's organizational structure is based upon three principal business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional ("Interventional"). The Company’s segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Medical Medical produces a broad array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The primary customers served by Medical are hospitals and clinics; physicians’ office practices; consumers and retail pharmacies; governmental and nonprofit public health agencies; pharmaceutical companies; and healthcare workers. Medical consists of the following organizational units: Organizational Unit Principal Product Lines Medication Delivery Solutions Peripheral intravenous ("IV") catheters (conventional, safety); advanced peripheral catheters (guidewire assisted peripherally inserted venous catheters, midline catheters, port access); central lines (peripherally inserted central catheters); acute dialysis catheters; vascular access technology (ultrasonic imaging); vascular care (lock solutions, prefilled flush syringes, disinfecting caps); vascular preparation (skin antiseptics, dressings, securement); needle-free IV connectors and extensions sets; closed-system drug transfer devices; hazardous drug detection; conventional and safety hypodermic syringes and needles, anesthesia needles (spinal, epidural) and trays; enteral syringes, sharps disposal systems. Medication Management Solutions IV medication safety and infusion therapy delivery systems, including infusion pumps, dedicated disposables, and IV fluids; medication compounding workflow systems; automated medication dispensing; automated supply management systems; medication inventory optimization and tracking systems; and informatics and analytics solutions for enterprise medication management. Diabetes Care Syringes, pen needles and other products related to the injection or infusion of insulin and other drugs used in the treatment of diabetes. Pharmaceutical Systems Prefillable drug delivery systems - prefillable syringes, safety, shielding and self-injection systems and support services - provided to pharmaceutical companies for use as containers for injectable pharmaceutical products, which are then placed on the market as drug/device combinations. Life Sciences Life Sciences provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections (“HAIs”) and cancers. In addition, Life Sciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. That information is used to aid the discovery and development of new drugs and vaccines, and to improve the diagnosis and management of diseases. The primary customers served by Life Sciences are hospitals, laboratories and clinics; blood banks; healthcare workers; public health agencies; physicians’ office practices; retail pharmacies; academic and government institutions; and pharmaceutical and biotechnology companies. Life Sciences consists of the following organizational units: Organizational Unit Principal Product Lines Preanalytical Systems Integrated systems for specimen collection; and safety-engineered blood collection products and systems. Diagnostic Systems Automated blood culturing and tuberculosis culturing systems; molecular testing systems for infectious diseases and women’s health; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays for testing of respiratory infections; microbiology laboratory automation and plated media for clinical and industrial applications. Biosciences Fluorescence-activated cell sorters and analyzers; antibodies and kits for performing cell analysis; reagent systems for life science research; solutions for high-throughput single-cell gene expression analysis; and clinical oncology, immunological (HIV) and transplantation diagnostic/monitoring reagents and analyzers. Effective October 1, 2019, Life Sciences joined its Preanalytical Systems and Diagnostic Systems organizational units to create a new Integrated Diagnostic Solutions organizational unit which will focus on driving growth and innovation around integrated specimen management to diagnostic solutions. The new Integrated Diagnostic Solution organizational unit will consist of the following principal product lines: Organizational Unit Principal Product Lines Integrated Diagnostic Solutions Integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing and tuberculosis culturing systems; molecular testing systems for infectious diseases and women’s health; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays for testing of respiratory infections; microbiology laboratory automation and plated media for clinical and industrial applications. Interventional Interventional provides vascular, urology, oncology and surgical specialty products that are, with the exception of the V. Muller surgical and laparoscopic instrumentation products, intended to be used once and then discarded or are either temporarily or permanently implanted. The primary customers served by Interventional are hospitals, individual healthcare professionals, extended care facilities, alternate site facilities and patients via the segment's Homecare business. The Interventional segment consists of the following organizational units: Organizational Unit Principal Product Lines Surgery Hernia and soft tissue repair, biological grafts, bioresorbable grafts, biosurgery, and other surgical products; BD ChloraPrep™ surgical infection prevention products, and V. Mueller™ surgical and laparoscopic instrumentation products. Peripheral Intervention Percutaneous transluminal angioplasty (“PTA”) balloon catheters, peripheral vascular stents, self-expanding and balloon-expandable stent grafts, vascular grafts, drug-coated balloons, ports, biopsy, chronic dialysis, feeding, IVC filters, endovascular fistula creation devices and drainage products. Urology and Critical Care Urine management devices, urological drainage products, intermittent catheters, kidney stone management devices, Targeted Temperature Management, and fecal management devices. Additional Segment Information Distribution of products is primarily through independent distribution channels, and directly to end-users by BD and independent sales representatives. No customer accounted for 10% or more of revenues in any of the three years presented. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon operating income, which represents revenues reduced by product costs and operating expenses. Beginning with its first quarter fiscal year 2018, the Company changed its management reporting approach so that certain general and administrative costs, which were previously allocated to the segments, are now excluded from the segments' operating expenses. The Medical and Life Sciences segments' operating income for the year ended September 30, 2017 included allocated general corporate costs of $166 million and $113 million , respectively. No such allocations were made in the year ended September 30, 2019 or September 30, 2018 . Financial information for the Company’s segments is detailed below. The Company has no material intersegment revenues. As discussed in Note 10 , the Company completed its acquisition of Bard on December 29, 2017. Bard's operating results were included in the Company’s consolidated results of operations beginning on January 1, 2018. (Millions of dollars) 2019 2018 2017 United States International Total United States International Total United States International Total Medical Medication Delivery Solutions $ 2,048 $ 1,811 $ 3,859 $ 1,892 $ 1,752 $ 3,644 $ 1,378 $ 1,434 $ 2,812 Medication Management Solutions 2,104 525 2,629 1,957 513 2,470 1,843 452 2,295 Diabetes Care 573 538 1,110 564 541 1,105 546 510 1,056 Pharmaceutical Systems 392 1,073 1,465 357 1,040 1,397 328 929 1,256 Total segment revenues $ 5,116 $ 3,947 $ 9,064 $ 4,770 $ 3,846 $ 8,616 $ 4,095 $ 3,325 $ 7,419 Life Sciences Preanalytical Systems $ 774 $ 784 $ 1,558 $ 761 $ 792 $ 1,553 $ 741 $ 730 $ 1,471 Diagnostic Systems 672 875 1,547 678 858 1,536 622 756 1,378 Biosciences 485 709 1,194 475 766 1,241 455 684 1,139 Total segment revenues $ 1,931 $ 2,368 $ 4,300 $ 1,914 $ 2,416 $ 4,330 $ 1,818 $ 2,170 $ 3,988 Interventional Surgery (a) $ 1,098 $ 299 $ 1,397 $ 946 $ 245 $ 1,192 $ 577 $ 89 $ 666 Peripheral Intervention (a) 787 602 1,389 594 451 1,045 14 6 19 Urology and Critical Care 797 342 1,140 544 256 800 — — — Total segment revenues $ 2,682 $ 1,244 $ 3,926 $ 2,084 $ 953 $ 3,037 $ 591 $ 95 $ 685 Total Company revenues $ 9,730 $ 7,560 $ 17,290 $ 8,768 $ 7,215 $ 15,983 $ 6,504 $ 5,589 $ 12,093 (a) Amounts presented in 2017 are associated with certain product offerings that were moved from the Medical segment to the Interventional segment in order to align with the reportable segment structure that became effective beginning in the second quarter of fiscal year 2018. (Millions of dollars) 2019 2018 2017 Income Before Income Taxes Medical (a) (b) (c) $ 2,824 $ 2,624 $ 1,907 Life Sciences (d) 1,248 1,207 772 Interventional (b) (e) (f) 903 306 248 Total Segment Operating Income 4,976 4,137 2,927 Acquisitions and other restructurings (480 ) (740 ) (354 ) Net interest expense (627 ) (641 ) (445 ) Other unallocated items (g) (2,693 ) (1,583 ) (1,152 ) Total Income Before Income Taxes $ 1,176 $ 1,173 $ 976 Assets Medical $ 22,925 $ 23,493 $ 15,552 Life Sciences 4,135 4,225 4,056 Interventional (f) 22,157 23,219 2,780 Total Segment Assets 49,217 50,938 22,388 Corporate and All Other (h) 2,548 2,966 15,347 Total Assets $ 51,765 $ 53,904 $ 37,734 Capital Expenditures Medical $ 577 $ 560 $ 486 Life Sciences 230 255 212 Interventional (f) 120 65 16 Corporate and All Other 30 14 13 Total Capital Expenditures $ 957 $ 895 $ 727 Depreciation and Amortization Medical $ 1,073 $ 1,028 $ 773 Life Sciences 284 275 254 Interventional (f) 881 658 52 Corporate and All Other 14 17 10 Total Depreciation and Amortization $ 2,253 $ 1,978 $ 1,088 (a) The amount in 2019 included $75 million of estimated remediation costs recorded to Other operating expense, net relating to a recall of a product component, which generally pre-dated the Company's acquisition of CareFusion in fiscal year 2015, within the Medication Management Solutions unit's infusion systems platform. (b) The amounts in 2018 included expense related to the recognition of a $478 million fair value step-up adjustment related to Bard's inventory on the acquisition date. The step-up adjustments recognized by the Medical and Interventional segments in 2018 were $60 million and $418 million , respectively. (c) The amount in 2018 included $58 million of charges to write down the value of fixed assets primarily in the Diabetes Care unit. (d) The amount in 2018 included $81 million of charges recorded to write down the carrying value of certain intangible and other assets in the Biosciences unit. (e) The amount in 2019 included a charge of $30 million recorded to write down the carrying value of certain intangible assets in the Surgery unit. (f) Amounts presented in 2017 are associated with certain product offerings that were moved from the Medical segment to the Interventional segment in order to align with the reportable segment structure that became effective beginning in the second quarter of fiscal year 2018. (g) Primarily comprised of foreign exchange, corporate expenses, and share-based compensation expense. The amount in 2019 included a pre-tax charge of $914 million related to certain product liability matters, which is further discussed in Note 5 , and also included the pre-tax gain recognized on the Company's sale of its Advanced Bioprocessing business of approximately $336 million , which is further discussed in Note 11 . Results in 2019 and 2018 were impacted by the Company's change in its management reporting approach, as further discussed above. The amount in 2018 included the pre-tax gain recognized on the Company's sale of its non-controlling interest in Vyaire Medical of approximately $303 million . Results in 2017 included a $748 million non-cash charge resulting from a modification to the Company's dispensing equipment lease contracts with customers, as well as the reversal of certain litigation reserves. (h) Includes cash and investments and corporate assets. Geographic Information The countries in which the Company has local revenue-generating operations have been combined into the following geographic areas: the United States (including Puerto Rico); Europe; Greater Asia (which includes countries in East Asia, South Asia, Southeast Asia and the Oceania region); and Other, which is comprised of Latin America, Canada, and EMA (which includes the Commonwealth of Independent States, Middle East and Africa). Revenues to unaffiliated customers are generally based upon the source of the product shipment. Long-lived assets, which include net property, plant and equipment, are based upon physical location. (Millions of dollars) 2019 2018 2017 Revenues United States $ 9,730 $ 8,768 $ 6,504 Europe 3,359 3,298 2,588 Greater Asia 2,726 2,460 1,744 Other 1,476 1,457 1,257 $ 17,290 $ 15,983 $ 12,093 Long-Lived Assets United States $ 37,053 $ 38,982 $ 13,151 Europe 5,483 5,640 4,421 Greater Asia 1,328 851 578 Other 861 645 584 Corporate 377 375 366 $ 45,101 $ 46,494 $ 19,101

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Share-Based Compensation	Share-Based Compensation The Company grants share-based awards under the 2004 Employee and Director Equity-Based Compensation Plan (“2004 Plan”), which provides long-term incentive compensation to employees and directors consisting of: stock appreciation rights (“SARs”), performance-based restricted stock units, time-vested restricted stock units and other stock awards. The fair value of share-based payments is recognized as compensation expense in net income. The amounts and location of compensation cost relating to share-based payments included in the consolidated statements of income is as follows: (Millions of dollars) 2019 2018 2017 Cost of products sold $ 37 $ 36 $ 30 Selling and administrative expense 145 136 113 Research and development expense 32 29 24 Acquisitions and other restructurings 50 130 10 $ 265 $ 332 $ 177 Tax benefit associated with share-based compensation costs recognized $ 62 $ 79 $ 61 Upon the Company's acquisition of Bard in 2018, certain pre-acquisition equity awards of Bard were converted into either BD SARs or BD restricted stock awards, as applicable. These awards have substantially the same terms and conditions as the converted Bard awards immediately prior to the acquisition date. Compensation expense of $40 million and $126 million associated with these replacement awards was recorded in Acquisitions and other restructurings in 2019 and 2018, respectively. Stock Appreciation Rights SARs represent the right to receive, upon exercise, shares of common stock having a value equal to the difference between the market price of common stock on the date of exercise and the exercise price on the date of grant. SARs vest over a period of four years and have a term of ten years . The fair value was estimated on the date of grant using a lattice-based binomial option valuation model that uses the following weighted-average assumptions: 2019 2018 2017 Risk-free interest rate 3.05% 2.32% 2.33% Expected volatility 18.0% 19.0% 20.0% Expected dividend yield 1.27% 1.33% 1.71% Expected life 7.2 years 7.4 years 7.5 years Fair value derived $51.86 $46.10 $33.81 Expected volatility is based upon historical volatility for the Company’s common stock and other factors. The expected life of SARs granted is derived from the output of the lattice-based model, using assumed exercise rates based on historical exercise and termination patterns, and represents the period of time that SARs granted are expected to be outstanding. The risk-free interest rate used is based upon the published U.S. Treasury yield curve in effect at the time of grant for instruments with a similar life. The dividend yield is based upon the most recently declared quarterly dividend as of the grant date. The Company issued 1.0 million shares during 2019 to satisfy the SARs exercised. A summary of SARs outstanding as of September 30, 2019 and changes during the year then ended is as follows: SARs (in thousands) Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (Millions of dollars) Balance at October 1 7,986 $ 125.73 Granted 859 242.10 Exercised (1,779 ) 102.14 Forfeited, canceled or expired (168 ) 186.18 Balance at September 30 6,899 $ 144.84 5.70 $ 746 Vested and expected to vest at September 30 6,692 $ 142.87 5.62 $ 737 Exercisable at September 30 4,833 $ 117.65 4.69 $ 654 A summary of SARs exercised 2019 , 2018 and 2017 is as follows: (Millions of dollars) 2019 2018 2017 Total intrinsic value of SARs exercised $ 260 $ 333 $ 148 Tax benefit realized from SAR exercises $ 62 $ 90 $ 53 Total fair value of SARs vested $ 66 $ 107 $ 30 Performance-Based and Time-Vested Restricted Stock Units Performance-based restricted stock units cliff vest three years after the date of grant. These units are tied to the Company’s performance against pre-established targets over a performance period of three years . The performance measures for fiscal years 2019 , 2018 and 2017 were relative total shareholder return (measures the Company’s stock performance during the performance period against that of peer companies) and average annual return on invested capital. Under the Company’s long-term incentive program, the actual payout under these awards may vary from zero to 200% of an employee’s target payout, based on the Company’s actual performance over the performance period of three years . The fair value is based on the market price of the Company’s stock on the date of grant. Compensation cost initially recognized assumes that the target payout level will be achieved and is adjusted for subsequent changes in the expected outcome of performance-related conditions. For units for which the performance conditions are modified after the date of grant, any incremental increase in the fair value of the modified units, over the original units, is recorded as compensation expense on the date of the modification for vested units, or over the remaining performance period for units not yet vested. Time-vested restricted stock unit awards vest on a graded basis over a period of three years , except for certain key executives of the Company, including the executive officers, for which such units generally vest one year following the employee’s retirement. The related share-based compensation expense is recorded over the requisite service period, which is the vesting period or is based on retirement eligibility. The fair value of all time-vested restricted stock units is based on the market value of the Company’s stock on the date of grant. A summary of restricted stock units outstanding as of September 30, 2019 and changes during the year then ended is as follows: Performance-Based Time-Vested Stock Units (in thousands) Weighted Average Grant Date Fair Value Stock Units (in thousands) Weighted Average Grant Date Fair Value Balance at October 1 1,032 $ 190.57 2,765 $ 194.92 Granted 381 237.55 755 235.50 Distributed (142 ) 153.73 (906 ) 189.06 Forfeited or canceled (316 ) 182.50 (546 ) 201.85 Balance at September 30 955 (a) $ 221.73 2,068 $ 210.48 Expected to vest at September 30 306 (b) $ 218.06 1,964 $ 209.67 (a) Based on 200% of target payout. (b) Net of expected forfeited units and units in excess of the expected performance payout of 65 thousand and 585 thousand shares, respectively. The weighted average grant date fair value of restricted stock units granted during the years 2019 , 2018 and 2017 are as follows: Performance-Based Time-Vested 2019 2018 2017 2019 2018 2017 Weighted average grant date fair value of units granted $ 237.55 $ 251.75 $ 174.92 $ 235.50 $ 216.06 $ 165.96 The total fair value of stock units vested during 2019 , 2018 and 2017 was as follows: Performance-Based Time-Vested (Millions of dollars) 2019 2018 2017 2019 2018 2017 Total fair value of units vested $ 33 $ 31 $ 32 $ 254 $ 362 $ 139 At September 30, 2019 , the weighted average remaining vesting term of performance-based and time vested restricted stock units is 1.22 and 0.90 years, respectively. Unrecognized Compensation Expense and Other Stock Plans The amount of unrecognized compensation expense for all non-vested share-based awards as of September 30, 2019 , is approximately $266 million , which is expected to be recognized over a weighted-average remaining life of approximately 1.91 years. At September 30, 2019 , 5.6 million shares were authorized for future grants under the 2004 Plan. The Company has a policy of satisfying share-based payments through either open market purchases or shares held in treasury. At September 30, 2019 , the Company has sufficient shares held in treasury to satisfy these payments. As of September 30, 2019 , 105 thousand shares were held in trust relative to a Director's Deferral plan, which provides a means to defer director compensation, from time to time, on a deferred stock or cash basis. Also as of September 30, 2019 , 320 thousand shares were issuable under a Deferred Compensation Plan that allows certain highly-compensated employees, including executive officers, to defer salary, annual incentive awards and certain equity-based compensation.

Benefit Plans

Benefit Plans	12 Months Ended
	Sep. 30, 2019
Retirement Benefits [Abstract]
Benefit Plans	Benefit Plans The Company has defined benefit pension plans covering certain employees in the United States and certain international locations. Postretirement healthcare and life insurance benefits provided to qualifying domestic retirees as well as other postretirement benefit plans in international countries are not material. The measurement date used for the Company’s employee benefit plans is September 30. Effective January 1, 2018, the legacy U.S. pension plan was frozen to limit the participation of employees who are hired or re-hired by the Company, or who transfer employment to the Company, on or after January 1, 2018. Net pension cost for the years ended September 30 included the following components: Pension Plans (Millions of dollars) 2019 2018 2017 Service cost $ 134 $ 136 $ 110 Interest cost 107 90 61 Expected return on plan assets (180 ) (154 ) (112 ) Amortization of prior service credit (13 ) (13 ) (14 ) Amortization of loss 78 78 92 Settlements 10 2 — Net pension cost $ 135 $ 137 $ 138 Net pension cost included in the preceding table that is attributable to international plans $ 32 $ 34 $ 43 The amounts provided above for amortization of prior service credit and amortization of loss represent the reclassifications of prior service credits and net actuarial losses that were recognized in Accumulated other comprehensive income (loss) in prior periods. The settlement losses recorded in 2019 and 2018 primarily included lump sum benefit payments associated with the Company’s U.S. supplemental pension plan. The Company recognizes pension settlements when payments from the supplemental plan exceed the sum of service and interest cost components of net periodic pension cost associated with this plan for the fiscal year. As further discussed in Note 2 , upon adopting an accounting standard update on October 1, 2018, all components of the Company’s net periodic pension and postretirement benefit costs, aside from service cost, are recorded to Other income (expense), net on its consolidated statements of income, for all periods presented. The change in benefit obligation, change in fair value of pension plan assets, funded status and amounts recognized in the Consolidated Balance Sheets for these plans were as follows: Pension Plans (Millions of dollars) 2019 2018 Change in benefit obligation: Beginning obligation $ 3,246 $ 2,647 Service cost 134 136 Interest cost 107 90 Plan amendments 3 — Benefits paid (153 ) (162 ) Impact of (divestitures) acquisitions (9 ) 758 Actuarial loss (gain) 514 (82 ) Settlements (63 ) (122 ) Other, includes translation (49 ) (19 ) Benefit obligation at September 30 $ 3,731 $ 3,246 Change in fair value of plan assets: Beginning fair value $ 2,642 $ 1,932 Actual return on plan assets 279 70 Employer contribution 258 400 Benefits paid (153 ) (162 ) Impact of (divestitures) acquisitions (7 ) 539 Settlements (63 ) (122 ) Other, includes translation (30 ) (15 ) Plan assets at September 30 $ 2,926 $ 2,642 Funded Status at September 30: Unfunded benefit obligation $ (804 ) $ (604 ) Amounts recognized in the Consolidated Balance Sheets at September 30: Other $ 11 $ 15 Salaries, wages and related items (22 ) (15 ) Long-term Employee Benefit Obligations (793 ) (604 ) Net amount recognized $ (804 ) $ (604 ) Amounts recognized in Accumulated other comprehensive income (loss) before income taxes at September 30: Prior service credit $ 44 $ 60 Net actuarial loss (1,289 ) (982 ) Net amount recognized $ (1,246 ) $ (921 ) International pension plan assets at fair value included in the preceding table were $859 million and $821 million at September 30, 2019 and 2018 , respectively. The international pension plan projected benefit obligations were $1.244 billion and $1.064 billion at September 30, 2019 and 2018 , respectively. The benefit obligation associated with postretirement healthcare and life insurance plans provided to qualifying domestic retirees, which was largely recorded to Long-Term Employee Benefit Obligations, was $153 million and $148 million at September 30, 2019 and 2018 , respectively. Pension plans with accumulated benefit obligations in excess of plan assets and plans with projected benefit obligations in excess of plan assets consist of the following at September 30: Accumulated Benefit Obligation Exceeds the Fair Value of Plan Assets Projected Benefit Obligation Exceeds the Fair Value of Plan Assets (Millions of dollars) 2019 2018 2019 2018 Projected benefit obligation $ 3,623 $ 2,618 $ 3,698 $ 3,121 Accumulated benefit obligation $ 3,476 $ 2,533 Fair value of plan assets $ 2,821 $ 2,012 $ 2,882 $ 2,502 The estimated net actuarial loss and prior service credit that will be amortized from Accumulated other comprehensive income (loss) into net pension costs over the next fiscal year for pension benefits and other postretirement benefits are not material. The weighted average assumptions used in determining pension plan information were as follows: 2019 2018 2017 Net Cost Discount rate: U.S. plans (a) 4.26 % 3.71 % 3.42 % International plans 2.30 2.30 1.70 Expected return on plan assets: U.S. plans 7.25 7.20 7.25 International plans 4.98 4.95 4.65 Rate of compensation increase: U.S. plans 4.29 4.51 4.25 International plans 2.36 2.31 2.33 Benefit Obligation Discount rate: U.S. plans 3.21 4.26 3.72 International plans 1.39 2.30 2.25 Rate of compensation increase: U.S. plans 4.29 4.29 4.51 International plans 2.35 2.36 2.30 (a) The Company calculated the service and interest components utilizing an approach that discounts the individual expected cash flows using the applicable spot rates derived from the yield curve over the projected cash flow period. Expected Rate of Return on Plan Assets The expected rate of return on plan assets is based upon expectations of long-term average rates of return to be achieved by the underlying investment portfolios. In establishing this assumption, the Company considers many factors, including historical assumptions compared with actual results; benchmark data; expected returns on various plan asset classes, as well as current and expected asset allocations. Expected Funding The Company’s funding policy for its defined benefit pension plans is to contribute amounts sufficient to meet legal funding requirements, plus any additional amounts that may be appropriate considering the funded status of the plans, tax consequences, the cash flow generated by the Company and other factors. The Company made a discretionary contribution of $200 million to its BD U.S. pension in October 2018. The Company does not anticipate any significant required contributions to its pension plans in 2020. Expected benefit payments are as follows: (Millions of dollars) Pension Plans 2020 $ 212 2021 171 2022 173 2023 185 2024 190 2025-2029 1,066 Expected benefit payments associated with postretirement healthcare plans are immaterial to the Company's consolidated financial results. Investments The Company’s primary objective is to achieve returns sufficient to meet future benefit obligations. It seeks to generate above market returns by investing in more volatile asset classes such as equities while at the same time controlling risk through diversification in non-correlated asset classes and through allocations to more stable asset classes like fixed income. U.S. Plans The Company’s U.S. pension plans comprise 71% of total benefit plan investments, based on September 30, 2019 market values and have a target asset mix of 40% fixed income, 25% diversifying investments and 35% equities. This mix was established based on an analysis of projected benefit payments and estimates of long-term returns, volatilities and correlations for various asset classes. The asset allocations to diversifying investments include high-yield bonds, hedge funds, real estate, infrastructure, commodities, leveraged loans and emerging markets bonds. The actual portfolio investment mix may, from time to time, deviate from the established target mix due to various factors such as normal market fluctuations, the reliance on estimates in connection with the determination of allocations and normal portfolio activity such as additions and withdrawals. Rebalancing of the asset portfolio on a quarterly basis is required to address any allocations that deviate from the established target allocations in excess of defined allowable ranges. The target allocations are subject to periodic review, including a review of the asset portfolio’s performance, by the named fiduciary of the plans. Any tactical deviations from the established asset mix require the approval of the named fiduciary. The U.S. plans may enter into both exchange traded and non-exchange traded derivative transactions in order to manage interest rate exposure, volatility, term structure of interest rates, and sector and currency exposures within the fixed income portfolios. The Company has established minimum credit quality standards for counterparties in such transactions. The following table provides the fair value measurements of U.S. plan assets, as well as the measurement techniques and inputs utilized to measure fair value of these assets, at September 30, 2019 and 2018 . The categorization of fund investments is based upon the categorization of these funds’ underlying assets. (Millions of dollars) Total U.S. Investments Measured at Net Asset Value (a) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) 2019 2018 2019 2018 2019 2018 2019 2018 2019 2018 Fixed Income: Mortgage and asset-backed securities $ — $ 28 $ — $ — $ — $ — $ — $ 28 $ — $ — Corporate bonds 401 484 — — 48 101 353 383 — — Government and agency-U.S. 108 257 — — 85 199 23 57 — — Government and agency-Foreign 85 122 — 8 69 85 16 28 — — Other fixed income 37 — — — — — 37 — — — Equity securities 922 536 782 360 140 176 — — — — Cash and cash equivalents 254 39 — — 254 39 — — — — Other 261 356 124 356 138 — — — — — Fair value of plan assets $ 2,068 $ 1,821 $ 906 $ 724 $ 733 $ 600 $ 429 $ 497 $ — $ — (a) As per applicable disclosure requirements, certain investments that were measured at net asset value per share or its equivalent have not been categorized within the fair value hierarchy. Values of such assets are based on the corroborated net asset value provided by the fund administrator. Fixed Income Securities U.S. pension plan assets categorized above as fixed income securities include fund investments comprised of mortgage-backed, corporate, government and agency and asset-backed instruments. Mortgage-backed securities consist of residential mortgage pass-through certificates. Investments in corporate bonds are diversified across industry and sector and consist of investment-grade, as well as high-yield debt instruments. U.S. government investments consist of obligations of the U.S. Treasury, other U.S. government agencies, state governments and local municipalities. Assets categorized as foreign government and agency debt securities included investments in developed and emerging markets. The values of fixed income investments classified within Level 1 are based on the closing price reported on the major market on which the investments are traded. A portion of the fixed income instruments classified within Level 2 are valued based upon estimated prices from independent vendors’ pricing models and these prices are derived from market observable sources including: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers and other market-related data. Equity Securities U.S. pension plan assets categorized as equity securities consist of fund investments in publicly-traded U.S. and non-U.S. equity securities. In order to achieve appropriate diversification, these portfolios are invested across market sectors, investment styles, capitalization weights and geographic regions. The values of equity securities classified within Level 1 are based on the closing price reported on the major market on which the investments are traded. Cash and Cash Equivalents A portion of the U.S. plans’ assets consists of investments in cash and cash equivalents, primarily to accommodate liquidity requirements relating to trade settlement and benefit payment activity, and the values of these assets are based upon quoted market prices. Other Securities Other U.S. pension plan assets include fund investments comprised of underlying assets of real estate, infrastructure, commodities and hedge funds. The values of such instruments classified within Level 1 are based on the closing price reported on the major market on which the investments are traded. International Plans International plan assets comprise 29% of the Company’s total benefit plan assets, based on market value at September 30, 2019 . Such plans have local independent fiduciary committees, with responsibility for development and oversight of investment policy, including asset allocation decisions. In making such decisions, consideration is given to local regulations, investment practices and funding rules. The following table provides the fair value measurements of international plan assets, as well as the measurement techniques and inputs utilized to measure fair value of these assets, at September 30, 2019 and 2018 . (Millions of dollars) Total International Plan Asset Balances Investments Measured at Net Asset Value (a) Quoted Prices in Significant Significant 2019 2018 2019 2018 2019 2018 2019 2018 2019 2018 Fixed Income: Corporate bonds $ 33 $ 28 $ — $ — $ 15 $ 14 $ 18 $ 14 $ — $ — Government and agency-U.S. 3 6 — — — 3 3 3 — — Government and agency-Foreign 199 150 — — 105 104 94 46 — — Other fixed income 100 96 — — 63 63 37 33 — — Equity securities 319 314 14 15 305 299 — — — — Cash and cash equivalents 8 9 — — 8 9 — — — — Real estate 30 30 — — — — 30 30 — — Insurance contracts 113 114 — — — — — — 113 114 Other 53 74 — — 52 55 1 20 — — Fair value of plan assets $ 859 $ 821 $ 14 $ 15 $ 549 $ 546 $ 182 $ 146 $ 113 $ 114 (a) As per applicable disclosure requirements, certain investments that were measured at net asset value per share or its equivalent have not been categorized within the fair value hierarchy. Values of such assets are based on the corroborated net asset value provided by the fund administrator. (b) Changes in the fair value of international pension assets measured using Level 3 inputs for the years ended September 30, 2019 and 2018 were immaterial. Fixed Income Securities Fixed income investments held by international pension plans include corporate, U.S. government and non-U.S. government securities. The values of fixed income securities classified within Level 1 are based on the closing price reported on the major market on which the investments are traded. Values of investments classified within Level 2 are based upon estimated prices from independent vendors’ pricing models and these prices are derived from market observable sources. Equity Securities Equity securities included in the international plan assets consist of publicly-traded U.S. and non-U.S. equity securities. The values of equity securities classified within Level 1 are based on the closing price reported on the major market on which the investments are traded. Other Securities The international plans hold a portion of assets in cash and cash equivalents, in order to accommodate liquidity requirements and the values are based upon quoted market prices. Real estate investments consist of investments in funds holding an interest in real properties and the corresponding values represent the estimated fair value based on the fair value of the underlying investment value or cost, adjusted for any accumulated earnings or losses. The values of insurance contracts approximately represent cash surrender value. Other investments include fund investments for which values are based upon either quoted market prices or market observable sources. Defined Contribution Plans The cost of voluntary defined contribution plans which provide for a Company match or contribution was $126 million in 2019 , $108 million in 2018 and $83 million in 2017

Acquisitions

Acquisitions	12 Months Ended
	Sep. 30, 2019
Business Combinations [Abstract]
Acquisitions	Acquisitions Bard On December 29, 2017, the Company completed its acquisition of Bard, to create a medical technology company which is uniquely positioned to improve both the treatment of disease for patients and the process of care for health care providers. Under the terms of the transaction, Bard common shareholders received approximately $222.93 in cash and 0.5077 shares of BD stock per Bard share. The Company financed the cash portion of total consideration transferred with available cash, which included net proceeds raised in the third quarter of fiscal year 2017 through registered public offerings of securities and debt transactions of approximately $4.8 billion and $9.6 billion , respectively. The operating activities of Bard from the acquisition date through December 31, 2017 were not material to the Company’s consolidated results of operations. As such, Bard's operating results were included in the Company’s consolidated results of operations beginning on January 1, 2018. The acquisition-date fair value of consideration transferred consisted of the components below. The fair value of the shares and equity awards issued as consideration was recognized as a $6.5 billion increase to Capital in excess of par value and a $2.1 billion decrease to Common stock in treasury. (Millions of dollars) Cash consideration $ 16,400 Non-cash consideration-fair value of shares issued 8,004 Non-cash consideration-fair value of equity awards issued 613 Total consideration transferred $ 25,017 The acquisition-date fair value of the Company’s ordinary shares issued to Bard shareholders was calculated per the following (shares in millions): (Millions of dollars, except per share data) Total Bard shares outstanding 73.359 Conversion factor 0.5077 Conversion of Bard shares outstanding 37.243 Conversion of pre-acquisition equity awards 0.104 Total number of the Company's share issued 37.347 Closing price of the Company’s stock $ 214.32 Fair value of the Company’s issued shares $ 8,004 Allocation of Consideration Transferred to Net Assets Acquired The majority of Bard's product offerings are reported, beginning with the second quarter of fiscal year 2018, under the Interventional segment and Bard's remaining product offerings are reported under the Company's Medical segment. The acquisition was accounted for under the acquisition method of accounting for business combinations. During the first quarter of fiscal year 2019, the Company finalized its allocation of the fair value of consideration transferred to the individual assets acquired and liabilities assumed in this acquisition, which resulted in no material adjustments to the allocation. The allocations of the purchase price below represent the estimated fair values of assets acquired and liabilities assumed in this acquisition, which were largely allocated to the Company's Interventional segment. (Millions of dollars) Cash and equivalents $ 1,480 Trade receivables 472 Inventories 974 Property, plant and equipment 553 Developed technology 10,469 Customer relationships 1,146 Other assets 661 Total identifiable assets acquired 15,755 Payables, accrued expenses and other liabilities 1,280 Short term and long-term debt 1,692 Product liability and other legal reserves 2,004 Deferred tax liabilities 1,686 Total liabilities assumed 6,663 Net identifiable assets acquired 9,093 Goodwill 15,924 Net assets acquired $ 25,017 Identifiable Intangible Assets Acquired The developed technology assets acquired represented Bard’s developed technologies in the fields of vascular, urology, oncology, and surgical specialties. The technologies’ fair values were determined based on the present value of projected cash flows utilizing an income approach with a risk-adjusted discount rate of 8% . The technologies will be amortized over an estimated weighted-average amortization period of 14 years , which is the weighted average period over which the technologies are expected to generate substantial cash flows. The customer relationships assets acquired represented Bard’s relationships with its customers. The fair value of these customer relationships was determined based on the present value of projected cash flows utilizing an income approach with a risk-adjusted discount rate of 8% . The estimated weighted-average amortization period of the customer relationships was determined to be 13 years and this period corresponds with the weighted average of lives determined for the product technology which underlies the customer contracts. Goodwill Goodwill typically results through expected synergies from combining operations of the acquiree and the acquirer, as well as from intangible assets that do not qualify for separate recognition. The goodwill recognized as a result of this acquisition includes, among other things, the value of combining the Company's leadership in medication management and infection prevention with an expanded offering of solutions across the care continuum. Additionally, Bard's strong product portfolio and innovation pipeline are expected to increase the Company's opportunities in fast-growing clinical areas. Revenue synergies are also expected to result from enhanced growth opportunities for the combined company in non-U.S. markets. No portion of goodwill from this acquisition was deductible for tax purposes. Amounts Related to Bard's Legal Proceedings and Claims Accruals for Bard-related product liability and other legal matters represented approximately $2.0 billion of the liabilities assumed. Cash and equivalents include a restricted cash balance acquired which largely represents funds that are restricted for certain product liability matters assumed. Additional disclosures regarding Bard's legal proceedings and claims are provided in Note 5 . The Tax Cuts and Job Act Transition Tax The net assets acquired included approximately $183 million of transition tax payable based on the Company’s best estimate of its transition tax liability under U.S. tax legislation which is further discussed in Note 17 . Transaction Costs Transaction costs related to this acquisition incurred during the years ended September 30, 2018 and 2017 were approximately $56 million and $25 million , respectively. These transaction costs were recorded as Acquisitions and other restructurings and consisted of legal, advisory and other costs. See Note 12 for discussion regarding restructuring costs incurred relative to the Bard acquisition. Unaudited Pro Forma Information As noted above, Bard's operating activities from the acquisition date through December 31, 2017 were not material and the Company included Bard in its consolidated results of operations beginning on January 1, 2018. Revenues in 2018 were $3 billion . Net Income in 2018 included loss attributable to Bard of $(107) million . The following table provides the pro forma results for the fiscal years 2018 and 2017 as if Bard had been acquired as of October 1, 2016. (Millions of dollars, except per share data) 2018 2017 Revenues $ 16,947 $ 15,781 Net Income $ 390 $ 1,145 Diluted Earnings per Share $ 0.90 $ 3.60 The pro forma results above include the impact of the following adjustments, as necessary: additional amortization and depreciation expense relating to assets acquired; interest and other financing costs relating to the acquisition transaction; and the elimination of one-time or nonrecurring items. The one-time or nonrecurring items eliminated for the year ended September 30, 2018 were primarily comprised of fair value step-up adjustments of $478 million recorded relative to Bard's inventory on the acquisition date, the transaction costs discussed above, as well as certain Bard-related restructuring costs disclosed in Note 12 . In addition, amounts previously reported by Bard as revenues related to a royalty income stream have been reclassified to Other income (expense), net to conform to the Company's reporting classification. The pro forma results do not include any anticipated cost savings or other effects of the planned integration of Bard. Accordingly, the pro forma results above are not necessarily indicative of the results that would have been if the acquisition had occurred on the dates indicated, nor are the pro forma results indicative of results which may occur in the future.

Divestiture

Divestiture	12 Months Ended
	Sep. 30, 2019
Discontinued Operations and Disposal Groups [Abstract]
Divestiture	Divestitures Advanced Bioprocessing The Company completed the sale of its Life Sciences segment's Advanced Bioprocessing business in October 2018 pursuant to a definitive agreement that was signed in September 2018. Assets held for sale on the consolidated balance sheet at September 30, 2018 , subject to this agreement, were approximately $137 million . Liabilities held for sale under the agreement were immaterial. The Company recognized a pre-tax gain on the sale of approximately $336 million which was recorded as a component of Other operating expense, net in fiscal year 2019 . The historical financial results for the Advanced Bioprocessing business have not been classified as a discontinued operation. Respiratory Solutions and Vyaire Medical On October 3, 2016, the Company sold a 50.1% controlling financial interest in its Respiratory Solutions business, a component of the Medical segment, to form a venture, Vyaire Medical. The Company retained a 49.9% non-controlling interest in the new standalone entity. The Company agreed to various contract manufacturing and certain logistical and transition services agreements with the new entity for a period of up to two years after the sale. The Company accounted for its remaining interest in the new entity as an equity method investment and recorded its share of the new entity's earnings or losses on a one-quarter lag to Other income (expense), net . In April 2018, the Company completed the sale of its remaining interest in Vyaire Medical. The Company received gross cash proceeds of approximately $435 million and recognized a pre-tax gain on the sale of approximately $303 million , which was recognized in Other income (expense), net .

Business Restructuring Charges

Business Restructuring Charges	12 Months Ended
	Sep. 30, 2019
Restructuring and Related Activities [Abstract]
Business Restructuring Charges	Business Restructuring Charges In connection with the Company's acquisition of Bard, the 2015 acquisition of CareFusion and portfolio rationalization initiatives, the Company incurred restructuring costs which were largely recorded within Acquisitions and other restructurings on its consolidated statements of income. Additional disclosures regarding these restructuring activities and the related costs are provided in Notes 8 , 10 and 11 . Restructuring liability activity in 2019 , 2018 and 2017 was as follows: Employee Termination Other Total (Millions of dollars) Bard Other Initiatives (a) Bard (b) Other Initiatives (a) Bard Other Initiatives (a) Balance at September 30, 2016 $ — $ 67 $ — $ 2 $ — $ 69 Charged to expense — 27 — 58 — 85 Cash payments — (45 ) — (12 ) — (57 ) Non-cash settlements — — — (9 ) — (9 ) Other adjustments — — — (33 ) — (33 ) Balance at September 30, 2017 $ — $ 49 $ — $ 6 $ — $ 55 Charged to expense 136 30 156 22 292 52 Cash payments (103 ) (56 ) (3 ) (23 ) (106 ) (79 ) Non-cash settlements — — (153 ) (1 ) (153 ) (1 ) Balance at September 30, 2018 $ 33 $ 23 $ — $ 4 $ 33 $ 27 Charged to expense 23 29 95 33 118 62 Cash payments (34 ) (21 ) (5 ) (31 ) (39 ) (52 ) Non-cash settlements — — (89 ) (3 ) (89 ) (3 ) Balance at September 30, 2019 $ 22 $ 31 $ 1 $ 3 $ 23 $ 34 (a) Restructuring costs in 2019, 2018 and 2017 included expenses related to the Company's acquisition of CareFusion in fiscal year 2015 and other initiatives. (b) Expenses in 2019 and 2018 largely represented the costs associated with the conversion of certain pre-acquisition equity awards of Bard which, to encourage post-acquisition employee retention, were converted to BD equity awards with substantially the same terms and conditions as were applicable under such Bard awards immediately prior to the acquisition date. Expenses in 2018 also included costs relating to Bard’s pension plan, partially offset by a gain on the sale of the Company's soft tissue core needle biopsy product line which was recorded in the second quarter of fiscal year 2018.

Intangible Assets

Intangible Assets	12 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets Intangible assets at September 30 consisted of: 2019 2018 (Millions of dollars) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Amortized intangible assets Developed technology $ 13,960 $ 2,906 $ 13,966 $ 1,782 Customer relationships 4,608 1,183 4,584 861 Product rights 110 60 121 58 Trademarks 407 102 407 84 Patents and other 445 305 397 288 Amortized intangible assets $ 19,530 $ 4,555 $ 19,475 $ 3,073 Unamortized intangible assets Acquired in-process research and development (a) $ 1 $ 37 Trademarks 2 2 Unamortized intangible assets $ 3 $ 39 (a) The decrease in the carrying value of assets in 2019 primarily reflected a write-down recorded in the third quarter by the Interventional segment's Surgery unit. Intangible amortization expense was $1.497 billion , $1.255 billion and $0.553 billion in 2019 , 2018 and 2017 , respectively. The increases in intangible amortization expense beginning in 2018 were attributable to assets acquired in the Bard transaction, which is further discussed in Note 10 . The estimated aggregate amortization expense for the fiscal years ending September 30, 2020 to 2024 are as follows: 2020 — $1.350 billion ; 2021 — $1.346 billion ; 2022 — $1.336 billion ; 2023 — $1.331 billion ; 2024 — $1.311 billion . The following is a reconciliation of goodwill by business segment: (Millions of dollars) Medical Life Sciences Interventional Total Goodwill as of September 30, 2017 $ 6,802 $ 761 $ — $ 7,563 Acquisitions (a) 3,923 76 11,218 15,217 Divestitures and related adjustments (b) — (59 ) (57 ) (116 ) Reallocation of goodwill for change in segment and reporting unit composition (c) (877 ) — 877 — Purchase price allocation adjustments (d) 228 (2 ) 732 959 Currency translation (22 ) (2 ) — (24 ) Goodwill as of September 30, 2018 $ 10,054 $ 775 $ 12,771 $ 23,600 Divestitures and related adjustments (b) — 3 — 3 Purchase price allocation adjustments (e) (15 ) — (75 ) (90 ) Currency translation (50 ) (6 ) (81 ) (137 ) Goodwill as of September 30, 2019 $ 9,989 $ 772 $ 12,615 $ 23,376 (a) Represents goodwill primarily recognized upon the Company's acquisition of Bard in fiscal year 2018, which is further discussed in Note 10 . Also includes goodwill recognized relative to certain acquisitions which were not material individually or in the aggregate. (b) Represents goodwill derecognized upon the Company's sale of certain businesses, as further discussed in Note 11 . (c) Represents the reassignment of goodwill, determined based upon a relative fair value allocation approach, associated with the movement of certain product offerings from the Medical segment to the Interventional segment in order to align with the reportable segment structure that became effective beginning in the second quarter of fiscal year 2018. (d) The purchase price allocation adjustments increasing goodwill were primarily driven by the valuation of Bard developed technology assets, the associated deferred tax liability changes, increases to legal reserves and the alignment of the combined organization's accounting policies with respect to accrued liabilities and other accounts. (e)

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	12 Months Ended
	Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	Derivative Instruments and Hedging Activities The Company uses derivative instruments to mitigate certain exposures. The Company does not enter into derivative financial instruments for trading or speculative purposes. The effects these derivative instruments and hedged items have on financial position, financial performance, and cash flows are provided below. Foreign Currency Risks and Related Strategies The Company has foreign currency exposures throughout Europe, Greater Asia, Canada and Latin America. Transactional currency exposures that arise from entering into transactions, generally on an intercompany basis, in non-hyperinflationary countries that are denominated in currencies other than the functional currency are mitigated primarily through the use of forward contracts. In order to mitigate foreign currency exposure relating to its investments in certain foreign subsidiaries, the Company has hedged the currency risk associated with those investments with instruments, such as foreign currency-denominated debt, cross-currency swaps and currency exchange contracts, which are designated as net investment hedges. Hedges of the transactional foreign exchange exposures resulting primarily from intercompany payables and receivables are undesignated hedges. As such, the gains or losses on these instruments are recognized immediately in income. These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. The net amounts recognized in Other income (expense), net , during the years ending September 30, 2019 , 2018 and 2017 were immaterial to the Company's consolidated financial results. The total notional amounts of the Company’s outstanding foreign exchange contracts as of September 30, 2019 and 2018 were $2.3 billion and $3.1 billion , respectively. Certain of the Company's foreign currency-denominated long-term notes outstanding, which had a total carrying value of $1.4 billion and $3.0 billion , as of September 30, 2019 and 2018 , respectively, were designated as, and were effective as, economic hedges of net investments in certain of the Company's foreign subsidiaries. In connection with the Company's issuance of Euro-denominated notes during the third quarter of fiscal year 2019, the Company entered into cross-currency swaps, as well as a forward contract, which were designated and effective as economic hedges of net investments in certain of the Company's foreign subsidiaries. The notional amount of the cross-currency swaps was $2.3 billion as of September 30, 2019 . The forward contract was terminated in the third quarter, in conjunction with the Company's issuance of the Euro-denominated notes. Additional disclosures regarding the Company's issuance of Euro-denominated notes in the third quarter of fiscal year 2019 are provided in Note 16 . Net gains or losses relating to the net investment hedges, which are attributable to changes in the foreign currencies to U.S. dollar spot exchange rates, are recorded as accumulated foreign currency translation in Other comprehensive income (loss) . Upon the termination of a net investment hedge, any net gain or loss included in Accumulated other comprehensive income (loss) relative to the investment hedge remains until the foreign subsidiary investment is disposed of or is substantially liquidated. Net gains (losses) recorded to Accumulated other comprehensive income (loss) relating to the Company's net investment hedges as of September 30, 2019 and 2018 were as follows: (Millions of dollars) 2019 2018 Foreign currency-denominated debt $ 138 $ 81 Cross-currency swaps $ 73 $ — Foreign currency forward contract $ (9 ) $ — Interest Rate Risks and Related Strategies The Company’s primary interest rate exposure results from changes in U.S. dollar interest rates. The Company’s policy is to manage interest cost using a mix of fixed and variable rate debt. The Company periodically uses interest rate swaps to manage such exposures. Under these interest rate swaps, the Company exchanges, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. These swaps are designated as either fair value or cash flow hedges. For interest rate swaps designated as fair value hedges (i.e., hedges against the exposure to changes in the fair value of an asset or a liability or an identified portion thereof that is attributable to a particular risk), changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt due to changes in market interest rates. The total notional amount of the Company’s outstanding interest rate swaps designated as fair value hedges was $375 million and $1.2 billion at September 30, 2019 and 2018 , respectively. The outstanding swaps represent fixed-to-floating interest rate swap agreements the Company entered into to convert the interest payments on certain long-term notes from the fixed rate to a floating interest rate based on LIBOR. Changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt. The amounts recorded during the years ended September 30, 2019 and 2018 for changes in the fair value of these hedges were immaterial to the Company's consolidated financial results. Changes in the fair value of the interest rate swaps designated as cash flow hedges (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk) are recorded in Other comprehensive income (loss) . If interest rate derivatives designated as cash flow hedges are terminated, the balance in Accumulated other comprehensive income (loss) attributable to those derivatives is reclassified into earnings over the remaining life of the hedged debt. The net realized loss related to terminated interest rate swaps expected to be reclassified and recorded in Interest expense within the next 12 months is $6 million , net of tax. The total notional value of the Company's outstanding forward starting interest rate swaps was $1.5 billion at September 30, 2019 . The Company entered into these contracts in August 2019 to mitigate its exposure to interest rate risk. The amounts recognized in other comprehensive income relating to interest rate hedges during the year ended September 30, 2019 were immaterial. The Company had no outstanding interest rate swaps designated as cash flow hedges at September 30, 2018 . Other Risk Exposures The Company purchases resins, which are oil-based components used in the manufacture of certain products. Significant increases in world oil prices that lead to increases in resin purchase costs could impact future operating results. From time to time, the Company has managed price risks associated with these commodity purchases through commodity derivative forward contracts. The Company's outstanding commodity derivative forward contracts at September 30, 2019 were immaterial to the Company's consolidated financial results. The Company had no outstanding commodity derivative forward contracts at September 30, 2018 . Financial Statement Effects The fair values of derivative instruments outstanding at September 30, 2019 and 2018 were not material to the Company's consolidated balance sheets. The amounts reclassified from accumulated other comprehensive income relating to cash flow hedges during 2019 , 2018 and 2017 were not material to the Company's consolidated financial results.

Financial Instruments and Fair

Financial Instruments and Fair Value Measurements	12 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measurements	Financial Instruments and Fair Value Measurements The following reconciles cash and equivalents and restricted cash reported within the Company's consolidated balance sheets at September 30, 2019 and 2018 to the total of these amounts shown on the Company's consolidated statements of cash flows: (Millions of dollars) September 30, 2019 September 30, 2018 Cash and equivalents $ 536 $ 1,140 Restricted cash 54 96 Cash and equivalents and restricted cash $ 590 $ 1,236 The Company’s cash and equivalents include institutional money market accounts which permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions, which are considered Level 1 inputs in the fair value hierarchy. The fair values of these accounts were $39 million and $228 million at September 30, 2019 and 2018 , respectively. The Company’s remaining cash and equivalents, excluding restricted cash, were $497 million and $913 million at September 30, 2019 and 2018 , respectively. Short-term investments are held to their maturities and are carried at cost, which approximates fair value. The short-term investments consist of instruments with maturities greater than three months and less than one year . Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments, which are considered Level 2 inputs in the fair value hierarchy. The fair value of long-term debt was $19.2 billion and $18.8 billion at September 30, 2019 and 2018 , respectively. The fair value of the current portion of long-term debt was $1.3 billion and $1.9 billion at September 30, 2019 and 2018 , respectively. All other instruments measured by the Company at fair value, including derivatives and contingent consideration liabilities, are immaterial to the Company's consolidated balance sheets. Nonrecurring Fair Value Measurements In fiscal year 2019, the Company recorded a charge of $30 million to write down the carrying value of certain intangible assets in the Surgery unit. In fiscal year 2018, the Company recorded charges of $58 million to write down the value of fixed assets, primarily in the Diabetes Care unit, as well as charges of $81 million to write down the carrying value of certain intangible and other assets in the Biosciences unit. The amounts recognized in 2019 and 2018 were recorded to adjust the carrying amount of assets to the assets' fair values, which were estimated, based upon a market participant's perspective, using either Level 2 inputs, including quoted prices for similar assets, or Level 3 inputs, including values estimated using the income approach. Concentration of Credit Risk The Company maintains cash deposits in excess of government-provided insurance limits. Such cash deposits are exposed to loss in the event of nonperformance by financial institutions. Substantially all of the Company’s trade receivables are due from public and private entities involved in the healthcare industry. Due to the large size and diversity of the Company’s customer base, concentrations of credit risk with respect to trade receivables are limited. The Company does not normally require collateral. The Company is exposed to credit loss in the event of nonperformance by financial institutions with which it conducts business. However, this loss is limited to the amounts, if any, by which the obligations of the counterparty to the financial instrument contract exceed the obligations of the Company. The Company also minimizes exposure to credit risk by dealing with a diversified group of major financial institutions. The Company continually evaluates its accounts receivables for potential collection risks particularly those resulting from sales to government-owned or government-supported healthcare facilities in certain countries as payment may be dependent upon the financial stability and creditworthiness of those countries’ national economies. The Company continually evaluates all governmental receivables for potential collection risks associated with the availability of government funding and reimbursement practices. The Company believes the current reserves related to all governmental receivables are adequate and that this concentration of credit risk will not have a material adverse impact on its financial position or liquidity.

Debt

Debt	12 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Debt	Debt Short-term debt The carrying value of Short-term debt , net of unamortized debt issuance costs, at September 30 consisted of: (Millions of dollars) 2019 2018 Current portion of long-term debt 2.675% Notes due December 15, 2019 (a) $ 300 $ — 2.404% Notes due June 5, 2020 999 — 2.133% Notes due June 6, 2019 — 724 0.368% Notes due June 6, 2019 (a) — 1,157 Term Loan Facility due September 5, 2019 (b) — 710 Other 10 10 Total short-term debt $ 1,309 $ 2,601 (a) All or a portion of the aggregate principal amount outstanding was redeemed or repaid during 2019, as further discussed below. (b) Term loan facility entered into during the fourth quarter of fiscal year 2018, as further discussed below. The weighted average interest rates for short-term debt were 2.48% and 1.58% at September 30, 2019 and 2018 , respectively. Long-term debt The carrying value of Long-Term Debt , net of unamortized debt issuance costs, at September 30 consisted of: (Millions of dollars) 2019 2018 2.675% Notes due December 15, 2019 $ — $ 1,123 2.404% Notes due June 5, 2020 — 998 3.250% Notes due November 12, 2020 699 699 Floating Rate Notes due December 29, 2020 (a) 748 996 0.174% Notes due June 4, 2021 (b) 651 — 3.125% Notes due November 8, 2021 1,004 990 2.894% Notes due June 6, 2022 1,795 1,793 Floating Rate Notes due June 6, 2022 498 498 1.000% Notes due December 15, 2022 542 576 Revolving Credit Facility due December 29, 2022 480 — 3.300% Notes due March 1, 2023 295 296 1.401% Notes due May 24, 2023 325 346 0.632% Notes due June 4, 2023 (b) 867 — 3.875% Notes due May 15, 2024 181 182 3.363% Notes due June 6, 2024 1,740 1,738 3.734% Notes due December 15, 2024 1,369 1,368 3.020% Notes due May 24, 2025 306 324 1.208% Notes due June 4, 2026 (b) 649 — 6.700% Notes due December 1, 2026 (c) 174 177 1.900% Notes due December 15, 2026 541 575 3.700% Notes due June 6, 2027 (a) 1,714 2,383 7.000% Debentures due August 1, 2027 175 156 6.700% Debentures due August 1, 2028 175 154 6.000% Notes due May 15, 2039 246 246 5.000% Notes due November 12, 2040 (a) 124 296 4.875% Notes due May 15, 2044 (a) 248 331 4.685% Notes due December 15, 2044 (a) 1,045 1,159 4.669% Notes due June 6, 2047 1,485 1,484 Other long-term debt 5 8 Total Long-Term Debt $ 18,081 $ 18,894 (a) A portion of the aggregate principal amount outstanding was redeemed or repurchased during 2019, as further discussed below. (b) Includes notes issued during 2019, as further discussed below. (c) Includes notes assumed in connection with the Company's acquisition of Bard, as further discussed below. The aggregate annual maturities of debt including interest during the fiscal years ending September 30, 2020 to 2024 are as follows: 2020 — $1.9 billion ; 2021 — $2.6 billion ; 2022 — $3.7 billion ; 2023 — $2.9 billion ; 2024 — $2.3 billion . Other current credit facilities In May 2017, the Company entered into a five -year senior unsecured revolving credit facility which provides borrowing of up to $2.25 billion . This facility will expire in December 2022. Under the revolving facility, the Company is able to issue up to $100 million in letters of credit and it also includes a provision that enables the Company, subject to additional commitments made by the lenders, to access up to an additional $500 million in financing through the facility for a maximum aggregate commitment of $2.75 billion . Borrowings outstanding under the revolving credit facility at September 30, 2019 were $485 million . There were no borrowings outstanding under the revolving credit facility at September 30, 2018 . In addition, the Company has informal lines of credit outside of the United States. During the fourth quarter of 2019, the Company fully repaid its borrowings outstanding on a 364 -day senior unsecured term loan facility that the Company entered in September 2018. The Company had no commercial paper borrowings outstanding as of September 30, 2019 . 2019 Debt-Related Transactions In March 2019, the Company redeemed an aggregate principal amount of $250 million of its outstanding floating rate senior unsecured U.S. notes due December 29, 2020. Based upon the $249 million carrying value of the notes redeemed and the $250 million the Company paid to redeem the aggregate principal amount of the notes, the Company recorded a loss on this debt extinguishment transaction in the second quarter of fiscal year 2019 of $1 million as Other income (expense), net , on its consolidated statements of income. In June 2019, Becton Dickinson Euro Finance S.à r.l., a private limited liability company (société à responsabilité limitée), which is an indirect, wholly-owned finance subsidiary of the Company, issued Euro-denominated debt consisting of 600 million Euros ( $672 million ) of 0.174% notes due June 4, 2021, 800 million Euros ( $896 million ) of 0.632% notes due June 4, 2023, and 600 million Euros ( $672 million ) of 1.208% notes due June 4, 2026. The notes are fully and unconditionally guaranteed on a senior unsecured basis by the Company. No other of the Company's subsidiaries provide any guarantees with respect to these notes. The indenture covenants include a limitation on liens and a restriction on sale and leasebacks, change of control and consolidation, merger and sale of assets covenants. These covenants are subject to a number of exceptions, limitations and qualifications. The indenture does not restrict the Company, Becton Dickinson Euro Finance S.à r.l., or any other of the Company's subsidiaries from incurring additional debt or other liabilities, including additional senior debt. Additionally, the indenture does not restrict Becton Dickinson Euro Finance S.à r.l. and the Company from granting security interests over its assets. The Company used the net proceeds from this long-term debt offering, together with cash on hand, to repay all the 1.000 billion Euros ( $1.120 billion ) of principal outstanding on 0.368% notes due June 6, 2019, as well as to fund the Company's repurchase of certain of its long-term senior notes outstanding. Under this cash tender offer, the Company repurchased the following aggregate principal amounts of its long-term debt at an aggregate market price of $1.169 billion : Interest Rate and Maturity Aggregate Principal Amount (Millions of dollars) 3.700% Notes due June 6, 2027 $ 675 5.000% Notes due November 12, 2040 175 4.875% Notes due May 15, 2044 75 4.685% Notes due December 15, 2044 175 Total notes purchased $ 1,100 The carrying value of these long-term notes was $1.112 billion , and the Company recognized a loss on this debt extinguishment of $57 million , which was recorded in June 2019 as Other income (expense), net , on the Company’s consolidated statements of income. In September 2019, the Company redeemed an aggregate principal amount of $825 million of its outstanding 2.675% notes due December 15, 2019. Based upon the $825 million carrying value of the notes redeemed and the $826 million the Company paid to redeem the aggregate principal amount of the notes, the Company recorded a loss on this debt extinguishment transaction in the fourth quarter of fiscal year 2019 of $1 million as Other income (expense), net , on its consolidated statements of income. 2018 Debt-Related Transactions In connection with the Company's acquisition of Bard, the Company exchanged certain outstanding notes issued by Bard for a like-amount of new notes issued by the Company. The exchange offers, which were conditioned upon the closing of the Bard acquisition, expired on December 29, 2017. The aggregate principal amounts of Bard notes which were validly tendered for notes issued by the Company are provided below. (Millions of dollars) Interest Rate and Maturity Aggregate Principal Amount Principal Amount Accepted for Exchange 4.400% Notes due January 15, 2021 $ 500 $ 432 3.000% Notes due May 15, 2026 500 470 6.700% Notes due December 1, 2026 150 137 Total $ 1,150 $ 1,039 This exchange transaction was accounted for as a modification of the assumed debt instruments. Following the exchange of the notes, the aggregate principal amount of Bard notes that remained outstanding after settlement of the exchange transaction was $111 million . In January 2018, the Company commenced an offer to repurchase any and all of the outstanding 3.000% Notes due May 15, 2026 that were issued as a result of the exchange transaction discussed above. Under the terms of the repurchase offer, holders were entitled to receive cash equal to 101% of the principal amount of notes validly tendered, plus accrued and unpaid interest, if any, to the date of purchase. The offer to repurchase the 3.000% Notes expired on March 1, 2018 and a total of $461 million aggregate principal amount of notes were validly tendered at a market price of $465 million . Based upon the carrying value of $452 million , the Company recorded a loss relating to this debt extinguishment in the second quarter of fiscal year 2018 of $13 million as Other income (expense), net , on its consolidated statements of income. During the second quarter of fiscal year 2018, the Company issued Euro-denominated debt consisting of 300 million Euros ( $370 million ) of 0.368% notes due June 6, 2019 under an indenture pursuant to which the Company previously issued, in the third quarter of fiscal year 2017, 0.368% notes due June 6, 2019. Also in the second quarter of fiscal year 2018, the Company issued $1 billion of floating rate senior unsecured U.S. notes due December 29, 2020. The Company used the net proceeds from these long-term debt offerings to repay portions of the balances outstanding on its term loan and revolving credit facilities, which are discussed above, as well as accrued interest, related premiums, fees and expenses related to these repaid amounts. In June 2018, the Company redeemed all of the 4.400% Notes due January 15, 2021 and 3.000% Notes due May 15, 2026 which were issued by Bard and that remained outstanding after the exchange offer discussed above. Also in June 2018, the Company redeemed all of the 4.400% Notes due January 15, 2021 which were issued by the Company upon the exchange offer, as well as all of the 3.000% Notes due May 15, 2026 issued by the Company which remained outstanding after the repurchase offer also discussed above. The total aggregate principal amount of notes redeemed was $539 million . Based upon the $556 million carrying value of these notes and the $559 million the Company paid to redeem the aggregate principal amount of the notes, the Company recorded a loss on these debt extinguishment transactions in the third quarter of fiscal year 2018 of $3 million as Other income (expense), net , on its consolidated statements of income. During the third quarter of fiscal year 2018, the Company issued Euro-denominated debt consisting of 300 million Euros ( $354 million ) of 1.401% notes due May 24, 2023. Also in the third quarter of fiscal year 2018, the Company issued British Pound-denominated debt of 250 million British Pounds ( $337.5 million ) of 3.02% notes due May 24, 2025. The Company used the net proceeds from these long-term debt offerings to redeem certain notes in the third quarter and to repay a portion of the balance outstanding on its term loan, as well as accrued interest, related premiums, fees and expenses related to this repaid amount. Capitalized interest The Company capitalizes interest costs as a component of the cost of construction in progress. A summary of interest costs and payments for the years ended September 30 is as follows: (Millions of dollars) 2019 2018 2017 Charged to operations $ 639 $ 706 $ 521 Capitalized 44 42 32 Total interest costs $ 683 $ 748 $ 553 Interest paid, net of amounts capitalized $ 658 $ 674 $ 435

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Provision for Income Taxes The provision for income taxes the years ended September 30 consisted of: (Millions of dollars) 2019 2018 2017 Current: Federal $ 235 $ 665 $ (230 ) State and local, including Puerto Rico 41 73 (20 ) Foreign 300 387 200 $ 576 $ 1,124 $ (50 ) Deferred: Domestic $ (566 ) $ (201 ) $ (64 ) Foreign (67 ) (61 ) (10 ) (633 ) (262 ) (74 ) Income tax (benefit) provision $ (57 ) $ 862 $ (124 ) The components of Income Before Income Taxes for the years ended September 30 consisted of: (Millions of dollars) 2019 2018 2017 Domestic, including Puerto Rico $ 1,340 $ (135 ) $ (386 ) Foreign (164 ) 1,308 1,362 Income Before Income Taxes $ 1,176 $ 1,173 $ 976 U.S. tax legislation, commonly referred to as the Tax Cuts and Jobs Act (the "Act"), was enacted on December 22, 2017. The Act reduced the U.S. federal corporate tax rate from 35% to 21% , required companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred, and created new taxes on certain foreign-sourced earnings. During fiscal year 2019 , the Company finalized its accounting for the income tax effects of the Act, and all adjustments related to finalization of its calculations were included as a component of Income tax (benefit) provision in fiscal year 2019 . The Company recognized additional tax benefit of $50 million and additional tax cost of $640 million in 2019 and 2018 , respectively, as a result of this legislation. These amounts are reflected in the Company's consolidated statements of income within Income tax (benefit) provision . The Act subjects a U.S. shareholder to tax on global intangible low-taxed income ("GILTI") earned by certain foreign subsidiaries. The Company has elected to account for its GILTI tax due as a period expense in the year the tax is incurred. The Company has analyzed its U.S. cash needs in conjunction with the Internal Revenue Service ("IRS") and Treasury Regulations that were released during fiscal year 2019 and has concluded that it will assert indefinite reinvestment for all historical unremitted foreign earnings as of September 30, 2019. As a result of the change in assertion, the deferred tax liability recorded in connection with the hypothetical repatriation of the unremitted foreign earnings was reversed during the fourth quarter of fiscal 2019 . The change in assertion resulted in a total tax benefit of $138 million , of which $67 million is related to the tax legislation benefit previously recorded, and is included as a component of Income tax (benefit) provision in fiscal 2019. Unrecognized Tax Benefits The table below summarizes the gross amounts of unrecognized tax benefits without regard to reduction in tax liabilities or additions to deferred tax assets and liabilities if such unrecognized tax benefits were settled. The Company believes it is reasonably possible that the amount of unrecognized benefits will change due to one or more of the following events in the next twelve months: expiring statutes, audit activity, tax payments, other activity, or final decisions in matters that are the subject of controversy in various taxing jurisdictions in which we operate. (Millions of dollars) 2019 2018 2017 Balance at October 1 $ 543 $ 349 $ 469 Increase due to acquisitions 3 140 — Increase due to current year tax positions 11 43 41 Increase due to prior year tax positions 6 43 19 Decreases due to prior year tax positions (39 ) — (30 ) Decrease due to settlements with tax authorities — (29 ) (145 ) Decrease due to lapse of statute of limitations (5 ) (3 ) (5 ) Balance at September 30 $ 519 $ 543 $ 349 Upon the Company's acquisition of CareFusion in 2015, the Company became a party to a tax matters agreement with Cardinal Health resulting from Cardinal Health's spin-off of CareFusion in fiscal year 2010. Under the tax matters agreement, the Company is obligated to indemnify Cardinal Health for certain tax exposures and transaction taxes prior to CareFusion’s spin-off from Cardinal Health. The indemnification payable is approximately $156 million at September 30, 2019 and is included in Deferred Income Taxes and Other on the consolidated balance sheet. At September 30, 2019 , 2018 and 2017 , there are $624 million , $632 million and $415 million of unrecognized tax benefits that if recognized, would affect the effective tax rate. During the fiscal years ended September 30, 2019 , 2018 and 2017 , the Company reported interest and penalties associated with unrecognized tax benefits of $26 million , $20 million and $57 million on the consolidated statements of income as a component of Income tax (benefit) provision . The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of tax jurisdictions. The IRS has completed its audit for fiscal year 2014 for the BD business prior to its acquisition of CareFusion. The IRS has also completed its audit for fiscal years 2016 and 2017 for the combined BD and CareFusion business. For the BD legacy business, all years are effectively settled with the exception of 2015 for which the Company believes it is adequately reserved for any potential exposures. The IRS is currently examining the CareFusion legacy fiscal year 2014 and short period 2015. With the exception of the CareFusion legacy fiscal year 2010 audit, all other periods are at various stages of appeals or protests. With regard to Bard, all examinations have been completed through calendar year 2014. The IRS has commenced the examination of calendar years 2015, 2016 and 2017. For the other major tax jurisdictions where the Company conducts business, tax years are generally open after 2013 . Deferred Income Taxes Deferred income taxes at September 30 consisted of: 2019 2018 (Millions of dollars) Assets Liabilities Assets Liabilities Compensation and benefits $ 513 $ — $ 458 $ — Property and equipment — 255 — 253 Intangibles — 2,624 — 2,948 Loss and credit carryforwards 1,327 — 1,290 — Other 634 189 707 384 2,474 3,068 2,455 3,585 Valuation allowance (1,240 ) — (1,181 ) — Net (a) $ 1,234 $ 3,068 $ 1,275 $ 3,585 (a) Net deferred tax assets are included in Other Assets and net deferred tax liabilities are included in Deferred Income Taxes and Other on the consolidated balance sheets . Deferred tax assets and liabilities are netted on the balance sheet by separate tax jurisdictions. Deferred taxes have not been provided on undistributed earnings of foreign subsidiaries as of September 30, 2019 since the determination of the total amount of unrecognized deferred tax liability is not practicable. Generally, deferred tax assets have been established as a result of net operating losses and credit carryforwards with expiration dates from 2020 to an unlimited expiration date. Valuation allowances have been established as a result of an evaluation of the uncertainty associated with the realization of certain deferred tax assets on these losses and credit carryforwards. The valuation allowance at September 30, 2019 is primarily the result of foreign losses due to the Company’s global re-organization of its foreign entities and these generally have no expiration date. Valuation allowances are also maintained with respect to deferred tax assets for certain federal and state carryforwards that may not be realized and that principally expire in 2022 . Tax Rate Reconciliation A reconciliation of the federal statutory tax rate to the Company’s effective income tax rate was as follows: 2019 2018 2017 Federal statutory tax rate 21.0 % 24.5 % 35.0 % New U.S. tax legislation (see discussion above) (4.3 ) 54.6 — State and local income taxes, net of federal tax benefit 0.1 0.8 (2.6 ) Effect of foreign and Puerto Rico (losses) earnings and foreign tax credits (12.2 ) 7.3 (40.8 ) Effect of Research Credits and FDII/Domestic Production Activities (3.3 ) (2.8 ) (2.7 ) Effect of change in accounting for excess tax benefit relating to share-based compensation (see Note 2) (4.7 ) (6.7 ) (7.9 ) Effect of gain on divestitures (2.0 ) 1.3 — Effect of uncertain tax position — 3.3 — Effect of valuation allowance release — (4.8 ) — Effect of application for change in accounting method — (4.5 ) — Effect of nondeductible compensation — 1.6 — Other, net 0.6 (1.1 ) 6.3 Effective income tax rate (4.8 )% 73.5 % (12.7 )% The Company has reassessed its permanent reinvestment assertion that was in effect as of September 30, 2018 in light of the IRS and Treasury Regulations that were released in June of 2019 and the impact of certain transactions that were executed in the fourth quarter of fiscal 2019. The Company changed its assertion such that the Company is now permanently reinvested with respect to all of its historical foreign earnings as of September 30, 2019 . The Company recorded a benefit of $138 million within Income tax (benefit) provision in 2019 as a result of this change in its permanent reinvestment assertion. Tax Holidays and Payments The approximate amounts of tax reductions related to tax holidays in various countries in which the Company does business were $157 million , $107 million and $146 million , in 2019 , 2018 and 2017 , respectively. The benefit of the tax holiday on diluted earnings per share was approximately $0.57 , $0.40 and $0.65 for fiscal years 2019 , 2018 and 2017 , respectively. The tax holidays expire at various dates through 2028. The Company made income tax payments, net of refunds, of $536 million in 2019 , $235 million in 2018 and $265 million in 2017 .

Sale-Type Leases and Financing

Sale-Type Leases and Financing Receivables	12 Months Ended
	Sep. 30, 2019
Receivables [Abstract]
Sale-Type Leases and Financing Receivable	Sales-Type Leases and Financing Receivables In April 2017, in conjunction with the implementation of a new “go-to-market” business model for the Company's U.S. dispensing business within the Medication Management Solutions (“MMS”) unit of the Medical segment, the Company amended the terms of certain customer leases for dispensing equipment within the MMS unit. The modification provided customers the ability to reduce its dispensing asset base via a return provision, resulting in a more flexible lease term. Prior to the modification, these leases were accounted for as sales-type leases in accordance with Accounting Standards Codification Topic 840, "Leases", as the non-cancellable lease term of 5 years exceeded 75% of the equipment’s estimated useful life and the present value of the minimum lease payments exceeded 90% of the equipment’s fair value. As a result of the lease modification, the Company was required to reassess the classification of the leases due to the amended lease term. Accordingly, most amended lease contracts were classified as operating leases beginning in April 2017. The change in lease classification resulted in a pre-tax charge to earnings in fiscal year 2017 of $748 million , which was recorded in Other operating expense, net. Beginning April 1, 2017, revenue associated with these modified contracts has been recognized on a straight-line basis over the remaining lease term, along with depreciation on the reinstated leased assets. The Company's consolidated financial results in 2019 and 2018 were not materially impacted by the financing receivables remaining subsequent to the lease modification discussed above.

Supplemental Financial Informat

Supplemental Financial Information	12 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Financial Information	Supplemental Financial Information Other Income (Expense), Net (Millions of dollars) 2019 2018 2017 Royalty income (a) $ 64 $ 51 $ — Hurricane-related insurance proceeds 35 — — Vyaire Medical-related amounts and other income from divestitures (b) 6 288 (3 ) Other investment gains/losses 18 8 3 Net pension and postretirement benefit cost (c) (2 ) (13 ) (44 ) Losses on undesignated foreign exchange derivatives, net (23 ) (14 ) (11 ) Losses on debt extinguishment (d) (59 ) (16 ) (73 ) Gains on previously held investments (e) — — 24 Other 4 — 3 Other income (expense), net $ 43 $ 305 $ (101 ) (a) Primarily represents the royalty income stream acquired in the Bard transaction, net of non-cash purchase accounting amortization. The royalty income stream was previously reported by Bard as revenues. (b) The amount in 2019 represents income from transition services agreements (“TSA”) related to the Company’s 2018 and 2017 divestitures. The amount in 2018 includes the gain on the sale of the remaining ownership interest in its former Respiratory Solutions business and subsequent TSA income, net of the Company's share of equity investee results in the business. The amount in 2017 represents the Company’s share of equity investee results in the former business, net of TSA income. Additional disclosures regarding the Company’s divestiture transactions are provided in Note 11 . (c) Represents all components of the Company’s net periodic pension and postretirement benefit costs, aside from service cost, as a result of the adoption of an accounting standard as further discussed in Note 2 . (d) Represents losses recognized upon the extinguishment of certain senior notes, as further discussed in Note 16 . (e) Represents an acquisition-date accounting gain related to a previously-held equity method investment in an entity the Company acquired. Trade Receivables, Net The amounts recognized in 2019 , 2018 and 2017 relating to allowances for doubtful accounts and cash discounts, which are netted against trade receivables, are provided in the following table: (Millions of dollars) Allowance for Doubtful Accounts Allowance for Cash Discounts Total Balance at September 30, 2016 $ 61 $ 6 $ 67 Additions charged to costs and expenses 25 43 68 Deductions and other (32 ) (a) (45 ) (76 ) Balance at September 30, 2017 $ 54 $ 4 $ 58 Additions charged to costs and expenses 31 58 89 Deductions and other (11 ) (a) (50 ) (61 ) Balance at September 30, 2018 $ 75 $ 12 $ 86 Additions charged to costs and expenses 31 94 125 Deductions and other (31 ) (a) (92 ) (123 ) Balance at September 30, 2019 $ 75 $ 13 $ 88 (a) Accounts written off. Inventories Inventories at September 30 consisted of: (Millions of dollars) 2019 2018 Materials $ 544 $ 510 Work in process 318 297 Finished products 1,717 1,644 $ 2,579 $ 2,451 Property, Plant and Equipment, Net Property, Plant and Equipment, Net at September 30 consisted of: (Millions of dollars) 2019 2018 Land $ 164 $ 173 Buildings 2,842 2,724 Machinery, equipment and fixtures 7,932 7,405 Leasehold improvements 190 182 11,128 10,485 Less accumulated depreciation and amortization 5,469 5,111 $ 5,659 $ 5,375

Supplementary Data (Unaudited)

Supplementary Data (Unaudited)	12 Months Ended
	Sep. 30, 2019
Quarterly Financial Information Disclosure [Abstract]
Supplemental Financial Data (Unaudited)	SUPPLEMENTARY QUARTERLY DATA (UNAUDITED) Millions of dollars, except per share amounts 2019 1 st 2 nd 3 rd 4 th Year (a) Revenues $ 4,160 $ 4,195 $ 4,350 $ 4,584 $ 17,290 Gross Profit 1,974 1,974 2,074 2,266 8,288 Net Income 599 20 451 163 1,233 Earnings (loss) per Share: Basic 2.09 (0.07 ) 1.53 0.46 4.01 Diluted 2.05 (0.07 ) 1.51 0.45 3.94 2018 1 st 2 nd 3 rd 4 th Year (a) Revenues $ 3,080 $ 4,222 $ 4,278 $ 4,402 $ 15,983 Gross Profit 1,553 1,606 2,017 2,094 7,269 Net (Loss) Income (136 ) (12 ) 594 (135 ) 311 (Loss) earnings per Share: (b) Basic (0.76 ) (0.19 ) 2.08 (0.64 ) 0.62 Diluted (0.76 ) (0.19 ) 2.03 (0.64 ) 0.60 (a) Quarterly amounts may not add to the year-to-date totals due to rounding. Earnings per share amounts are calculated from the underlying whole-dollar amounts. (b) The sums of basic and diluted earnings per share for the quarters of 2018 do not equal year-to-date amounts due to the impacts of shares issued during this fiscal year, in connection with the Bard acquisition, on the weighted average common shares included in the calculations of basic and diluted earnings per share. Additional disclosures regarding shares issued related to the Bard acquisition are provided in Notes 3 and 10.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying Consolidated Financial Statements and Notes to Consolidated Financial Statements of Becton, Dickinson and Company (the “Company” or "BD") have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). Within the financial statements and tables presented, certain columns and rows may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. Our fiscal year ends on September 30.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the Company’s accounts and those of its majority-owned subsidiaries after the elimination of intercompany transactions. The Company has no material interests in variable interest entities.
Cash Equivalents	Cash Equivalents Cash equivalents consist of all highly liquid investments with a maturity of three months or less at time of purchase.
Restricted Cash	Restricted Cash Restricted cash consists of cash restricted from withdrawal and usage and largely represents funds that are restricted for certain product liability matters assumed in the acquisition of C.R. Bard, Inc. ("Bard") which is further discussed in Note 10 .
Trade and Financing Receivables	Trade Receivables The Company grants credit to customers in the normal course of business and the resulting trade receivables are stated at their net realizable value. The allowance for doubtful accounts represents the Company’s estimate of probable credit losses relating to trade receivables and is determined based on historical experience and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectible.
Inventories	Inventories Inventories are stated at the lower of approximate cost determined on the first-in, first-out basis or market.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are principally provided on the straight-line basis over estimated useful lives, which range from 20 to 45 years for buildings, four to 13 years for machinery and equipment and one to 20
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets The Company’s unamortized intangible assets include goodwill which arise from acquisitions. The Company currently reviews goodwill for impairment using quantitative models. Goodwill is reviewed at least annually for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. The Company’s reporting units generally represent one level below reporting segments. Potential impairment of goodwill is generally identified by comparing the fair value of a reporting unit, estimated using an income approach, with its carrying value. The annual impairment review performed on July 1, 2019 indicated that all identified reporting units’ fair values exceeded their respective carrying values. Amortized intangible assets include developed technology assets which arise from acquisitions. These assets represent acquired intellectual property that is already technologically feasible upon the acquisition date or acquired in-process research and development assets that are completed subsequent to acquisition. Developed technology assets are generally amortized over periods ranging from 15 to 20 years, using the straight-line method. Customer relationship assets are generally amortized over periods ranging from 10 to 15 years, using the straight-line method. Other intangibles with finite useful lives, which include patents, are amortized over periods principally ranging from one to 40 years, using the straight-line method. Finite-lived intangible assets, including developed technology assets, are periodically reviewed when impairment indicators are present to assess recoverability from future operations using undiscounted cash flows. The carrying values of these finite-lived assets are compared to the undiscounted cash flows they are expected to generate and an impairment loss is recognized in operating results to the extent any finite-lived intangible asset’s carrying value exceeds its calculated fair value.
Foreign Currency Translation	Foreign Currency Translation Generally, foreign subsidiaries’ functional currency is the local currency of operations and the net assets of foreign operations are translated into U.S. dollars using current exchange rates. The U.S. dollar results that arise from such translation, as well as exchange gains and losses on intercompany balances of a long-term investment nature, are included in the foreign currency translation adjustments in Accumulated other comprehensive income (loss).
Revenue Recognition	Revenue Recognition The Company recognizes revenue from product sales when the customer obtains control of the product, which is generally upon shipment or delivery, depending on the delivery terms specified in the sales agreement. Revenues associated with certain instruments and equipment for which installation is complex, and therefore significantly affects the customer’s ability to use and benefit from the product, are recognized upon customer acceptance of these installed products. Revenue for certain service arrangements, including extended warranty and software maintenance contracts, is recognized ratably over the contract term. When arrangements include multiple performance obligations, the total transaction price of the contract is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. Variable consideration such as rebates, sales discounts and sales returns are estimated and treated as a reduction of revenue in the same period the related revenue is recognized. These estimates are based on contractual terms, historical practices, and current trends, and are adjusted as new information becomes available. Revenues exclude any taxes that the Company collects from customers and remits to tax authorities. Equipment lease transactions with customers are evaluated and classified as either operating or sales-type leases. Generally, these arrangements are accounted for as operating leases and therefore, revenue is recognized at the contracted rate over the rental period defined within the customer agreement.
Shipping and Handling Costs	Shipping and Handling Costs The Company considers its shipping and handling costs to be contract fulfillment costs and records them within
Derivative Financial Instruments	Derivative Financial Instruments
Income Taxes	Income Taxes The Company has reviewed its needs in the United States for possible repatriation of undistributed earnings of its foreign subsidiaries and continues to invest foreign subsidiaries earnings outside of the United States to fund foreign investments or meet foreign working capital and property, plant and equipment expenditure needs. As a result, after reevaluation of the permanent reinvestment assertion, the Company is permanently reinvested with respect to all of its historical foreign earnings as of September 30, 2019. Deferred taxes are not provided on undistributed earnings of foreign subsidiaries that are indefinitely reinvested. The determination of the amount of the unrecognized deferred tax liability related to the undistributed earnings is not practicable because of the complexities associated with its hypothetical calculation. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of tax jurisdictions. In evaluating the exposure associated with various tax filing positions, the Company records accruals for uncertain tax positions, based on the technical support for the positions, past audit experience with similar situations, and the potential interest and penalties related to the matters.
Earnings per Share	Earnings per Share Basic earnings per share are computed by dividing income available to common stockholders by the weighted average number of common shares outstanding. Diluted earnings per share reflect the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. In computing diluted earnings per share, only potential common shares that are dilutive (i.e., those that reduce earnings per share or increase loss per share) are included in the calculation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions. These estimates or assumptions affect reported assets, liabilities, revenues and expenses as reflected in the consolidated financial statements. Actual results could differ from these estimates.
New Accounting Principle Adopted and New Accounting Principles Not Yet Adopted	New Accounting Principles Adopted On October 1, 2018, the Company adopted Accounting Standards Codification Topic 606, "Revenue from Contracts with Customers" ("ASC 606") using the modified retrospective method. Under ASC 606, revenue is recognized upon the transfer of control of goods or services to customers and reflects the amount of consideration to which a reporting entity expects to be entitled in exchange for those goods or services. The Company assessed the impact of this new standard on its consolidated financial statements based upon a review of contracts that were not completed as of October 1, 2018. Amounts presented in the Company's financial statements for the prior-year periods have not been revised and are reflective of the revenue recognition requirements which were in effect for those periods. This accounting standard adoption, which is further discussed in Note 6, did not materially impact any line items of the Company's consolidated income statements and balance sheet. On October 1, 2018, the Company retrospectively adopted an accounting standard update which requires all components of net periodic pension and postretirement benefit costs to be disaggregated from the service cost component and to be presented on the income statement outside a subtotal of income from operations, if one is presented. Upon the Company's adoption of the accounting standard update, which did not have a material impact on its consolidated financial statements, all components of the Company’s net periodic pension and postretirement benefit costs, aside from service cost, are recorded to Other income (expense), net on its consolidated income statements for all periods presented. Revisions of prior-year amounts were estimated based upon previously disclosed amounts. On October 1, 2018, the Company adopted an accounting standard update which requires that the income tax effects of intercompany sales or transfers of assets, except those involving inventory, be recognized in the income statement as income tax expense (or benefit) in the period that the sale or transfer occurs. The Company adopted this accounting standard update, which did not have a material impact on its consolidated financial statements, using the modified retrospective method. In the second quarter of its fiscal year 2018, the Company prospectively adopted an accounting standard update relating to the stranded income tax effects on items within Accumulated other comprehensive income (loss) resulting from the enactment of new U.S. tax legislation, which legislation is further discussed in Note 17. Additional disclosures regarding this accounting standard adoption are provided in Note 3. On October 1, 2016, the Company prospectively adopted amended requirements relating to the timing of recognition and classification of share-based compensation award-related income tax effects. Upon adoption of the requirements in 2017, the Company has recorded tax benefits relating to share-based compensation awards within Income tax (benefit) provision on its consolidated statement of income. These tax benefits had been previously recorded within Capital in excess of par value on the Company's consolidated balance sheet. Also upon adoption of the amended guidance in 2017, the Company has classified excess tax benefits on its consolidated statement of cash flows within Net Cash Provided by Operating Activities , rather than Net Cash (Used for) Provided by Financing Activities . New Accounting Principles Not Yet Adopted In February 2016, the Financial Accounting Standards Board ("FASB") issued a new lease accounting standard which requires lessees to recognize lease assets and lease liabilities on the balance sheet. The new standard also requires expanded disclosures regarding leasing arrangements. The Company will adopt the standard on October 1, 2019 and expects to elect certain practical expedients permitted under the transition guidance, including a transition method which allows application of the new standard at its adoption date, rather than at the earliest comparative period presented in the financial statements. The Company has also elected a practical expedient which allows entities to account for the lease and non-lease components in an arrangement as a single lease component. Upon adoption of the standard, the Company's operating leases will be recognized as right-of-use assets and corresponding lease liabilities on its consolidated balance sheet. The Company's measurement of these assets and liabilities will be finalized during the first quarter of fiscal year 2020. The Company does not expect the adoption of this standard to materially impact its consolidated financial statements. In June 2016, the FASB issued a new accounting standard which requires earlier recognition of credit losses on loans and other financial instruments held by entities, including trade receivables. The new standard requires entities to measure all expected credit losses for financial assets held at each reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company is currently evaluating the impact that this new accounting standard will have on its consolidated financial statements upon its adoption on October 1, 2020.
Contingencies	Contingencies Given the uncertain nature of litigation generally, the Company is not able, in all cases, to estimate the amount or range of loss that could result from an unfavorable outcome of the litigation to which the Company is a party. In accordance with U.S. GAAP, the Company establishes accruals to the extent probable future losses are estimable (in the case of environmental matters, without considering possible third-party recoveries). With respect to putative class action lawsuits in the United States and certain of the Canadian lawsuits described below relating to product liability matters, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class. With respect to the civil investigative demand served by the Department of Justice, as discussed below, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved. In view of the uncertainties discussed below, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations and consolidated cash flows. Product Liability Matters The Company believes that certain settlements and judgments, as well as legal defense costs, relating to product liability matters are or may be covered in whole or in part under its product liability insurance policies with a limited number of insurance carriers, or, in some circumstances, indemnification obligations to the Company from other parties, which if disputed, the Company intends to vigorously contest. Amounts recovered under the Company’s product liability insurance policies or indemnification arrangements may be less than the stated coverage limits or less than otherwise expected and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers or other parties will pay claims or that coverage or indemnity will be otherwise available. Hernia Product Claims As of September 30, 2019 , the Company is defending approximately 12,040 product liability claims involving the Company’s line of hernia repair devices (collectively, the “Hernia Product Claims”). The majority of those claims are currently pending in a coordinated proceeding in Rhode Island State Court, but claims are also pending in other state and/or federal court jurisdictions. In addition, those claims include multiple putative class actions in Canada. Generally, the Hernia Product Claims seek damages for personal injury allegedly resulting from use of the products. From time to time, the Company engages in resolution discussions with plaintiffs’ law firms regarding certain of the Hernia Product Claims, but the Company also intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. Trials are scheduled throughout 2020 in various state and/or federal courts. The Company expects additional trials of Hernia Product Claims to take place over the next 12 months. In August 2018, a new hernia multi-district litigation (“MDL”) was ordered to be established in the Southern District of Ohio. The Company cannot give any assurances that the resolution of the Hernia Product Claims that have not settled, including asserted and unasserted claims and the putative class action lawsuits, will not have a material adverse effect on the Company’s business, results of operations, financial condition and/or liquidity. Women’s Health Product Claims As of September 30, 2019 , the Company is defending approximately 885 product liability claims involving the Company’s line of pelvic mesh devices. The majority of those claims are currently pending in various federal court jurisdictions, and a coordinated proceeding in New Jersey State Court, but claims are also pending in other state court jurisdictions. In addition, those claims include putative class actions filed in the United States. Not included in the figures above are approximately 1,010 filed and unfiled claims that have been asserted or threatened against the Company but lack sufficient information to determine whether a pelvic mesh device of the Company is actually at issue. The claims identified above also include products manufactured by both the Company and two subsidiaries of Medtronic plc (as successor in interest to Covidien plc) (“Medtronic”), each a supplier of the Company. Medtronic has an obligation to defend and indemnify the Company with respect to any product defect liability relating to products its subsidiaries had manufactured. As described below, in July 2015 the Company reached an agreement with Medtronic (which was amended in June 2017) regarding certain aspects of Medtronic’s indemnification obligation. The foregoing lawsuits, unfiled claims, putative class actions, and other claims, together with claims that have settled or are the subject of agreements or agreements in principle to settle, are referred to collectively as the “Women’s Health Product Claims.” The Women’s Health Product Claims generally seek damages for personal injury allegedly resulting from use of the products. As of September 30, 2019 , the Company has reached agreements or agreements in principle with various plaintiffs’ law firms to settle their respective inventories of cases totaling approximately 15,160 of the Women’s Health Product Claims. The Company believes that these Women’s Health Product Claims are not the subject of Medtronic’s indemnification obligation. These settlement agreements and agreements in principle include unfiled and previously unknown claims held by various plaintiffs’ law firms, which are not included in the approximate number of lawsuits set forth in the first paragraph of this section. Each agreement is subject to certain conditions, including requirements for participation in the proposed settlements by a certain minimum number of plaintiffs. The Company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Women’s Health Product Claims, which may include additional inventory settlements. Starting in 2014 in the MDL, the court entered certain pre-trial orders requiring trial work up and remand of a significant number of Women’s Health Product Claims, including an order entered in the MDL on January 30, 2018, that requires the work up and remand of all remaining unsettled cases (the “WHP Pre-Trial Orders”). The WHP Pre-Trial Orders may result in material additional costs or trial verdicts in future periods in defending Women’s Health Product Claims. Trials are anticipated throughout 2020 in state and federal courts. A trial in the New Jersey coordinated proceeding began in March 2018, and in April 2018 a jury entered a verdict against the Company in the total amount of $68 million ( $33 million compensatory; $35 million punitive). The Company is in the process of appealing that verdict. A consolidated trial involving three plaintiffs is scheduled to begin in January 2020 in the New Jersey coordinated proceeding. The Company expects additional trials of Women’s Health Product Claims to take place over the next 12 months, which may potentially include consolidated trials. In July 2015, as part of the agreement with Medtronic noted above, Medtronic agreed to take responsibility for pursuing settlement of certain of the Women’s Health Product Claims that relate to products distributed by the Company under supply agreements with Medtronic, and the Company has paid Medtronic $121 million towards these potential settlements. In June 2017, the Company amended the agreement with Medtronic to transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on terms similar to the July 2015 agreement, including with respect to the obligation to make payments to Medtronic towards these potential settlements. In August 2019, the Company paid Medtronic an additional $20 million toward additional settlements. The Company also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms. The agreements do not resolve the dispute between the Company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any. During the course of engaging in settlement discussions with plaintiffs’ law firms, the Company has learned, and may in future periods learn, additional information regarding these and other unfiled claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company. Filter Product Claims As of September 30, 2019 , the Company is defending approximately 4,485 product liability claims involving the Company’s line of inferior vena cava filters (collectively, the “Filter Product Claims”). The majority of those claims are currently pending in an MDL in the United States District Court for the District of Arizona, but those MDL claims are in the process of bring remanded to various federal jurisdictions. Filter Product Claims are also pending in various state court jurisdictions, including a coordinated proceeding in Arizona State Court. In addition, those claims include putative class actions filed in the United States and Canada. The Filter Product Claims generally seek damages for personal injury allegedly resulting from use of the products. The Company has limited information regarding the nature and quantity of certain of the Filter Product Claims. The Company continues to receive claims and lawsuits and may in future periods learn additional information regarding other unfiled or unknown claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company. On May 31, 2019, the MDL Court ceased accepting direct filings or transfers into the Filter Product Claims MDL and, as noted above, remands for non-settled cases have begun and are expected to continue over the next three to six months. Federal and state court trials are scheduled throughout 2020. As of September 30, 2019 , the Company entered into settlement agreements and/or settlement agreements in principle for approximately 4,200 cases. On March 30, 2018, a jury in the first MDL trial found the Company liable for negligent failure to warn and entered a verdict in favor of plaintiffs. The jury found the Company was not liable for (a) strict liability design defect; (b) strict liability failure to warn; and (c) negligent design. The Company has appealed that verdict. On June 1, 2018, a jury in the second MDL trial unanimously found in favor of the Company on all claims. On August 17, 2018, the Court entered summary judgment in favor of the Company on all claims in the third MDL trial. On October 5, 2018, a jury in the fourth MDL trial unanimously found in favor of the Company on all claims. The Company expects additional trials of Filter Product Claims may take place over the next 12 months. In most product liability litigations (like those described above), plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the Company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions and, consequently, is unable to fully evaluate the claims. The Company expects that it will receive and review additional information regarding any remaining unsettled product liability matters. In January 2017, the Company reached an agreement to resolve litigation filed in the Southern District of New York by its insurance carriers in connection with Women’s Health Product Claims and Filter Product Claims. The agreement requires the insurance carriers to reimburse the Company for certain future costs incurred in connection with Filter Product Claims up to an agreed amount. For certain product liability claims or lawsuits, the Company does not maintain or has limited remaining insurance coverage. Other Legal Matters Since early 2013, the Company has received subpoenas or Civil Investigative Demands from a number of State Attorneys General seeking information related to the sales and marketing of certain of the Company’s products that are the subject of the Hernia Product Claims and the Women’s Health Product Claims. The Company is cooperating with these requests. Although the Company has had, and continues to have, discussions with the State Attorneys General with respect to overall potential resolution of this matter, there can be no assurance that a resolution will be reached or what the terms of any such resolution may be. In July 2017, a civil investigative demand was served by the Department of Justice seeking documents and information relating to an investigation into possible violations of the False Claims Act in connection with the sales and marketing of FloChec ® and QuantaFlo TM devices. The Company is cooperating with these requests. Since it is not feasible to predict the outcome of these matters, the Company cannot give any assurances that the resolution of these matters will not have a material adverse effect on the Company’s business, results of operations, financial condition and/or liquidity. The Company is a potentially responsible party to a number of federal administrative proceedings in the United States brought under the Comprehensive Environment Response, Compensation and Liability Act, also known as “Superfund,” and similar state laws. The affected sites are in varying stages of development. In some instances, the remedy has been completed, while in others, environmental studies are underway or commencing. For several sites, there are other potentially responsible parties that may be jointly or severally liable to pay all or part of cleanup costs. While it is not feasible to predict the outcome of these proceedings, based upon the Company’s experience, current information and applicable law, the Company does not expect these proceedings to have a material adverse effect on its financial condition and/or liquidity. However, one or more of the proceedings could be material to the Company’s business and/or results of operations. The Company is also involved both as a plaintiff and a defendant in other legal proceedings and claims that arise in the ordinary course of business. The Company believes that it has meritorious defenses to these suits pending against the Company and is engaged in a vigorous defense of each of these matters. Litigation Reserves The Company regularly monitors and evaluates the status of product liability and other legal matters, and may, from time-to-time, engage in settlement and mediation discussions taking into consideration developments in the matters and the risks and uncertainties surrounding litigation. These discussions could result in settlements of one or more of these claims at any time. During fiscal year 2019, the Company recorded pre-tax charges to Other operating expense, net , of approximately $914 million related to certain of the product liability matters discussed above under the heading “Product Liability Matters,” including the related legal defense costs. The Company recorded these charges based on additional information obtained during the year, including but not limited to: the nature and quantity of unfiled and filed claims and the continued rate of claims being filed in certain product liability matters; the status of certain settlement discussions with plaintiffs’ counsel; the allegations and documentation supporting or refuting such allegations; publicly available information regarding similar medical device mass tort settlements; historical information regarding other product liability settlements involving the Company; and the stage of litigation. Accruals for the Company's product liability claims which are specifically discussed above, as well as the related legal defense costs, amounted to approximately $2.5 billion at September 30, 2019 and $2.0 billion at September 30, 2018 . These accruals, which are generally long-term in nature, are largely recorded within Deferred Income Taxes and Other on the Company's consolidated balance sheets. As of September 30, 2019 and 2018 , the Company had $53 million and $94 million , respectively, in qualified settlement funds (“QSFs”), subject to certain settlement conditions, for certain product liability matters. Payments to QSFs are recorded as a component of Restricted cash . The Company's expected recoveries related to product liability claims and related legal defense costs were approximately $150 million and $343 million at September 30, 2019 and 2018 , respectively. A substantial amount of these expected recoveries at September 30, 2019 and 2018 related to the Company’s agreements with Medtronic related to certain Women’s Health Product Claims. During fiscal year 2019 , Medtronic provided the Company with releases from liability for certain claims that were the subject of the agreement discussed further above. Accordingly, adjustments to reduce accruals for the Company's product liability claims, as well as the balance recorded for expected recoveries related to product liability claims, were recorded during fiscal year 2019 . The terms of the Company’s agreements with Medtronic are substantially consistent with the assumptions underlying, and the manner in which, the Company has recorded expected recoveries related to the indemnification obligation. The expected recoveries at September 30, 2019 related to the indemnification obligation are not in dispute with respect to claims that Medtronic settles pursuant to the agreements. As described above, the agreements do not resolve the dispute between the Company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any, and the Company also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms.
Revenue from Contract with Customer [Policy Text Block]	Timing of Revenue Recognition The Company's revenues are primarily recognized when the customer obtains control of the product sold, which is generally upon shipment or delivery, depending on the delivery terms specified in the sales agreement. Revenues associated with certain instruments and equipment for which installation is complex, and therefore significantly affects the customer’s ability to use and benefit from the product, are recognized when customer acceptance of these installed products has been confirmed. For certain service arrangements, including extended warranty and software maintenance contracts, revenue is recognized ratably over the contract term. The majority of revenues relating to extended warranty contracts associated with certain instruments and equipment is generally recognized within a few years whereas deferred revenue relating to software maintenance contracts is generally recognized over a longer period. Measurement of Revenues The Company acts as the principal in substantially all of its customer arrangements and as such, generally records revenues on a gross basis. Revenues exclude any taxes that the Company collects from customers and remits to tax authorities. The Company considers its shipping and handling costs to be costs of contract fulfillment and has made the accounting policy election to record these costs within Selling and administrative expense . Payment terms extended to the Company's customers are based upon commercially reasonable terms for the markets in which the Company's products are sold. Because the Company generally expects to receive payment within one year or less from when control of a product is transferred to the customer, the Company does not generally adjust its revenues for the effects of a financing component. The Company’s estimate of probable credit losses relating to trade receivables is determined based on historical experience and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectible. Such amounts are not material to the Company's consolidated financial results. The Company's gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration include rebates, sales discounts and sales returns. Because these deductions represent estimates of the related obligations, judgment is required when determining the impact of these revenue deductions on gross revenues for a reporting period. Rebates provided by the Company are based upon prices determined under the Company's agreements with its end-user customers. Additional factors considered in the estimate of the Company's rebate liability include the quantification of inventory that is either in stock at or in transit to the Company's distributors, as well as the estimated lag time between the sale of product and the payment of corresponding rebates. The impact of other forms of variable consideration, including sales discounts and sales returns, is not material to the Company's revenues. Additional disclosures relating to sales discounts and sales returns are provided in Note 19. The Company's agreements with customers within certain organizational units including Medication Management Solutions, Diagnostic Systems and Biosciences, contain multiple performance obligations including both products and certain services noted above. The transaction price for these agreements is allocated to each performance obligation based upon its relative standalone selling price. Standalone selling price is the amount at which the Company would sell a promised good or service separately to a customer. The Company generally estimates standalone selling prices using its list prices and a consideration of typical discounts offered to customers.
Fair Value of Financial Instruments	Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments, which are considered Level 2 inputs in the fair value hierarchy.
Concentration of Credit Risk	Concentration of Credit Risk The Company maintains cash deposits in excess of government-provided insurance limits. Such cash deposits are exposed to loss in the event of nonperformance by financial institutions. Substantially all of the Company’s trade receivables are due from public and private entities involved in the healthcare industry. Due to the large size and diversity of the Company’s customer base, concentrations of credit risk with respect to trade receivables are limited. The Company does not normally require collateral. The Company is exposed to credit loss in the event of nonperformance by financial institutions with which it conducts business. However, this loss is limited to the amounts, if any, by which the obligations of the counterparty to the financial instrument contract exceed the obligations of the Company. The Company also minimizes exposure to credit risk by dealing with a diversified group of major financial institutions. The Company continually evaluates its accounts receivables for potential collection risks particularly those resulting from sales to government-owned or government-supported healthcare facilities in certain countries as payment may be dependent upon the financial stability and creditworthiness of those countries’ national economies. The Company continually evaluates all governmental receivables for potential collection risks associated with the availability of government funding and reimbursement practices. The Company believes the current reserves related to all governmental receivables are adequate and that this concentration of credit risk will not have a material adverse impact on its financial position or liquidity.

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Sep. 30, 2019
Stockholders' Equity Note [Abstract]
Changes in Certain Components of Shareholders' Equity	Changes in certain components of shareholders’ equity were as follows: Common Stock Issued at Par Value Capital in Excess of Par Value Retained Earnings Deferred Compensation Treasury Stock (Millions of dollars) Shares (in thousands) Amount Balance at September 30, 2016 $ 333 $ 4,693 $ 12,727 $ 22 (119,371 ) $ (8,212 ) Net income — — 1,100 — — — Cash dividends: Common ($2.92 per share) — — (645 ) — — — Preferred — — (70 ) — — — Common stock issued for: Public equity offerings (a) 14 4,810 — — — — Share-based compensation and other plans, net — (65 ) (1 ) (3 ) 1,908 6 Share-based compensation — 180 — — — — Common stock held in trusts, net (b) — — — — 7 — Repurchase of common stock (c) — — — — (1,289 ) (220 ) Balance at September 30, 2017 $ 347 $ 9,619 $ 13,111 $ 19 (118,745 ) $ (8,427 ) Net income — — 311 — — — Cash dividends: Common ($3.00 per share) — — (775 ) — — — Preferred — — (152 ) — — — Common stock issued for: Acquisition (see Note 10) — 6,478 — — 37,306 2,121 Share-based compensation and other plans, net — (246 ) (2 ) 3 2,982 62 Share-based compensation — 328 — — — — Common stock held in trusts, net (b) — — — — (6 ) — Effect of change in accounting principle (see Note 2 and further discussion below) — — 103 — — — Balance at September 30, 2018 $ 347 $ 16,179 $ 12,596 $ 22 (78,463 ) $ (6,243 ) Net income — — 1,233 — — — Cash dividends: Common ($3.08 per share) — — (832 ) — — — Preferred — — (152 ) — — — Common stock issued for share-based compensation and other plans, net — (170 ) (1 ) 1 2,155 53 Share-based compensation — 261 — — — — Common stock held in trusts, net (b) — — — — 48 — Effect of change in accounting principle (see Note 2) — — 68 — — — Balance at September 30, 2019 $ 347 $ 16,270 $ 12,913 $ 23 (76,260 ) $ (6,190 ) (a) In May 2017 and in connection with the Company's acquisition of Bard, which is further discussed in Note 10 , the Company completed registered public offerings of equity securities including 14.025 million shares of the Company's common stock and 2.475 million shares of the Company's mandatory convertible preferred stock (ownership is held in the form of depositary shares, each representing a 1/20th interest in a share of preferred stock) for total net proceeds of $4.8 billion . If and when declared, dividends on the mandatory convertible preferred stock are payable on a cumulative basis at an annual rate of 6.125% on the liquidation preference of $1,000 per preferred share ( $50 per depositary share). The shares of preferred stock are convertible to a minimum of 11.7 million and up to a maximum of 14.0 million shares of Company common stock at an exchange ratio that is based on the market price of the Company’s common stock at the date of conversion, and no later than the mandatory conversion date of May 1, 2020. (b) Common stock held in trusts represents rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan. (c) Using proceeds received from the divestiture of the Respiratory Solutions business in the first quarter of fiscal year 2017, the Company repurchased shares of its common stock under an accelerated share repurchase agreement.
Accumulated Other Comprehensive (Loss) Income	The components and changes of Accumulated other comprehensive income (loss) were as follows: (Millions of dollars) Total Foreign Currency Translation Benefit Plans Cash Flow Hedges Balance at September 30, 2016 $ (1,929 ) $ (1,011 ) $ (883 ) $ (35 ) Other comprehensive income before reclassifications, net of taxes 140 11 121 8 Amounts reclassified into income, net of 66 — 58 8 Balance at September 30, 2017 $ (1,723 ) $ (1,001 ) $ (703 ) $ (18 ) Other comprehensive (loss) income before reclassifications, net of taxes (142 ) (161 ) 19 — Amounts reclassified into income, net of 57 — 52 5 Tax effects reclassified to retained earnings (103 ) — (99 ) (4 ) Balance at September 30, 2018 $ (1,909 ) $ (1,162 ) $ (729 ) $ (17 ) Other comprehensive loss before reclassifications, net of taxes (427 ) (93 ) (325 ) (9 ) Amounts reclassified into income, net of taxes 52 — 49 3 Balance at September 30, 2019 $ (2,283 ) $ (1,256 ) $ (1,005 ) $ (23 )
Other Comprehensive Income (Loss), Tax	The tax impacts for amounts recognized in other comprehensive income before reclassifications were as follows: (Millions of dollars) 2019 2018 2017 Benefit Plans Income tax benefit (provision) for net (losses) gains recorded in other comprehensive income $ 91 $ (19 ) $ (60 )

Earnings per Share (Tables)

Earnings per Share (Tables)	12 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings Per Share	The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) for the years ended September 30 were as follows: 2019 2018 2017 Average common shares outstanding 269,943 258,354 218,943 Dilutive share equivalents from share-based plans (a) 4,832 6,267 4,645 Average common and common equivalent shares outstanding — assuming dilution 274,775 264,621 223,588 (a) For the years ended September 30, 2019 , 2018 and 2017 , dilutive share equivalents associated with mandatory convertible preferred stock of 12 million , 12 million and 5 million , respectively, were excluded from the diluted shares outstanding calculation because the result would have been antidilutive. The issuance of the convertible preferred stock is further discussed in Note 3 . For the years ended September 30, 2019 , 2018 and 2017 , there were no options to purchase shares of common stock which were excluded from the diluted earnings per share calculation.

Commitments and Contingencies F

Commitments and Contingencies Future Minimum Rental Commitments (Tables)	12 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	Future minimum rental commitments on non-cancelable leases are as follows: (Millions of dollars) Future minimum rental commitments on non-cancelable leases 2020 $ 122 2021 103 2022 83 2023 57 2024 56 Thereafter 123

Segment Data (Tables)

Segment Data (Tables)	12 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Revenue from External Customers by Geographic Areas	Financial information for the Company’s segments is detailed below. The Company has no material intersegment revenues. As discussed in Note 10 , the Company completed its acquisition of Bard on December 29, 2017. Bard's operating results were included in the Company’s consolidated results of operations beginning on January 1, 2018. (Millions of dollars) 2019 2018 2017 United States International Total United States International Total United States International Total Medical Medication Delivery Solutions $ 2,048 $ 1,811 $ 3,859 $ 1,892 $ 1,752 $ 3,644 $ 1,378 $ 1,434 $ 2,812 Medication Management Solutions 2,104 525 2,629 1,957 513 2,470 1,843 452 2,295 Diabetes Care 573 538 1,110 564 541 1,105 546 510 1,056 Pharmaceutical Systems 392 1,073 1,465 357 1,040 1,397 328 929 1,256 Total segment revenues $ 5,116 $ 3,947 $ 9,064 $ 4,770 $ 3,846 $ 8,616 $ 4,095 $ 3,325 $ 7,419 Life Sciences Preanalytical Systems $ 774 $ 784 $ 1,558 $ 761 $ 792 $ 1,553 $ 741 $ 730 $ 1,471 Diagnostic Systems 672 875 1,547 678 858 1,536 622 756 1,378 Biosciences 485 709 1,194 475 766 1,241 455 684 1,139 Total segment revenues $ 1,931 $ 2,368 $ 4,300 $ 1,914 $ 2,416 $ 4,330 $ 1,818 $ 2,170 $ 3,988 Interventional Surgery (a) $ 1,098 $ 299 $ 1,397 $ 946 $ 245 $ 1,192 $ 577 $ 89 $ 666 Peripheral Intervention (a) 787 602 1,389 594 451 1,045 14 6 19 Urology and Critical Care 797 342 1,140 544 256 800 — — — Total segment revenues $ 2,682 $ 1,244 $ 3,926 $ 2,084 $ 953 $ 3,037 $ 591 $ 95 $ 685 Total Company revenues $ 9,730 $ 7,560 $ 17,290 $ 8,768 $ 7,215 $ 15,983 $ 6,504 $ 5,589 $ 12,093 (a) Amounts presented in 2017 are associated with certain product offerings that were moved from the Medical segment to the Interventional segment in order to align with the reportable segment structure that became effective beginning in the second quarter of fiscal year 2018.
Financial Information for Company's Segments	(Millions of dollars) 2019 2018 2017 Income Before Income Taxes Medical (a) (b) (c) $ 2,824 $ 2,624 $ 1,907 Life Sciences (d) 1,248 1,207 772 Interventional (b) (e) (f) 903 306 248 Total Segment Operating Income 4,976 4,137 2,927 Acquisitions and other restructurings (480 ) (740 ) (354 ) Net interest expense (627 ) (641 ) (445 ) Other unallocated items (g) (2,693 ) (1,583 ) (1,152 ) Total Income Before Income Taxes $ 1,176 $ 1,173 $ 976 Assets Medical $ 22,925 $ 23,493 $ 15,552 Life Sciences 4,135 4,225 4,056 Interventional (f) 22,157 23,219 2,780 Total Segment Assets 49,217 50,938 22,388 Corporate and All Other (h) 2,548 2,966 15,347 Total Assets $ 51,765 $ 53,904 $ 37,734 Capital Expenditures Medical $ 577 $ 560 $ 486 Life Sciences 230 255 212 Interventional (f) 120 65 16 Corporate and All Other 30 14 13 Total Capital Expenditures $ 957 $ 895 $ 727 Depreciation and Amortization Medical $ 1,073 $ 1,028 $ 773 Life Sciences 284 275 254 Interventional (f) 881 658 52 Corporate and All Other 14 17 10 Total Depreciation and Amortization $ 2,253 $ 1,978 $ 1,088 (a) The amount in 2019 included $75 million of estimated remediation costs recorded to Other operating expense, net relating to a recall of a product component, which generally pre-dated the Company's acquisition of CareFusion in fiscal year 2015, within the Medication Management Solutions unit's infusion systems platform. (b) The amounts in 2018 included expense related to the recognition of a $478 million fair value step-up adjustment related to Bard's inventory on the acquisition date. The step-up adjustments recognized by the Medical and Interventional segments in 2018 were $60 million and $418 million , respectively. (c) The amount in 2018 included $58 million of charges to write down the value of fixed assets primarily in the Diabetes Care unit. (d) The amount in 2018 included $81 million of charges recorded to write down the carrying value of certain intangible and other assets in the Biosciences unit. (e) The amount in 2019 included a charge of $30 million recorded to write down the carrying value of certain intangible assets in the Surgery unit. (f) Amounts presented in 2017 are associated with certain product offerings that were moved from the Medical segment to the Interventional segment in order to align with the reportable segment structure that became effective beginning in the second quarter of fiscal year 2018. (g) Primarily comprised of foreign exchange, corporate expenses, and share-based compensation expense. The amount in 2019 included a pre-tax charge of $914 million related to certain product liability matters, which is further discussed in Note 5 , and also included the pre-tax gain recognized on the Company's sale of its Advanced Bioprocessing business of approximately $336 million , which is further discussed in Note 11 . Results in 2019 and 2018 were impacted by the Company's change in its management reporting approach, as further discussed above. The amount in 2018 included the pre-tax gain recognized on the Company's sale of its non-controlling interest in Vyaire Medical of approximately $303 million . Results in 2017 included a $748 million non-cash charge resulting from a modification to the Company's dispensing equipment lease contracts with customers, as well as the reversal of certain litigation reserves. (h) Includes cash and investments and corporate assets.
Revenues to Unaffiliated Customers and Long-lived Assets Including Property, Plant and Equipment	Revenues to unaffiliated customers are generally based upon the source of the product shipment. Long-lived assets, which include net property, plant and equipment, are based upon physical location. (Millions of dollars) 2019 2018 2017 Revenues United States $ 9,730 $ 8,768 $ 6,504 Europe 3,359 3,298 2,588 Greater Asia 2,726 2,460 1,744 Other 1,476 1,457 1,257 $ 17,290 $ 15,983 $ 12,093 Long-Lived Assets United States $ 37,053 $ 38,982 $ 13,151 Europe 5,483 5,640 4,421 Greater Asia 1,328 851 578 Other 861 645 584 Corporate 377 375 366 $ 45,101 $ 46,494 $ 19,101

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Compensation Cost Relating to Share-Based Payments	The amounts and location of compensation cost relating to share-based payments included in the consolidated statements of income is as follows: (Millions of dollars) 2019 2018 2017 Cost of products sold $ 37 $ 36 $ 30 Selling and administrative expense 145 136 113 Research and development expense 32 29 24 Acquisitions and other restructurings 50 130 10 $ 265 $ 332 $ 177 Tax benefit associated with share-based compensation costs recognized $ 62 $ 79 $ 61
Assumptions for Estimation of Fair Values of Stock Appreciation Rights Granted During Reporting Periods	The fair value was estimated on the date of grant using a lattice-based binomial option valuation model that uses the following weighted-average assumptions: 2019 2018 2017 Risk-free interest rate 3.05% 2.32% 2.33% Expected volatility 18.0% 19.0% 20.0% Expected dividend yield 1.27% 1.33% 1.71% Expected life 7.2 years 7.4 years 7.5 years Fair value derived $51.86 $46.10 $33.81
Summary of SARs Outstanding	A summary of SARs outstanding as of September 30, 2019 and changes during the year then ended is as follows: SARs (in thousands) Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (Millions of dollars) Balance at October 1 7,986 $ 125.73 Granted 859 242.10 Exercised (1,779 ) 102.14 Forfeited, canceled or expired (168 ) 186.18 Balance at September 30 6,899 $ 144.84 5.70 $ 746 Vested and expected to vest at September 30 6,692 $ 142.87 5.62 $ 737 Exercisable at September 30 4,833 $ 117.65 4.69 $ 654
Schedule Of Share Based Compensation, Summary of Stock Appreciation Rights Exercised	A summary of SARs exercised 2019 , 2018 and 2017 is as follows: (Millions of dollars) 2019 2018 2017 Total intrinsic value of SARs exercised $ 260 $ 333 $ 148 Tax benefit realized from SAR exercises $ 62 $ 90 $ 53 Total fair value of SARs vested $ 66 $ 107 $ 30
Summary of Performance-Based Restricted Stock Units Outstanding	A summary of restricted stock units outstanding as of September 30, 2019 and changes during the year then ended is as follows: Performance-Based Time-Vested Stock Units (in thousands) Weighted Average Grant Date Fair Value Stock Units (in thousands) Weighted Average Grant Date Fair Value Balance at October 1 1,032 $ 190.57 2,765 $ 194.92 Granted 381 237.55 755 235.50 Distributed (142 ) 153.73 (906 ) 189.06 Forfeited or canceled (316 ) 182.50 (546 ) 201.85 Balance at September 30 955 (a) $ 221.73 2,068 $ 210.48 Expected to vest at September 30 306 (b) $ 218.06 1,964 $ 209.67 (a) Based on 200% of target payout. (b) Net of expected forfeited units and units in excess of the expected performance payout of 65 thousand and 585 thousand shares, respectively.
Schedule Of Share Based Compensation, Restricted Stock Units, Grant Date Fair Value of Units Granted	The weighted average grant date fair value of restricted stock units granted during the years 2019 , 2018 and 2017 are as follows: Performance-Based Time-Vested 2019 2018 2017 2019 2018 2017 Weighted average grant date fair value of units granted $ 237.55 $ 251.75 $ 174.92 $ 235.50 $ 216.06 $ 165.96
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	The total fair value of stock units vested during 2019 , 2018 and 2017 was as follows: Performance-Based Time-Vested (Millions of dollars) 2019 2018 2017 2019 2018 2017 Total fair value of units vested $ 33 $ 31 $ 32 $ 254 $ 362 $ 139

Benefit Plans (Tables)

Benefit Plans (Tables)	12 Months Ended
	Sep. 30, 2019
Net Pension and Other Postretirement Cost	Net pension cost for the years ended September 30 included the following components: Pension Plans (Millions of dollars) 2019 2018 2017 Service cost $ 134 $ 136 $ 110 Interest cost 107 90 61 Expected return on plan assets (180 ) (154 ) (112 ) Amortization of prior service credit (13 ) (13 ) (14 ) Amortization of loss 78 78 92 Settlements 10 2 — Net pension cost $ 135 $ 137 $ 138 Net pension cost included in the preceding table that is attributable to international plans $ 32 $ 34 $ 43
Change in Benefit Obligation, Change in Fair Value of Plan Assets	The change in benefit obligation, change in fair value of pension plan assets, funded status and amounts recognized in the Consolidated Balance Sheets for these plans were as follows: Pension Plans (Millions of dollars) 2019 2018 Change in benefit obligation: Beginning obligation $ 3,246 $ 2,647 Service cost 134 136 Interest cost 107 90 Plan amendments 3 — Benefits paid (153 ) (162 ) Impact of (divestitures) acquisitions (9 ) 758 Actuarial loss (gain) 514 (82 ) Settlements (63 ) (122 ) Other, includes translation (49 ) (19 ) Benefit obligation at September 30 $ 3,731 $ 3,246 Change in fair value of plan assets: Beginning fair value $ 2,642 $ 1,932 Actual return on plan assets 279 70 Employer contribution 258 400 Benefits paid (153 ) (162 ) Impact of (divestitures) acquisitions (7 ) 539 Settlements (63 ) (122 ) Other, includes translation (30 ) (15 ) Plan assets at September 30 $ 2,926 $ 2,642 Funded Status at September 30: Unfunded benefit obligation $ (804 ) $ (604 ) Amounts recognized in the Consolidated Balance Sheets at September 30: Other $ 11 $ 15 Salaries, wages and related items (22 ) (15 ) Long-term Employee Benefit Obligations (793 ) (604 ) Net amount recognized $ (804 ) $ (604 ) Amounts recognized in Accumulated other comprehensive income (loss) before income taxes at September 30: Prior service credit $ 44 $ 60 Net actuarial loss (1,289 ) (982 ) Net amount recognized $ (1,246 ) $ (921 )
Pension Plans with Accumulated Benefit Obligations	Pension plans with accumulated benefit obligations in excess of plan assets and plans with projected benefit obligations in excess of plan assets consist of the following at September 30: Accumulated Benefit Obligation Exceeds the Fair Value of Plan Assets Projected Benefit Obligation Exceeds the Fair Value of Plan Assets (Millions of dollars) 2019 2018 2019 2018 Projected benefit obligation $ 3,623 $ 2,618 $ 3,698 $ 3,121 Accumulated benefit obligation $ 3,476 $ 2,533 Fair value of plan assets $ 2,821 $ 2,012 $ 2,882 $ 2,502
Weighted Average Assumptions Determining Pension Plan	The weighted average assumptions used in determining pension plan information were as follows: 2019 2018 2017 Net Cost Discount rate: U.S. plans (a) 4.26 % 3.71 % 3.42 % International plans 2.30 2.30 1.70 Expected return on plan assets: U.S. plans 7.25 7.20 7.25 International plans 4.98 4.95 4.65 Rate of compensation increase: U.S. plans 4.29 4.51 4.25 International plans 2.36 2.31 2.33 Benefit Obligation Discount rate: U.S. plans 3.21 4.26 3.72 International plans 1.39 2.30 2.25 Rate of compensation increase: U.S. plans 4.29 4.29 4.51 International plans 2.35 2.36 2.30 (a) The Company calculated the service and interest components utilizing an approach that discounts the individual expected cash flows using the applicable spot rates derived from the yield curve over the projected cash flow period.
Expected Benefit Payments	Expected benefit payments are as follows: (Millions of dollars) Pension Plans 2020 $ 212 2021 171 2022 173 2023 185 2024 190 2025-2029 1,066
Fair Value Measurements of U.S. Plan Assets	The following table provides the fair value measurements of U.S. plan assets, as well as the measurement techniques and inputs utilized to measure fair value of these assets, at September 30, 2019 and 2018 . The categorization of fund investments is based upon the categorization of these funds’ underlying assets. (Millions of dollars) Total U.S. Investments Measured at Net Asset Value (a) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) 2019 2018 2019 2018 2019 2018 2019 2018 2019 2018 Fixed Income: Mortgage and asset-backed securities $ — $ 28 $ — $ — $ — $ — $ — $ 28 $ — $ — Corporate bonds 401 484 — — 48 101 353 383 — — Government and agency-U.S. 108 257 — — 85 199 23 57 — — Government and agency-Foreign 85 122 — 8 69 85 16 28 — — Other fixed income 37 — — — — — 37 — — — Equity securities 922 536 782 360 140 176 — — — — Cash and cash equivalents 254 39 — — 254 39 — — — — Other 261 356 124 356 138 — — — — — Fair value of plan assets $ 2,068 $ 1,821 $ 906 $ 724 $ 733 $ 600 $ 429 $ 497 $ — $ — (a) As per applicable disclosure requirements, certain investments that were measured at net asset value per share or its equivalent have not been categorized within the fair value hierarchy. Values of such assets are based on the corroborated net asset value provided by the fund administrator.
Fair Value Measurements of Foreign Plan Assets	The following table provides the fair value measurements of international plan assets, as well as the measurement techniques and inputs utilized to measure fair value of these assets, at September 30, 2019 and 2018 . (Millions of dollars) Total International Plan Asset Balances Investments Measured at Net Asset Value (a) Quoted Prices in Significant Significant 2019 2018 2019 2018 2019 2018 2019 2018 2019 2018 Fixed Income: Corporate bonds $ 33 $ 28 $ — $ — $ 15 $ 14 $ 18 $ 14 $ — $ — Government and agency-U.S. 3 6 — — — 3 3 3 — — Government and agency-Foreign 199 150 — — 105 104 94 46 — — Other fixed income 100 96 — — 63 63 37 33 — — Equity securities 319 314 14 15 305 299 — — — — Cash and cash equivalents 8 9 — — 8 9 — — — — Real estate 30 30 — — — — 30 30 — — Insurance contracts 113 114 — — — — — — 113 114 Other 53 74 — — 52 55 1 20 — — Fair value of plan assets $ 859 $ 821 $ 14 $ 15 $ 549 $ 546 $ 182 $ 146 $ 113 $ 114 (a) As per applicable disclosure requirements, certain investments that were measured at net asset value per share or its equivalent have not been categorized within the fair value hierarchy. Values of such assets are based on the corroborated net asset value provided by the fund administrator. (b) Changes in the fair value of international pension assets measured using Level 3 inputs for the years ended September 30, 2019 and 2018 were immaterial.

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Sep. 30, 2019
Business Combinations [Abstract]
Schedule Of Business Acquisition By Acquisition Fair Value Of Consideration Transferred Table	The acquisition-date fair value of consideration transferred consisted of the components below. The fair value of the shares and equity awards issued as consideration was recognized as a $6.5 billion increase to Capital in excess of par value and a $2.1 billion decrease to Common stock in treasury. (Millions of dollars) Cash consideration $ 16,400 Non-cash consideration-fair value of shares issued 8,004 Non-cash consideration-fair value of equity awards issued 613 Total consideration transferred $ 25,017
Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable	The acquisition-date fair value of the Company’s ordinary shares issued to Bard shareholders was calculated per the following (shares in millions): (Millions of dollars, except per share data) Total Bard shares outstanding 73.359 Conversion factor 0.5077 Conversion of Bard shares outstanding 37.243 Conversion of pre-acquisition equity awards 0.104 Total number of the Company's share issued 37.347 Closing price of the Company’s stock $ 214.32 Fair value of the Company’s issued shares $ 8,004
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The allocations of the purchase price below represent the estimated fair values of assets acquired and liabilities assumed in this acquisition, which were largely allocated to the Company's Interventional segment. (Millions of dollars) Cash and equivalents $ 1,480 Trade receivables 472 Inventories 974 Property, plant and equipment 553 Developed technology 10,469 Customer relationships 1,146 Other assets 661 Total identifiable assets acquired 15,755 Payables, accrued expenses and other liabilities 1,280 Short term and long-term debt 1,692 Product liability and other legal reserves 2,004 Deferred tax liabilities 1,686 Total liabilities assumed 6,663 Net identifiable assets acquired 9,093 Goodwill 15,924 Net assets acquired $ 25,017
Business Acquisition, Pro Forma Information	The following table provides the pro forma results for the fiscal years 2018 and 2017 as if Bard had been acquired as of October 1, 2016. (Millions of dollars, except per share data) 2018 2017 Revenues $ 16,947 $ 15,781 Net Income $ 390 $ 1,145 Diluted Earnings per Share $ 0.90 $ 3.60

Business Restructuring Charges

Business Restructuring Charges (Tables)	12 Months Ended
	Sep. 30, 2019
Restructuring and Related Activities [Abstract]
Summary of Restructuring Accrual Activity	Restructuring liability activity in 2019 , 2018 and 2017 was as follows: Employee Termination Other Total (Millions of dollars) Bard Other Initiatives (a) Bard (b) Other Initiatives (a) Bard Other Initiatives (a) Balance at September 30, 2016 $ — $ 67 $ — $ 2 $ — $ 69 Charged to expense — 27 — 58 — 85 Cash payments — (45 ) — (12 ) — (57 ) Non-cash settlements — — — (9 ) — (9 ) Other adjustments — — — (33 ) — (33 ) Balance at September 30, 2017 $ — $ 49 $ — $ 6 $ — $ 55 Charged to expense 136 30 156 22 292 52 Cash payments (103 ) (56 ) (3 ) (23 ) (106 ) (79 ) Non-cash settlements — — (153 ) (1 ) (153 ) (1 ) Balance at September 30, 2018 $ 33 $ 23 $ — $ 4 $ 33 $ 27 Charged to expense 23 29 95 33 118 62 Cash payments (34 ) (21 ) (5 ) (31 ) (39 ) (52 ) Non-cash settlements — — (89 ) (3 ) (89 ) (3 ) Balance at September 30, 2019 $ 22 $ 31 $ 1 $ 3 $ 23 $ 34 (a) Restructuring costs in 2019, 2018 and 2017 included expenses related to the Company's acquisition of CareFusion in fiscal year 2015 and other initiatives. (b) Expenses in 2019 and 2018 largely represented the costs associated with the conversion of certain pre-acquisition equity awards of Bard which, to encourage post-acquisition employee retention, were converted to BD equity awards with substantially the same terms and conditions as were applicable under such Bard awards immediately prior to the acquisition date. Expenses in 2018 also included costs relating to Bard’s pension plan, partially offset by a gain on the sale of the Company's soft tissue core needle biopsy product line which was recorded in the second quarter of fiscal year 2018.

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Components of Intangible Assets	Intangible assets at September 30 consisted of: 2019 2018 (Millions of dollars) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Amortized intangible assets Developed technology $ 13,960 $ 2,906 $ 13,966 $ 1,782 Customer relationships 4,608 1,183 4,584 861 Product rights 110 60 121 58 Trademarks 407 102 407 84 Patents and other 445 305 397 288 Amortized intangible assets $ 19,530 $ 4,555 $ 19,475 $ 3,073 Unamortized intangible assets Acquired in-process research and development (a) $ 1 $ 37 Trademarks 2 2 Unamortized intangible assets $ 3 $ 39 (a) The decrease in the carrying value of assets in 2019 primarily reflected a write-down recorded in the third quarter by the Interventional segment's Surgery unit.
Reconciliation of Goodwill by Business Segment	The following is a reconciliation of goodwill by business segment: (Millions of dollars) Medical Life Sciences Interventional Total Goodwill as of September 30, 2017 $ 6,802 $ 761 $ — $ 7,563 Acquisitions (a) 3,923 76 11,218 15,217 Divestitures and related adjustments (b) — (59 ) (57 ) (116 ) Reallocation of goodwill for change in segment and reporting unit composition (c) (877 ) — 877 — Purchase price allocation adjustments (d) 228 (2 ) 732 959 Currency translation (22 ) (2 ) — (24 ) Goodwill as of September 30, 2018 $ 10,054 $ 775 $ 12,771 $ 23,600 Divestitures and related adjustments (b) — 3 — 3 Purchase price allocation adjustments (e) (15 ) — (75 ) (90 ) Currency translation (50 ) (6 ) (81 ) (137 ) Goodwill as of September 30, 2019 $ 9,989 $ 772 $ 12,615 $ 23,376 (a) Represents goodwill primarily recognized upon the Company's acquisition of Bard in fiscal year 2018, which is further discussed in Note 10 . Also includes goodwill recognized relative to certain acquisitions which were not material individually or in the aggregate. (b) Represents goodwill derecognized upon the Company's sale of certain businesses, as further discussed in Note 11 . (c) Represents the reassignment of goodwill, determined based upon a relative fair value allocation approach, associated with the movement of certain product offerings from the Medical segment to the Interventional segment in order to align with the reportable segment structure that became effective beginning in the second quarter of fiscal year 2018. (d) The purchase price allocation adjustments increasing goodwill were primarily driven by the valuation of Bard developed technology assets, the associated deferred tax liability changes, increases to legal reserves and the alignment of the combined organization's accounting policies with respect to accrued liabilities and other accounts. (e)

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities (Tables)	12 Months Ended
	Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)	Net gains (losses) recorded to Accumulated other comprehensive income (loss) relating to the Company's net investment hedges as of September 30, 2019 and 2018 were as follows: (Millions of dollars) 2019 2018 Foreign currency-denominated debt $ 138 $ 81 Cross-currency swaps $ 73 $ — Foreign currency forward contract $ (9 ) $ —

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measurements (Tables)	12 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Schedule of Cash and Cash Equivalents	The following reconciles cash and equivalents and restricted cash reported within the Company's consolidated balance sheets at September 30, 2019 and 2018 to the total of these amounts shown on the Company's consolidated statements of cash flows: (Millions of dollars) September 30, 2019 September 30, 2018 Cash and equivalents $ 536 $ 1,140 Restricted cash 54 96 Cash and equivalents and restricted cash $ 590 $ 1,236

Debt (Tables)

Debt (Tables)	12 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Summary of Short-Term Debt	Short-term debt , net of unamortized debt issuance costs, at September 30 consisted of: (Millions of dollars) 2019 2018 Current portion of long-term debt 2.675% Notes due December 15, 2019 (a) $ 300 $ — 2.404% Notes due June 5, 2020 999 — 2.133% Notes due June 6, 2019 — 724 0.368% Notes due June 6, 2019 (a) — 1,157 Term Loan Facility due September 5, 2019 (b) — 710 Other 10 10 Total short-term debt $ 1,309 $ 2,601 (a) All or a portion of the aggregate principal amount outstanding was redeemed or repaid during 2019, as further discussed below. (b) Term loan facility entered into during the fourth quarter of fiscal year 2018, as further discussed below.
Summary of Long-Term Debt	Long-Term Debt , net of unamortized debt issuance costs, at September 30 consisted of: (Millions of dollars) 2019 2018 2.675% Notes due December 15, 2019 $ — $ 1,123 2.404% Notes due June 5, 2020 — 998 3.250% Notes due November 12, 2020 699 699 Floating Rate Notes due December 29, 2020 (a) 748 996 0.174% Notes due June 4, 2021 (b) 651 — 3.125% Notes due November 8, 2021 1,004 990 2.894% Notes due June 6, 2022 1,795 1,793 Floating Rate Notes due June 6, 2022 498 498 1.000% Notes due December 15, 2022 542 576 Revolving Credit Facility due December 29, 2022 480 — 3.300% Notes due March 1, 2023 295 296 1.401% Notes due May 24, 2023 325 346 0.632% Notes due June 4, 2023 (b) 867 — 3.875% Notes due May 15, 2024 181 182 3.363% Notes due June 6, 2024 1,740 1,738 3.734% Notes due December 15, 2024 1,369 1,368 3.020% Notes due May 24, 2025 306 324 1.208% Notes due June 4, 2026 (b) 649 — 6.700% Notes due December 1, 2026 (c) 174 177 1.900% Notes due December 15, 2026 541 575 3.700% Notes due June 6, 2027 (a) 1,714 2,383 7.000% Debentures due August 1, 2027 175 156 6.700% Debentures due August 1, 2028 175 154 6.000% Notes due May 15, 2039 246 246 5.000% Notes due November 12, 2040 (a) 124 296 4.875% Notes due May 15, 2044 (a) 248 331 4.685% Notes due December 15, 2044 (a) 1,045 1,159 4.669% Notes due June 6, 2047 1,485 1,484 Other long-term debt 5 8 Total Long-Term Debt $ 18,081 $ 18,894 (a) A portion of the aggregate principal amount outstanding was redeemed or repurchased during 2019, as further discussed below. (b) Includes notes issued during 2019, as further discussed below. (c) Includes notes assumed in connection with the Company's acquisition of Bard, as further discussed below. (Millions of dollars) Interest Rate and Maturity Aggregate Principal Amount Principal Amount Accepted for Exchange 4.400% Notes due January 15, 2021 $ 500 $ 432 3.000% Notes due May 15, 2026 500 470 6.700% Notes due December 1, 2026 150 137 Total $ 1,150 $ 1,039
Schedule of Extinguishment of Debt	Under this cash tender offer, the Company repurchased the following aggregate principal amounts of its long-term debt at an aggregate market price of $1.169 billion : Interest Rate and Maturity Aggregate Principal Amount (Millions of dollars) 3.700% Notes due June 6, 2027 $ 675 5.000% Notes due November 12, 2040 175 4.875% Notes due May 15, 2044 75 4.685% Notes due December 15, 2044 175 Total notes purchased $ 1,100
Summary of Interest Costs and Payments	A summary of interest costs and payments for the years ended September 30 is as follows: (Millions of dollars) 2019 2018 2017 Charged to operations $ 639 $ 706 $ 521 Capitalized 44 42 32 Total interest costs $ 683 $ 748 $ 553 Interest paid, net of amounts capitalized $ 658 $ 674 $ 435

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Provision for Income Taxes from Continuing Operations	The provision for income taxes the years ended September 30 consisted of: (Millions of dollars) 2019 2018 2017 Current: Federal $ 235 $ 665 $ (230 ) State and local, including Puerto Rico 41 73 (20 ) Foreign 300 387 200 $ 576 $ 1,124 $ (50 ) Deferred: Domestic $ (566 ) $ (201 ) $ (64 ) Foreign (67 ) (61 ) (10 ) (633 ) (262 ) (74 ) Income tax (benefit) provision $ (57 ) $ 862 $ (124 )
Components of Income from Continuing Operations Before Income Taxes	The components of Income Before Income Taxes for the years ended September 30 consisted of: (Millions of dollars) 2019 2018 2017 Domestic, including Puerto Rico $ 1,340 $ (135 ) $ (386 ) Foreign (164 ) 1,308 1,362 Income Before Income Taxes $ 1,176 $ 1,173 $ 976
Summary of Gross Amounts of Unrecognized Tax Benefits	The table below summarizes the gross amounts of unrecognized tax benefits without regard to reduction in tax liabilities or additions to deferred tax assets and liabilities if such unrecognized tax benefits were settled. The Company believes it is reasonably possible that the amount of unrecognized benefits will change due to one or more of the following events in the next twelve months: expiring statutes, audit activity, tax payments, other activity, or final decisions in matters that are the subject of controversy in various taxing jurisdictions in which we operate. (Millions of dollars) 2019 2018 2017 Balance at October 1 $ 543 $ 349 $ 469 Increase due to acquisitions 3 140 — Increase due to current year tax positions 11 43 41 Increase due to prior year tax positions 6 43 19 Decreases due to prior year tax positions (39 ) — (30 ) Decrease due to settlements with tax authorities — (29 ) (145 ) Decrease due to lapse of statute of limitations (5 ) (3 ) (5 ) Balance at September 30 $ 519 $ 543 $ 349
Deferred Income Taxes	Deferred income taxes at September 30 consisted of: 2019 2018 (Millions of dollars) Assets Liabilities Assets Liabilities Compensation and benefits $ 513 $ — $ 458 $ — Property and equipment — 255 — 253 Intangibles — 2,624 — 2,948 Loss and credit carryforwards 1,327 — 1,290 — Other 634 189 707 384 2,474 3,068 2,455 3,585 Valuation allowance (1,240 ) — (1,181 ) — Net (a) $ 1,234 $ 3,068 $ 1,275 $ 3,585 (a) Net deferred tax assets are included in Other Assets and net deferred tax liabilities are included in Deferred Income Taxes and Other on the consolidated balance sheets .
Reconciliation of Federal Statutory Tax Rate to Company's Effective Tax Rate	A reconciliation of the federal statutory tax rate to the Company’s effective income tax rate was as follows: 2019 2018 2017 Federal statutory tax rate 21.0 % 24.5 % 35.0 % New U.S. tax legislation (see discussion above) (4.3 ) 54.6 — State and local income taxes, net of federal tax benefit 0.1 0.8 (2.6 ) Effect of foreign and Puerto Rico (losses) earnings and foreign tax credits (12.2 ) 7.3 (40.8 ) Effect of Research Credits and FDII/Domestic Production Activities (3.3 ) (2.8 ) (2.7 ) Effect of change in accounting for excess tax benefit relating to share-based compensation (see Note 2) (4.7 ) (6.7 ) (7.9 ) Effect of gain on divestitures (2.0 ) 1.3 — Effect of uncertain tax position — 3.3 — Effect of valuation allowance release — (4.8 ) — Effect of application for change in accounting method — (4.5 ) — Effect of nondeductible compensation — 1.6 — Other, net 0.6 (1.1 ) 6.3 Effective income tax rate (4.8 )% 73.5 % (12.7 )%

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	12 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Other Nonoperating Income (Expense)	Other Income (Expense), Net (Millions of dollars) 2019 2018 2017 Royalty income (a) $ 64 $ 51 $ — Hurricane-related insurance proceeds 35 — — Vyaire Medical-related amounts and other income from divestitures (b) 6 288 (3 ) Other investment gains/losses 18 8 3 Net pension and postretirement benefit cost (c) (2 ) (13 ) (44 ) Losses on undesignated foreign exchange derivatives, net (23 ) (14 ) (11 ) Losses on debt extinguishment (d) (59 ) (16 ) (73 ) Gains on previously held investments (e) — — 24 Other 4 — 3 Other income (expense), net $ 43 $ 305 $ (101 ) (a) Primarily represents the royalty income stream acquired in the Bard transaction, net of non-cash purchase accounting amortization. The royalty income stream was previously reported by Bard as revenues. (b) The amount in 2019 represents income from transition services agreements (“TSA”) related to the Company’s 2018 and 2017 divestitures. The amount in 2018 includes the gain on the sale of the remaining ownership interest in its former Respiratory Solutions business and subsequent TSA income, net of the Company's share of equity investee results in the business. The amount in 2017 represents the Company’s share of equity investee results in the former business, net of TSA income. Additional disclosures regarding the Company’s divestiture transactions are provided in Note 11 . (c) Represents all components of the Company’s net periodic pension and postretirement benefit costs, aside from service cost, as a result of the adoption of an accounting standard as further discussed in Note 2 . (d) Represents losses recognized upon the extinguishment of certain senior notes, as further discussed in Note 16 . (e) Represents an acquisition-date accounting gain related to a previously-held equity method investment in an entity the Company acquired.
Trade Receivables, Allowances for Doubtful Accounts and Cash Discounts	The amounts recognized in 2019 , 2018 and 2017 relating to allowances for doubtful accounts and cash discounts, which are netted against trade receivables, are provided in the following table: (Millions of dollars) Allowance for Doubtful Accounts Allowance for Cash Discounts Total Balance at September 30, 2016 $ 61 $ 6 $ 67 Additions charged to costs and expenses 25 43 68 Deductions and other (32 ) (a) (45 ) (76 ) Balance at September 30, 2017 $ 54 $ 4 $ 58 Additions charged to costs and expenses 31 58 89 Deductions and other (11 ) (a) (50 ) (61 ) Balance at September 30, 2018 $ 75 $ 12 $ 86 Additions charged to costs and expenses 31 94 125 Deductions and other (31 ) (a) (92 ) (123 ) Balance at September 30, 2019 $ 75 $ 13 $ 88 (a) Accounts written off.
Inventories	Inventories at September 30 consisted of: (Millions of dollars) 2019 2018 Materials $ 544 $ 510 Work in process 318 297 Finished products 1,717 1,644 $ 2,579 $ 2,451
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net at September 30 consisted of: (Millions of dollars) 2019 2018 Land $ 164 $ 173 Buildings 2,842 2,724 Machinery, equipment and fixtures 7,932 7,405 Leasehold improvements 190 182 11,128 10,485 Less accumulated depreciation and amortization 5,469 5,111 $ 5,659 $ 5,375

Supplementary Data (Unaudited)

Supplementary Data (Unaudited) (Tables)	12 Months Ended
	Sep. 30, 2019
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	SUPPLEMENTARY QUARTERLY DATA (UNAUDITED) Millions of dollars, except per share amounts 2019 1 st 2 nd 3 rd 4 th Year (a) Revenues $ 4,160 $ 4,195 $ 4,350 $ 4,584 $ 17,290 Gross Profit 1,974 1,974 2,074 2,266 8,288 Net Income 599 20 451 163 1,233 Earnings (loss) per Share: Basic 2.09 (0.07 ) 1.53 0.46 4.01 Diluted 2.05 (0.07 ) 1.51 0.45 3.94 2018 1 st 2 nd 3 rd 4 th Year (a) Revenues $ 3,080 $ 4,222 $ 4,278 $ 4,402 $ 15,983 Gross Profit 1,553 1,606 2,017 2,094 7,269 Net (Loss) Income (136 ) (12 ) 594 (135 ) 311 (Loss) earnings per Share: (b) Basic (0.76 ) (0.19 ) 2.08 (0.64 ) 0.62 Diluted (0.76 ) (0.19 ) 2.03 (0.64 ) 0.60 (a) Quarterly amounts may not add to the year-to-date totals due to rounding. Earnings per share amounts are calculated from the underlying whole-dollar amounts. (b) The sums of basic and diluted earnings per share for the quarters of 2018 do not equal year-to-date amounts due to the impacts of shares issued during this fiscal year, in connection with the Bard acquisition, on the weighted average common shares included in the calculations of basic and diluted earnings per share. Additional disclosures regarding shares issued related to the Bard acquisition are provided in Notes 3 and 10.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Summary of Significant Accounting Policies [Line Items]
Depreciation and amortization expense	$ 633	$ 600	$ 406
Selling and administrative expense	4,332	4,016	2,909
Shipping and Handling
Summary of Significant Accounting Policies [Line Items]
Selling and administrative expense	$ 511	$ 479	$ 365
Minimum
Summary of Significant Accounting Policies [Line Items]
Maturity period of short-term investments at the time of purchase	3 months
Minimum | Core and Developed Technology
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	15 years
Minimum | Customer relationships
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	10 years
Minimum | Patents, Trademarks, and Other
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	1 year
Minimum | Buildings
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	20 years
Minimum | Machinery and Equipment
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	4 years
Minimum | Leasehold Improvements
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	1 year
Maximum
Summary of Significant Accounting Policies [Line Items]
Maturity period of short-term investments at the time of purchase	1 year
Maximum | Core and Developed Technology
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	20 years
Maximum | Customer relationships
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	15 years
Maximum | Patents, Trademarks, and Other
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	40 years
Maximum | Buildings
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	45 years
Maximum | Machinery and Equipment
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	13 years
Maximum | Leasehold Improvements
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	20 years

Shareholders' Equity - Changes

Shareholders' Equity - Changes in Certain Components of Shareholders' Equity (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance				$ 20,994					$ 20,994
Beginning balance (shares)				(78,462,971)					(78,462,971)
Net Income	$ 163	$ 451	$ 20	$ 599	$ (135)	$ 594	$ (12)	$ (136)	$ 1,233	$ 311	$ 1,100
Ending balance	$ 21,081				$ 20,994				$ 21,081	$ 20,994
Ending balance (shares)	(76,259,835)				(78,462,971)				(76,259,835)	(78,462,971)
Common Stock Issued at Par Value
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance				347				347	$ 347	$ 347	333
Stock Issued During Period, Value, New Issues											14
Ending balance	$ 347				$ 347				347	347	347
Capital in Excess of Par Value
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance				16,179				9,619	16,179	9,619	4,693
Stock Issued During Period, Value, New Issues											4,810
Share-based compensation and other plans, net									(170)	(246)	(65)
Share-based compensation									261	328	180
Stock Issued During Period, Value, Acquisitions										6,478
Ending balance	16,270				16,179				16,270	16,179	9,619
Retained Earnings
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance				12,596				13,111	12,596	13,111	12,727
Net Income									1,233	311	1,100
Cash dividends, common									(832)	(775)	(645)
Dividends, Preferred Stock									(152)	(152)	(70)
Share-based compensation and other plans, net									(1)	(2)	(1)
Effect of change in accounting principle (see Note 2)	68				103				68	103
Ending balance	12,913				12,596				12,913	12,596	13,111
Deferred Compensation
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance				22				19	22	19	22
Share-based compensation and other plans, net									1	3	(3)
Ending balance	23				22				23	22	19
Treasury Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance				$ (6,243)				$ (8,427)	$ (6,243)	$ (8,427)	$ (8,212)
Beginning balance (shares)				(78,463,000)				(118,745,000)	(78,463,000)	(118,745,000)	(119,371,000)
Share-based compensation and other plans, net									$ 53	$ 62	$ 6
Share-based compensation plans, net (shares)									2,155,000	2,982,000	1,908,000
Common stock held in trusts, net (shares)									48,000	(6,000)	7,000
Repurchase of common stock (shares)											1,289,000
Repurchase of common stock											$ 220
Stock Issued During Period, Value, Acquisitions										$ 2,121
Stock Issued During Period, Shares, Acquisitions										37,306,000
Ending balance	$ (6,190)				$ (6,243)				$ (6,190)	$ (6,243)	$ (8,427)
Ending balance (shares)	(76,260,000)				(78,463,000)				(76,260,000)	(78,463,000)	(118,745,000)

Shareholders' Equity - Change_2

Shareholders' Equity - Changes in Certain Components of Shareholders' Equity (Detail II) - $ / shares	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Stockholders' Equity Note [Abstract]
Common stock dividend per share (USD per share)	$ 3.08	$ 3	$ 2.92

Shareholders' Equity - Accumula

Shareholders' Equity - Accumulated Other Comprehensive (Loss) Income (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive (loss) income, beginning balance	$ (1,909)	$ (1,723)	$ (1,929)
Other comprehensive income before reclassifications, net of taxes	(427)	(142)	140
Amounts reclassified into income, net of taxes	52	57	66
Tax effects reclassified to retained earnings		(103)
Accumulated other comprehensive (loss) income, ending balance	(2,283)	(1,909)	(1,723)
Foreign Currency Translation
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive (loss) income, beginning balance	(1,162)	(1,001)	(1,011)
Other comprehensive income before reclassifications, net of taxes	(93)	(161)	11
Amounts reclassified into income, net of taxes	0	0	0
Tax effects reclassified to retained earnings		0
Accumulated other comprehensive (loss) income, ending balance	(1,256)	(1,162)	(1,001)
Benefit Plans
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive (loss) income, beginning balance	(729)	(703)	(883)
Other comprehensive income before reclassifications, net of taxes	(325)	19	121
Amounts reclassified into income, net of taxes	49	52	58
Tax effects reclassified to retained earnings		(99)
Accumulated other comprehensive (loss) income, ending balance	(1,005)	(729)	(703)
Cash Flow Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive (loss) income, beginning balance	(17)	(18)	(35)
Other comprehensive income before reclassifications, net of taxes	(9)	0	8
Amounts reclassified into income, net of taxes	3	5	8
Tax effects reclassified to retained earnings		(4)
Accumulated other comprehensive (loss) income, ending balance	$ (23)	$ (17)	$ (18)

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	May 31, 2017	Jun. 30, 2017	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Class of Stock [Line Items]
Proceeds from issuance of equity securities	$ 4,800,000,000	$ 4,800,000,000	$ 0	$ 0	$ 4,827,000,000
Minimum
Class of Stock [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion			11,700
Maximum
Class of Stock [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion			14,000
Common Stock Issued at Par Value
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	14,025
Convertible Preferred Stock
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	2,475
Preferred Stock, Depositary Share Ownership Interest, Percentage	5.00%
Preferred Stock, Dividend Rate, Percentage			6.125%
Preferred Stock, Liquidation Preference Per Share			$ 1,000
Depositary Share Liquidation Preference			$ 50

Shareholders' Equity - Other Co

Shareholders' Equity - Other Comprehensive Income (Loss), Tax (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Stockholders' Equity Note [Abstract]
Income tax benefit (provision) for net (losses) gains recorded in other comprehensive income	$ 91	$ (19)	$ (60)

Earnings per Share - Weighted A

Earnings per Share - Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings Per Share (Detail) - shares shares in Thousands	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Earnings Per Share [Abstract]
Average common shares outstanding (shares)	269,943	258,354	218,943
Dilutive share equivalents from share-based plans (shares)	4,832	6,267	4,645
Average common and common equivalent shares outstanding - assuming dilution (shares)	274,775	264,621	223,588

Earnings per Share - Weighted_2

Earnings per Share - Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings Per Share Footnotes (Detail) - shares	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	0	0
Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	12,000,000	12,000,000	5,000,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Millions	1 Months Ended	12 Months Ended
	Apr. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Aug. 31, 2019USD ($)
Loss Contingencies [Line Items]
Rental expense for operating leases		$ 169	$ 149	$ 110
Aggregate future purchase commitments		1,364
Loss Contingency Accrual		2,500	2,000
QualifiedSettlementFunds		53	94
Loss Contingency, Receivable		150	$ 343
Other Operating Income (Expense)
Loss Contingencies [Line Items]
Product Liability Accrual, Period Expense		$ 914
HerniaProductClaims
Loss Contingencies [Line Items]
Loss Contingency, Pending Claims, Number		12,040
WomensHealthProductClaims
Loss Contingencies [Line Items]
Loss Contingency, Pending Claims, Number		885
ClaimsLackingSufficientInformation		1,010
NumberOfClaimsInSettlementAgreement		15,160
Damages awarded	$ 68
PaymentstoSupplier		$ 121			$ 20
WomensHealthProductClaims | Compensatory
Loss Contingencies [Line Items]
Damages awarded	33
WomensHealthProductClaims | Punitive
Loss Contingencies [Line Items]
Damages awarded	$ 35
FilterProductClaims
Loss Contingencies [Line Items]
Loss Contingency, Pending Claims, Number		4,485
Loss Contingency, Claims Settled, Number		4,200

Commitments and Contingencies_2

Commitments and Contingencies Future Minimum Rental Commitments (Details) $ in Millions	Sep. 30, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
Future minimum rental commitments on noncancelable leases due in 2020	$ 122
Future minimum rental commitments on noncancelable leases due in 2021	103
Future minimum rental commitments on noncancelable leases due in 2022	83
Future minimum rental commitments on noncancelable leases due in 2023	57
Future minimum rental commitments on noncancelable leases due in 2024	56
Future minimum rental commitments on noncancelable leases thereafter	$ 123

Revenues Revenues - Additional

Revenues Revenues - Additional Information (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 $ in Billions	Sep. 30, 2019USD ($)
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	3 years
Products and/or Services
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Amount	$ 1.8
Consumables
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Amount	$ 2.8

Segment Data - Additional Infor

Segment Data - Additional Information (Detail) $ in Millions	12 Months Ended
	Sep. 30, 2019USD ($)customersegment	Sep. 30, 2018USD ($)customer	Sep. 30, 2017USD ($)customer
Segment Reporting Information [Line Items]
Number of principal business segments (segments) | segment	3
Number of customers accounted for 10% or more of revenues (customers) | customer	0	0	0
Inventory Recall Expense	$ 75
Gain (Loss) on Disposition of Business	336	$ 0	$ 0
Gain on Sale of Investments	0	303	0
Lease Contract Modification Related Charge	0	0	748
Advanced Bioprocessing
Segment Reporting Information [Line Items]
Gain (Loss) on Disposition of Business	336
CR Bard Inc
Segment Reporting Information [Line Items]
Recognition Of Fair Value Adjustment To Inventory Acquired		478
Medical
Segment Reporting Information [Line Items]
AllocatedCosts			166
Asset Impairment Charges		58
Medical | CR Bard Inc
Segment Reporting Information [Line Items]
Recognition Of Fair Value Adjustment To Inventory Acquired		60
Life Sciences
Segment Reporting Information [Line Items]
AllocatedCosts			$ 113
Impairment of Intangible Assets (Excluding Goodwill)		81
Interventional
Segment Reporting Information [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)	30
Interventional | CR Bard Inc
Segment Reporting Information [Line Items]
Recognition Of Fair Value Adjustment To Inventory Acquired		$ 418
Other Operating Income (Expense)
Segment Reporting Information [Line Items]
Product Liability Accrual, Period Expense	$ 914

Segment Data Segment Data - Rev

Segment Data Segment Data - Revenues by Geographic Areas (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Segment Reporting Information [Line Items]
Revenues	$ 4,584	$ 4,350	$ 4,195	$ 4,160	$ 4,402	$ 4,278	$ 4,222	$ 3,080	$ 17,290	$ 15,983	$ 12,093
Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues									9,064	8,616	7,419
Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues									4,300	4,330	3,988
Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues									3,926	3,037	685
Medication Delivery Solutions | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues									3,859	3,644	2,812
Medication Management Solutions | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues									2,629	2,470	2,295
Diabetes Care | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues									1,110	1,105	1,056
Pharmaceutical Systems | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues									1,465	1,397	1,256
Preanalytical Systems | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues									1,558	1,553	1,471
Diagnostic Systems | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues									1,547	1,536	1,378
Biosciences | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues									1,194	1,241	1,139
Surgery | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues									1,397	1,192	666
Peripheral Intervention | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues									1,389	1,045	19
Urology and Critical Care | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues									1,140	800	0
United States
Segment Reporting Information [Line Items]
Revenues									9,730	8,768	6,504
United States | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues									5,116	4,770	4,095
United States | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues									1,931	1,914	1,818
United States | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues									2,682	2,084	591
United States | Medication Delivery Solutions | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues									2,048	1,892	1,378
United States | Medication Management Solutions | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues									2,104	1,957	1,843
United States | Diabetes Care | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues									573	564	546
United States | Pharmaceutical Systems | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues									392	357	328
United States | Preanalytical Systems | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues									774	761	741
United States | Diagnostic Systems | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues									672	678	622
United States | Biosciences | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues									485	475	455
United States | Surgery | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues									1,098	946	577
United States | Peripheral Intervention | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues									787	594	14
United States | Urology and Critical Care | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues									797	544	0
Non-US
Segment Reporting Information [Line Items]
Revenues									7,560	7,215	5,589
Non-US | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues									3,947	3,846	3,325
Non-US | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues									2,368	2,416	2,170
Non-US | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues									1,244	953	95
Non-US | Medication Delivery Solutions | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues									1,811	1,752	1,434
Non-US | Medication Management Solutions | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues									525	513	452
Non-US | Diabetes Care | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues									538	541	510
Non-US | Pharmaceutical Systems | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues									1,073	1,040	929
Non-US | Preanalytical Systems | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues									784	792	730
Non-US | Diagnostic Systems | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues									875	858	756
Non-US | Biosciences | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues									709	766	684
Non-US | Surgery | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues									299	245	89
Non-US | Peripheral Intervention | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues									602	451	6
Non-US | Urology and Critical Care | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues									$ 342	$ 256	$ 0

Segment Data - Financial Inform

Segment Data - Financial Information for Company's Segments (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Segment Reporting Information [Line Items]
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	$ 1,176	$ 1,173	$ 976
Acquisitions and other restructurings	480	740	354
Total Assets	51,765	53,904	37,734
Total Capital Expenditures	957	895	727
Total Depreciation and Amortization	2,253	1,978	1,088
Operating Segments
Segment Reporting Information [Line Items]
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	4,976	4,137	2,927
Total Assets	49,217	50,938	22,388
Operating Segments | Medical
Segment Reporting Information [Line Items]
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	2,824	2,624	1,907
Total Assets	22,925	23,493	15,552
Total Capital Expenditures	577	560	486
Total Depreciation and Amortization	1,073	1,028	773
Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	1,248	1,207	772
Total Assets	4,135	4,225	4,056
Total Capital Expenditures	230	255	212
Total Depreciation and Amortization	284	275	254
Operating Segments | Interventional
Segment Reporting Information [Line Items]
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	903	306	248
Total Assets	22,157	23,219	2,780
Total Capital Expenditures	120	65	16
Total Depreciation and Amortization	881	658	52
Segment Reconciling Items
Segment Reporting Information [Line Items]
Acquisitions and other restructurings	480	740	354
Net interest expense	(627)	(641)	(445)
Corporate and All Other
Segment Reporting Information [Line Items]
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	(2,693)	(1,583)	(1,152)
Total Assets	2,548	2,966	15,347
Total Capital Expenditures	30	14	13
Total Depreciation and Amortization	$ 14	$ 17	$ 10

Segment Data - Revenues to Unaf

Segment Data - Revenues to Unaffiliated Customers and Long-lived Assets Including Property, Plant and Equipment (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 4,584	$ 4,350	$ 4,195	$ 4,160	$ 4,402	$ 4,278	$ 4,222	$ 3,080	$ 17,290	$ 15,983	$ 12,093
Long-Lived Assets	45,101				46,494				45,101	46,494	19,101
Corporate
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	377				375				377	375	366
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									9,730	8,768	6,504
Long-Lived Assets	37,053				38,982				37,053	38,982	13,151
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									3,359	3,298	2,588
Long-Lived Assets	5,483				5,640				5,483	5,640	4,421
Greater Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									2,726	2,460	1,744
Long-Lived Assets	1,328				851				1,328	851	578
Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									1,476	1,457	1,257
Long-Lived Assets	$ 861				$ 645				$ 861	$ 645	$ 584

Share-Based Compensation - Comp

Share-Based Compensation - Compensation Cost Relating to Share-Based Payments (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost relating to share-based payments	$ 265	$ 332	$ 177
Income tax benefit recognized	62	79	61
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost relating to share-based payments	37	36	30
Selling and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost relating to share-based payments	145	136	113
Research and development expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost relating to share-based payments	32	29	24
Acquisitions and other restructurings
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost relating to share-based payments	$ 50	$ 130	$ 10

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expense	$ 265	$ 332	$ 177
SARs vesting period	4 years
SARs terms of award	10 years
Stock Issued under SARs exercised (in shares)	1,000,000
Unrecognized compensation expense for all non-vested share-based awards	$ 266
Weighted-average remaining life non-vested share-based awards	1 year 10 months 28 days
Shares were authorized for future grants	5,600,000
Shares issuable under deferred compensation plan	320,000
Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferral plan, shares held in trust	105,000
Performance-Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units vesting period	3 years
Performance period	3 years
Weighted average remaining vesting term	1 year 2 months 19 days
Performance-Based Restricted Stock Units | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance payout, percent	0.00%
Performance-Based Restricted Stock Units | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance payout, percent	200.00%
Time-Vested Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units vesting period	3 years
Weighted average remaining vesting term	10 months 24 days
Time-Vested Restricted Stock Units | Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units vesting period	1 year
Acquisitions and other restructurings
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expense	$ 50	130	$ 10
Acquisitions and other restructurings | CR Bard Inc
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expense	$ 40	$ 126

Share-Based Compensation - Assu

Share-Based Compensation - Assumptions for Estimation of Fair Values of Stock Appreciation Rights Granted During Reporting Periods (Detail) - Stock Appreciation Rights (SARs) - $ / shares	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	3.05%	2.32%	2.33%
Expected volatility	18.00%	19.00%	20.00%
Expected dividend yield	1.27%	1.33%	1.71%
Expected life	7 years 2 months 12 days	7 years 4 months 24 days	7 years 6 months
Fair value derived (USD per share)	$ 51.86	$ 46.10	$ 33.81

Share-Based Compensation - Summ

Share-Based Compensation - Summary of SARs Outstanding (Detail) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
SARs, beginning balance (shares) | shares	7,986
SARs, granted (shares) | shares	859
SARs, exercised (shares) | shares	(1,779)
SARs, forfeited, canceled or expired (shares) | shares	(168)
SARs, ending balance (shares) | shares	6,899
SARs, Vested and expected to vest at ending balance (shares) | shares	6,692
SARs, Exercisable at ending balance (shares) | shares	4,833
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
SARs, weighted average exercise price, beginning balance (USD per share) | $ / shares	$ 125.73
SARs, weighted average exercise price, granted (USD per share) | $ / shares	242.10
SARs, weighted average exercise price, exercised (USD per share) | $ / shares	102.14
SARs, weighted average exercise price, forfeited, canceled or expired (USD per share) | $ / shares	186.18
SARs, weighted average exercise price, ending balance (USD per share) | $ / shares	144.84
SARs, weighted average exercise price, vested and expected to vest (USD per share) | $ / shares	142.87
SARs, weighted average exercise price, exercisable (USD per share) | $ / shares	$ 117.65
SARs, weighted average remaining contractual term	5 years 8 months 12 days
SARs, weighted average remaining contractual term, vested and expected to vest	5 years 7 months 13 days
SARs, weighted average remaining contractual term, exercisable	4 years 8 months 8 days
SARs, aggregate intrinsic value | $	$ 746
SARs, aggregate intrinsic value, vested and expected to vest | $	737
SARs, aggregate intrinsic value, exercisable | $	$ 654

Share-Based Compensation Summar

Share-Based Compensation Summary of SARs Exercised (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Share-based Payment Arrangement [Abstract]
Total intrinsic value of SARs exercised	$ 260	$ 333	$ 148
Share Based Compensation Tax Benefit Realized From Exercise Of Stock Appreciation Rights	62	90	53
Total fair value of SARs vested	$ 66	$ 107	$ 30

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Performance-Based Restricted Stock Units Outstanding (Detail) - $ / shares shares in Thousands	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Performance-Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Stock units, beginning balance (shares)	1,032
Granted, sock units (shares)	381
Distributed, stock units (shares)	(142)
Forfeited, canceled or expired, stock units (shares)	(316)
Stock units, ending balance (shares)	955	1,032
Stock units, vested and expected to vest at ending balance (shares)	306
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Stock units exercise price, beginning balance (USD per share)	$ 190.57
Granted, stock units weighted average grant date fair value (USD per share)	237.55	$ 251.75	$ 174.92
Distributed, stock units exercise price (USD per share)	153.73
Forfeited, canceled or expired, stock units exercise price (USD per share)	182.50
Stock units exercise price, ending balance (USD per share)	221.73	$ 190.57
Stock units, vested and expected to vest at ending balance, exercise price (USD per share)	$ 218.06
Time-Vested Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Stock units, beginning balance (shares)	2,765
Granted, sock units (shares)	755
Distributed, stock units (shares)	(906)
Forfeited, canceled or expired, stock units (shares)	(546)
Stock units, ending balance (shares)	2,068	2,765
Stock units, vested and expected to vest at ending balance (shares)	1,964
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Stock units exercise price, beginning balance (USD per share)	$ 194.92
Granted, stock units weighted average grant date fair value (USD per share)	235.50	$ 216.06	$ 165.96
Distributed, stock units exercise price (USD per share)	189.06
Forfeited, canceled or expired, stock units exercise price (USD per share)	201.85
Stock units exercise price, ending balance (USD per share)	210.48	$ 194.92
Stock units, vested and expected to vest at ending balance, exercise price (USD per share)	$ 209.67

Share-Based Compensation - Su_3

Share-Based Compensation - Summary of Performance-Based Restricted Stock Units Outstanding Footnote (Detail) shares in Thousands	12 Months Ended
	Sep. 30, 2019shares
Share-based Payment Arrangement [Abstract]
Percentage of target payout on which performance-based restricted stock units are based	200.00%
Expected forfeited performance-based restricted stock units (shares)	65
Units in excess of the expected performance payout (shares)	585

Share-Based Compensation Weight

Share-Based Compensation Weighted Average Grant Date Fair Value of Restricted Stock Units (Details) - $ / shares	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Performance-Based Restricted Stock Units
Schedule Of Share Based Compensation, Restricted Stock Units Award, Grant Date Fair Value of Units Granted [Line Items]
Granted, stock units weighted average grant date fair value (USD per share)	$ 237.55	$ 251.75	$ 174.92
Time-Vested Restricted Stock Units
Schedule Of Share Based Compensation, Restricted Stock Units Award, Grant Date Fair Value of Units Granted [Line Items]
Granted, stock units weighted average grant date fair value (USD per share)	$ 235.50	$ 216.06	$ 165.96

Share-Based Compensation Fair V

Share-Based Compensation Fair Value of Stock Units Vested (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Performance-Based Restricted Stock Units
Schedule Of Share Based Compensation, Restricted Stock Units, Fair Value of Stock Units Vested [Line Items]
Total fair value of restricted stock units	$ 33	$ 31	$ 32
Time-Vested Restricted Stock Units
Schedule Of Share Based Compensation, Restricted Stock Units, Fair Value of Stock Units Vested [Line Items]
Total fair value of restricted stock units	$ 254	$ 362	$ 139

Benefit Plans - Net Pension and

Benefit Plans - Net Pension and Other Postretirement Cost (Detail) - Pension Plans - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 134	$ 136	$ 110
Interest cost	107	90	61
Expected return on plan assets	(180)	(154)	(112)
Amortization of prior service credit	(13)	(13)	(14)
Amortization of loss	78	78	92
Settlements	10	2	0
Net pension cost	135	137	138
Foreign Plans
Defined Benefit Plan Disclosure [Line Items]
Net pension cost	$ 32	$ 34	$ 43

Benefit Plans - Additional Info

Benefit Plans - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Oct. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Defined Benefit Plan Disclosure [Line Items]
Percent of total assets domestic plans		71.00%
Cost of the savings incentive plan		$ 126	$ 108	$ 83
Fixed Income Funds
Defined Benefit Plan Disclosure [Line Items]
Company's Target allocation percentage for asset mix		40.00%
Diversified
Defined Benefit Plan Disclosure [Line Items]
Company's Target allocation percentage for asset mix		25.00%
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Company's Target allocation percentage for asset mix		35.00%
Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Pension plan assets at fair value		$ 2,926	2,642	1,932
Pension plan projected benefit obligations		3,731	3,246	$ 2,647
Employer contribution		258	400
Foreign Plans | Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Pension plan assets at fair value		859	821
Pension plan projected benefit obligations		$ 1,244	1,064
Percent of total plan assets foreign plans		29.00%
Foreign Plans | Pension Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Pension plan assets at fair value		$ 319	314
United States | Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Pension plan assets at fair value		2,068	1,821
Employer contribution	$ 200
United States | Pension Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Pension plan assets at fair value		922	536
United States | Other Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Pension plan projected benefit obligations		$ 153	$ 148

Benefit Plans - Change in Benef

Benefit Plans - Change in Benefit Obligation, Change in Fair Value of Plan Assets (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Amounts recognized in the Consolidated Balance Sheets at September 30:
Long-term Employee Benefit Obligations	$ (1,272)	$ (1,056)
Pension Plans
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Beginning obligation	3,246	2,647
Service cost	134	136	$ 110
Interest cost	107	90	61
Plan amendments	(3)	0
Benefits paid	(153)	(162)
Impact of (divestitures) acquisitions	(9)	758
Actuarial loss (gain)	514	(82)
Settlements	(63)	(122)
Other, includes translation	49	19
Ending obligation	3,731	3,246	2,647
Change in fair value of plan assets:
Beginning fair value	2,642	1,932
Actual return on plan assets	279	70
Employer contribution	258	400
Benefits paid	(153)	(162)
Impact of (divestitures) acquisitions	(7)	539
Settlements	(63)	(122)
Other, includes translation	(30)	(15)
Ending fair value	2,926	2,642	$ 1,932
Funded Status at September 30:
Unfunded benefit obligation	(804)	(604)
Amounts recognized in the Consolidated Balance Sheets at September 30:
Other	11	15
Salaries, wages and related items	(22)	(15)
Long-term Employee Benefit Obligations	(793)	(604)
Net amount recognized	(804)	(604)
Amounts recognized in Accumulated other comprehensive income (loss) before income taxes at September 30:
Prior service credit	44	60
Net actuarial loss	(1,289)	(982)
Net amount recognized	$ (1,246)	$ (921)

Benefit Plans - Pension Plans w

Benefit Plans - Pension Plans with Accumulated Benefit Obligations (Detail) - USD ($) $ in Millions	Sep. 30, 2019	Sep. 30, 2018
Retirement Benefits [Abstract]
Accumulated benefit obligation exceeds the fair value of plan assets, projected benefit obligation	$ 3,623	$ 2,618
Accumulated benefit obligation exceeds the fair value of plan assets, accumulated benefit obligation	3,476	2,533
Accumulated benefit obligation exceeds the fair value of plan assets, fair value of plan assets	2,821	2,012
Projected benefit obligation exceeds the fair value of plan assets, projected benefit obligation	3,698	3,121
Projected benefit obligation exceeds the fair value of plan assets, fair value of plan assets	$ 2,882	$ 2,502

Benefit Plans - Weighted Averag

Benefit Plans - Weighted Average Assumptions Determining Pension Plan (Detail) - Pension Plans	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Foreign Plans
Net Cost
Discount rate	2.30%	2.30%	1.70%
Expected return on plan assets	4.98%	4.95%	4.65%
Rate of compensation increase	2.36%	2.31%	2.33%
Benefit Obligation
Discount rate	1.39%	2.30%	2.25%
Rate of compensation increase	2.35%	2.36%	2.30%
United States
Net Cost
Discount rate	4.26%	3.71%	3.42%
Expected return on plan assets	7.25%	7.20%	7.25%
Rate of compensation increase	4.29%	4.51%	4.25%
Benefit Obligation
Discount rate	3.21%	4.26%	3.72%
Rate of compensation increase	4.29%	4.29%	4.51%

Benefit Plans - Expected Benefi

Benefit Plans - Expected Benefit Payments (Detail) - Pension Plans $ in Millions	Sep. 30, 2019USD ($)
Defined Benefit Plan Disclosure [Line Items]
2020	$ 212
2021	171
2022	173
2023	185
2024	190
2025-2029	$ 1,066

Benefit Plans - Fair Value Meas

Benefit Plans - Fair Value Measurements of U.S. Plan Assets (Detail) - Pension Plans - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 2,926	$ 2,642	$ 1,932
United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,068	1,821
United States | Mortgage and asset-backed securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	28
United States | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	401	484
United States | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	108	257
United States | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	85	122
United States | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	37	0
United States | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	922	536
United States | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	254	39
United States | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 261	$ 356
Foreign Plans
Defined Benefit Plan Disclosure [Line Items]
Discount rate	2.30%	2.30%	1.70%
Fair value of plan assets	$ 859	$ 821
Expected return on plan assets	4.98%	4.95%	4.65%
Rate of compensation increase	2.36%	2.31%	2.33%
Discount rate	1.39%	2.30%	2.25%
Rate of compensation increase	2.35%	2.36%	2.30%
Foreign Plans | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 33	$ 28
Foreign Plans | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3	6
Foreign Plans | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	199	150
Foreign Plans | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	100	96
Foreign Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	319	314
Foreign Plans | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	8	9
Foreign Plans | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	53	74
Quoted Prices in Active Markets for Identical Assets (Level 1) | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	733	600
Quoted Prices in Active Markets for Identical Assets (Level 1) | United States | Mortgage and asset-backed securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | United States | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	48	101
Quoted Prices in Active Markets for Identical Assets (Level 1) | United States | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	85	199
Quoted Prices in Active Markets for Identical Assets (Level 1) | United States | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	69	85
Quoted Prices in Active Markets for Identical Assets (Level 1) | United States | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | United States | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	140	176
Quoted Prices in Active Markets for Identical Assets (Level 1) | United States | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	254	39
Quoted Prices in Active Markets for Identical Assets (Level 1) | United States | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	138	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Foreign Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	549	546
Quoted Prices in Active Markets for Identical Assets (Level 1) | Foreign Plans | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	15	14
Quoted Prices in Active Markets for Identical Assets (Level 1) | Foreign Plans | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	3
Quoted Prices in Active Markets for Identical Assets (Level 1) | Foreign Plans | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	105	104
Quoted Prices in Active Markets for Identical Assets (Level 1) | Foreign Plans | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	63	63
Quoted Prices in Active Markets for Identical Assets (Level 1) | Foreign Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	305	299
Quoted Prices in Active Markets for Identical Assets (Level 1) | Foreign Plans | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	8	9
Quoted Prices in Active Markets for Identical Assets (Level 1) | Foreign Plans | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	52	55
Significant Other Observable Inputs (Level 2) | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	429	497
Significant Other Observable Inputs (Level 2) | United States | Mortgage and asset-backed securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	28
Significant Other Observable Inputs (Level 2) | United States | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	353	383
Significant Other Observable Inputs (Level 2) | United States | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	23	57
Significant Other Observable Inputs (Level 2) | United States | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	16	28
Significant Other Observable Inputs (Level 2) | United States | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	37	0
Significant Other Observable Inputs (Level 2) | United States | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Other Observable Inputs (Level 2) | United States | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Other Observable Inputs (Level 2) | United States | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Other Observable Inputs (Level 2) | Foreign Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	182	146
Significant Other Observable Inputs (Level 2) | Foreign Plans | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	18	14
Significant Other Observable Inputs (Level 2) | Foreign Plans | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3	3
Significant Other Observable Inputs (Level 2) | Foreign Plans | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	94	46
Significant Other Observable Inputs (Level 2) | Foreign Plans | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	37	33
Significant Other Observable Inputs (Level 2) | Foreign Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Other Observable Inputs (Level 2) | Foreign Plans | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Other Observable Inputs (Level 2) | Foreign Plans | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1	20
Significant Unobservable Inputs (Level 3) | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | United States | Mortgage and asset-backed securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | United States | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | United States | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | United States | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | United States | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | United States | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | United States | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | United States | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | Foreign Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	113	114
Significant Unobservable Inputs (Level 3) | Foreign Plans | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | Foreign Plans | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | Foreign Plans | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | Foreign Plans | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | Foreign Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | Foreign Plans | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Significant Unobservable Inputs (Level 3) | Foreign Plans | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	906	724
Net Asset Value | United States | Mortgage and asset-backed securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | United States | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | United States | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | United States | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	8
Net Asset Value | United States | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | United States | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	782	360
Net Asset Value | United States | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | United States | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	124	356
Net Asset Value | Foreign Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	14	15
Net Asset Value | Foreign Plans | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	14	15
Net Asset Value | Foreign Plans | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 0	$ 0

Benefit Plans - Fair Value Me_2

Benefit Plans - Fair Value Measurements of Foreign Plan Assets (Detail) - Pension Plans - USD ($) $ in Millions	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 2,926	$ 2,642	$ 1,932
Foreign Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	859	821
Foreign Plans | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	33	28
Foreign Plans | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3	6
Foreign Plans | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	199	150
Foreign Plans | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	100	96
Foreign Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	319	314
Foreign Plans | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	8	9
Foreign Plans | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	30	30
Foreign Plans | Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	113	114
Foreign Plans | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	53	74
Foreign Plans | Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	549	546
Foreign Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	15	14
Foreign Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	3
Foreign Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	105	104
Foreign Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	63	63
Foreign Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	305	299
Foreign Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	8	9
Foreign Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	52	55
Foreign Plans | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	182	146
Foreign Plans | Significant Other Observable Inputs (Level 2) | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	18	14
Foreign Plans | Significant Other Observable Inputs (Level 2) | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3	3
Foreign Plans | Significant Other Observable Inputs (Level 2) | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	94	46
Foreign Plans | Significant Other Observable Inputs (Level 2) | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	37	33
Foreign Plans | Significant Other Observable Inputs (Level 2) | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Significant Other Observable Inputs (Level 2) | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Significant Other Observable Inputs (Level 2) | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	30	30
Foreign Plans | Significant Other Observable Inputs (Level 2) | Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Significant Other Observable Inputs (Level 2) | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1	20
Foreign Plans | Significant Unobservable Inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	113	114
Foreign Plans | Significant Unobservable Inputs (Level 3) | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Significant Unobservable Inputs (Level 3) | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Significant Unobservable Inputs (Level 3) | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Significant Unobservable Inputs (Level 3) | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Significant Unobservable Inputs (Level 3) | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Significant Unobservable Inputs (Level 3) | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Significant Unobservable Inputs (Level 3) | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Foreign Plans | Significant Unobservable Inputs (Level 3) | Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	113	114
Foreign Plans | Significant Unobservable Inputs (Level 3) | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	14	15
Net Asset Value | Foreign Plans | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	14	15
Net Asset Value | Foreign Plans | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans | Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | Foreign Plans | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 0	$ 0

Acquisitions - Additional Info

Acquisitions - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	May 31, 2017	Jun. 30, 2017	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017	Dec. 29, 2017
Business Acquisition [Line Items]
Proceeds from issuance of equity securities	$ 4,800,000,000	$ 4,800,000,000	$ 0	$ 0	$ 4,827,000,000
BusinessCombinationConsiderationTransferredEquityInterestsRecognizedAsIncreaseToAdditionalPaidInCapitalCommonStock						$ 6,500,000,000
BusinessCombinationConsiderationTransferredEquityInterestsRecognizedAsDecreaseToTreasuryStock						2,100,000,000
TransitionTaxPayableAcquiree						$ 183,000,000
CR Bard Inc
Business Acquisition [Line Items]
Cash consideration per share (USD per share)						$ 222.93
Conversion factor						0.5077
Proceeds from Issuance of Debt		$ 9,600,000,000
Business Acquisition, Goodwill, Expected Tax Deductible Amount			$ 0
Product liability and other legal reserves						$ 2,004,000,000
Business Combination, Acquisition Related Costs				56,000,000	$ 25,000,000
Business combination, pro forma information, revenue of acquiree since acquisition date,				3,000,000,000
Business combination, pro forma information, loss of acquiree since acquisition date				107,000,000
Recognition Of Fair Value Adjustment To Inventory Acquired				$ 478,000,000
CR Bard Inc | Developed Technology
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			14 years
CR Bard Inc | Customer relationships
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			13 years
CR Bard Inc | Measurement Input, Discount Rate | Developed Technology
Business Acquisition [Line Items]
Business Combination Intangible Asset Measurement Input			8.00%
CR Bard Inc | Measurement Input, Discount Rate | Customer relationships
Business Acquisition [Line Items]
Business Combination Intangible Asset Measurement Input			8.00%

Acquisitions - Fair Value of C

Acquisitions - Fair Value of Consideration Transferred (Detail) - USD ($) $ in Millions	Dec. 29, 2017	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Business Acquisition [Line Items]
Noncash consideration-fair value of shares issued		$ 0	$ 8,004	$ 0
Noncash consideration-fair value of stock options and other equity awards		$ 0	$ 613	$ 0
CR Bard Inc
Business Acquisition [Line Items]
Cash consideration	$ 16,400
Noncash consideration-fair value of shares issued	8,004
Noncash consideration-fair value of stock options and other equity awards	613
Total consideration transferred	$ 25,017

Acquisitions - Fair Value of_2

Acquisitions - Fair Value of Company's Ordinary Shares Issued (Details) - USD ($) $ / shares in Units, $ in Millions	Dec. 29, 2017	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Business Acquisition [Line Items]
Fair value of the Company’s issued shares		$ 0	$ 8,004	$ 0
CR Bard Inc
Business Acquisition [Line Items]
Total Bard shares outstanding	73,359,000
Conversion factor	0.5077
Conversion of Bard shares outstanding	37,243,000
Conversion of pre-acquisition equity awards	104,000
Total number of the Company's share issued	37,347,000
Closing price of the Company’s stock	$ 214.32
Fair value of the Company’s issued shares	$ 8,004

Acquisitions - Fair Value of A

Acquisitions - Fair Value of Assets and Liabilities Assumed (Details) - USD ($) $ in Millions	Dec. 29, 2017	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Business Acquisition [Line Items]
Goodwill		$ 23,376	$ 23,600	$ 7,563
CR Bard Inc
Business Acquisition [Line Items]
Cash and equivalents	$ 1,480
Trade receivables	472
Inventories	974
Property, plant and equipment	553
Developed technology	10,469
Customer relationships	1,146
Other assets	661
Total identifiable assets acquired	15,755
Payables, accrued expenses and other liabilities	1,280
Short term and long-term debt	1,692
Product liability and other legal reserves	2,004
Deferred tax liabilities	1,686
Total liabilities assumed	6,663
Net identifiable assets acquired	9,093
Goodwill	15,924
Net assets acquired	$ 25,017

Acquisitions - Summary of Pro

Acquisitions - Summary of Pro Forma Results (Detail) - CR Bard Inc - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Business Acquisition [Line Items]
Revenues	$ 16,947	$ 15,781
Net Income	$ 390	$ 1,145
Diluted Earnings per Share (USD per share)	$ 0.90	$ 3.60

Divestiture - Additional Inform

Divestiture - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017	Oct. 03, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Assets held for sale		$ 0	$ 137
Gain (Loss) on Disposition of Business		336	0	$ 0
Proceeds from divestitures, net		477	534	165
Gain on Sale of Investments		0	303	$ 0
Advanced Bioprocessing
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (Loss) on Disposition of Business		$ 336
Vyaire Medical
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestitures, net	$ 435
Gain on Sale of Investments	$ 303
Disposal Group, Held-for-sale, Not Discontinued Operations | Advanced Bioprocessing
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Assets held for sale			$ 137
Disposal Group, Held-for-sale, Not Discontinued Operations | Respiratory Solutions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Percent Of Business Sold					50.10%
Disposal Group, Including Discontinued Operation, Percent Of Business Retained					49.90%

Business Restructuring Charge_2

Business Restructuring Charges - Changes in Restructuring Balance (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
CR Bard Inc
Restructuring Reserve [Roll Forward]
Beginning balance	$ 33	$ 0	$ 0
Charged to expense	118	292	0
Cash payments	(39)	(106)	0
Non-cash settlements	(89)	(153)	0
Other adjustments			0
Ending balance	23	33	0
CR Bard Inc | Employee Termination
Restructuring Reserve [Roll Forward]
Beginning balance	33	0	0
Charged to expense	23	136	0
Cash payments	(34)	(103)	0
Non-cash settlements	0	0	0
Other adjustments			0
Ending balance	22	33	0
CR Bard Inc | Other
Restructuring Reserve [Roll Forward]
Beginning balance	0	0	0
Charged to expense	95	156	0
Cash payments	(5)	(3)	0
Non-cash settlements	(89)	(153)	0
Other adjustments			0
Ending balance	1	0	0
CareFusion and Other Initiatives
Restructuring Reserve [Roll Forward]
Beginning balance		55	69
Charged to expense		52	85
Cash payments		(79)	(57)
Non-cash settlements		(1)	(9)
Other adjustments			(33)
Ending balance			55
CareFusion and Other Initiatives | Employee Termination
Restructuring Reserve [Roll Forward]
Beginning balance		49	67
Charged to expense		30	27
Cash payments		(56)	(45)
Non-cash settlements		0	0
Other adjustments			0
Ending balance			49
CareFusion and Other Initiatives | Other
Restructuring Reserve [Roll Forward]
Beginning balance		6	2
Charged to expense		22	58
Cash payments		(23)	(12)
Non-cash settlements		(1)	(9)
Other adjustments			(33)
Ending balance			$ 6
Other Initiatives
Restructuring Reserve [Roll Forward]
Beginning balance	27
Charged to expense	62
Cash payments	(52)
Non-cash settlements	(3)
Ending balance	34	27
Other Initiatives | Employee Termination
Restructuring Reserve [Roll Forward]
Beginning balance	23
Charged to expense	29
Cash payments	(21)
Non-cash settlements	0
Ending balance	31	23
Other Initiatives | Other
Restructuring Reserve [Roll Forward]
Beginning balance	4
Charged to expense	33
Cash payments	(31)
Non-cash settlements	(3)
Ending balance	$ 3	$ 4

Intangible Assets - Components

Intangible Assets - Components of Intangible Assets (Detail) - USD ($) $ in Millions	Sep. 30, 2019	Sep. 30, 2018
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 19,530	$ 19,475
Accumulated Amortization	4,555	3,073
Unamortized intangible assets	3	39
Acquired in-process research and development (a)
Finite And Indefinite Lived Intangible Assets [Line Items]
Unamortized intangible assets	1	37
Trademarks
Finite And Indefinite Lived Intangible Assets [Line Items]
Unamortized intangible assets	2	2
Developed technology
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	13,960	13,966
Accumulated Amortization	2,906	1,782
Customer relationships
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	4,608	4,584
Accumulated Amortization	1,183	861
Product rights
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	110	121
Accumulated Amortization	60	58
Trademarks
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	407	407
Accumulated Amortization	102	84
Patents and other
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	445	397
Accumulated Amortization	$ 305	$ 288

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible amortization expense	$ 1,497	$ 1,255	$ 553
Estimated aggregate amortization expense in 2020	1,350
Estimated aggregate amortization expense in 2021	1,346
Estimated aggregate amortization expense in 2022	1,336
Estimated aggregate amortization expense in 2023	1,331
Estimated aggregate amortization expense in 2024	$ 1,311

Intangible Assets - Reconciliat

Intangible Assets - Reconciliation of Goodwill by Business Segment (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 23,600	$ 7,563
Goodwill, Acquired During Period		15,217
Goodwill, Written off Related to Sale of Business Unit	3	116
Goodwill, Transfers		0
Goodwill, Purchase Accounting Adjustments	(90)	959
Goodwill, Foreign Currency Translation Gain (Loss)	(137)	(24)
Goodwill, ending balance	23,376	23,600
Medical
Goodwill [Roll Forward]
Goodwill, beginning balance	10,054	6,802
Goodwill, Acquired During Period		3,923
Goodwill, Written off Related to Sale of Business Unit	0	0
Goodwill, Transfers		(877)
Goodwill, Purchase Accounting Adjustments	(15)	228
Goodwill, Foreign Currency Translation Gain (Loss)	(50)	(22)
Goodwill, ending balance	9,989	10,054
Life Sciences
Goodwill [Roll Forward]
Goodwill, beginning balance	775	761
Goodwill, Acquired During Period		76
Goodwill, Written off Related to Sale of Business Unit	3	59
Goodwill, Transfers		0
Goodwill, Purchase Accounting Adjustments	0	(2)
Goodwill, Foreign Currency Translation Gain (Loss)	(6)	(2)
Goodwill, ending balance	772	775
Interventional
Goodwill [Roll Forward]
Goodwill, beginning balance	12,771	0
Goodwill, Acquired During Period		11,218
Goodwill, Written off Related to Sale of Business Unit	0	57
Goodwill, Transfers		877
Goodwill, Purchase Accounting Adjustments	(75)	732
Goodwill, Foreign Currency Translation Gain (Loss)	(81)	0
Goodwill, ending balance	$ 12,615	$ 12,771

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Additional Information (Detail) - USD ($)	Sep. 30, 2019	Sep. 30, 2018
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Reclassification of terminated interest rate swaps to interest expense within the next 12 months	$ 6,000,000
Debt | Net Investment Hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	1,400,000,000	$ 3,000,000,000
Forward exchange contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	2,300,000,000	3,100,000,000
Currency Swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	2,300,000,000
Fixed To Floating
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	375,000,000	1,200,000,000
Interest rate swaps | Cash Flow Hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	$ 1,500,000,000	0
Commodity forward contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount		$ 0

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities Disclosure - Gains (Losses) on Net Investment Hedges (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Forward exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax	$ 138	$ 81
Currency Swap
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax	73	0
Foreign Exchange Forward
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax	$ (9)	$ 0

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measurement - Cash and Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Cash and equivalents	$ 536	$ 1,140
Restricted Cash and Investments, Current	54	96
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 590	$ 1,236	$ 14,179	$ 1,541

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	$ 39	$ 228
Remaining cash equivalents	497	913
Fair value of long-term debt	19,200	18,800
Fair value of debt classified from long term to short term	$ 1,300	1,900
Minimum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Maturity period of short-term investments at the time of purchase	3 months
Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Maturity period of short-term investments at the time of purchase	1 year
Interventional
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)	$ 30
Medical
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Asset Impairment Charges		58
Life Sciences
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)		$ 81

Debt - Summary of Short-Term De

Debt - Summary of Short-Term Debt (Detail) - USD ($) $ in Millions	Sep. 30, 2019	Sep. 30, 2018	Mar. 31, 2018
Short-term Debt [Line Items]
Other Short-term Borrowings	$ 10	$ 10
Short-term debt	$ 1,309	2,601
2.675% Notes due December 15, 2019
Short-term Debt [Line Items]
Interest rate	2.675%
Current portion of long-term debt	$ 300	0
2.404% Notes due June 5, 2020
Short-term Debt [Line Items]
Interest rate	2.404%
Current portion of long-term debt	$ 999	0
2.133% Notes due June 6, 2019
Short-term Debt [Line Items]
Interest rate	2.133%
Current portion of long-term debt	$ 0	724
0.368% Notes due June 6, 2019
Short-term Debt [Line Items]
Interest rate	0.368%		0.368%
Current portion of long-term debt	$ 0	1,157
Term Loan Facility due September 5, 2019
Short-term Debt [Line Items]
Short-term Debt	$ 0	$ 710

Debt - Additional Information (

Debt - Additional Information (Detail) € in Millions, £ in Millions	1 Months Ended	3 Months Ended						12 Months Ended
	Jan. 31, 2018	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Jun. 30, 2017	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Jun. 30, 2019EUR (€)	Jun. 30, 2018EUR (€)	Jun. 30, 2018GBP (£)	Mar. 31, 2018EUR (€)	Dec. 29, 2017USD ($)
Debt Instrument [Line Items]
Short-term debt, weighted average interest rate		2.48%						2.48%	1.58%
Aggregate annual maturities of long-term debt, 2020		$ 1,900,000,000						$ 1,900,000,000
Aggregate annual maturities of long-term debt, 2021		2,600,000,000						2,600,000,000
Aggregate annual maturities of long-term debt, 2022		3,700,000,000						3,700,000,000
Aggregate annual maturities of long-term debt, 2023		2,900,000,000						2,900,000,000
Aggregate annual maturities of long-term debt, 2024		2,300,000,000						2,300,000,000
Letters Of Credit Issuable Under Credit Facility		100,000,000						100,000,000
Line Of Credit Facility Maximum Additional Principal Amount Commitments		500,000,000						500,000,000
Line of Credit Facility, Maximum Borrowing Capacity		2,750,000,000						2,750,000,000
Long-term Commercial Paper		0						0
Debt Instrument, Repurchased Face Amount			$ 1,100,000,000		$ 539,000,000	$ 461,000,000
Long-Term Debt		18,081,000,000						18,081,000,000	$ 18,894,000,000
Debt Instrument, Repurchase Amount			1,169,000,000		559,000,000	465,000,000
Extinguishment of Debt, Gain (Loss), Net of Tax			$ 57,000,000		3,000,000	13,000,000		59,000,000	16,000,000	$ 73,000,000
0.174% Notes due June 4, 2021
Debt Instrument [Line Items]
Long-Term Debt		$ 651,000,000						$ 651,000,000	0
Interest rate		0.174%	0.174%					0.174%			0.174%
0.632% Notes due June 4, 2023
Debt Instrument [Line Items]
Long-Term Debt		$ 867,000,000						$ 867,000,000	0
Interest rate		0.632%	0.632%					0.632%			0.632%
1.208% Notes due June 4, 2026
Debt Instrument [Line Items]
Long-Term Debt		$ 649,000,000						$ 649,000,000	0
Interest rate		1.208%	1.208%					1.208%			1.208%
Notes 0.368% due June 6, 2019
Debt Instrument [Line Items]
Interest rate			0.368%								0.368%
2.675% Notes due December 15, 2019
Debt Instrument [Line Items]
Debt Instrument, Repurchased Face Amount		$ 825,000,000						$ 825,000,000
Long-Term Debt		0						0	1,123,000,000
Debt Instrument, Repurchase Amount		826,000,000						$ 826,000,000
Extinguishment of Debt, Gain (Loss), Net of Tax		$ 1,000,000
Interest rate		2.675%						2.675%
Notes 3.000% due May 15, 2026
Debt Instrument [Line Items]
Long-Term Debt						452,000,000
0.368% Notes due June 6, 2019
Debt Instrument [Line Items]
Debt instrument, face amount						$ 370,000,000								€ 300
Interest rate		0.368%				0.368%		0.368%						0.368%
Floating Rate Notes due December 29, 2020
Debt Instrument [Line Items]
Long-Term Debt		$ 748,000,000						$ 748,000,000	996,000,000
Debt instrument, face amount						$ 1,000,000,000
Notes 4.400% due January 15, 2021 and notes 3.000% due May 15, 2026
Debt Instrument [Line Items]
Long-Term Debt					556,000,000
1.401% Notes due May 24, 2023
Debt Instrument [Line Items]
Long-Term Debt		$ 325,000,000						$ 325,000,000	346,000,000
Debt instrument, face amount					$ 354,000,000							€ 300
Interest rate		1.401%			1.401%			1.401%				1.401%	1.401%
3.020% Notes due May 24, 2025
Debt Instrument [Line Items]
Long-Term Debt		$ 306,000,000						$ 306,000,000	324,000,000
Debt instrument, face amount					$ 337,500,000								£ 250
Interest rate		3.02%			3.02%			3.02%				3.02%	3.02%
Revolving Credit Facility
Debt Instrument [Line Items]
Debt Instrument, Term							5 years
Maximum borrowing capacity of syndicated credit facility		$ 2,250,000,000						$ 2,250,000,000
Borrowings under credit facility		$ 485,000,000						$ 485,000,000	$ 0
Term Loan Facility
Debt Instrument [Line Items]
Debt Instrument, Term		364 days
Senior Notes | Floating Rate Notes Due December 29, 2020
Debt Instrument [Line Items]
Debt Instrument, Repurchased Face Amount				$ 250,000,000
Long-Term Debt				249,000,000
Debt Instrument, Repurchase Amount				250,000,000
Extinguishment of Debt, Gain (Loss), Net of Tax				$ 1,000,000
Exchanged Notes | Notes 3.000% due May 15, 2026
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage	101.00%
CR Bard Inc | Exchanged Notes
Debt Instrument [Line Items]
Long-Term Debt															$ 1,150,000,000
Principal Amount Outstanding After Exchange															111,000,000
CR Bard Inc | Exchanged Notes | Notes 3.000% due May 15, 2026
Debt Instrument [Line Items]
Long-Term Debt															500,000,000
Interest rate		3.00%			3.00%	3.00%		3.00%				3.00%	3.00%	3.00%
CR Bard Inc | Exchanged Notes | Notes 4.400% due January 15, 2021
Debt Instrument [Line Items]
Long-Term Debt															$ 500,000,000
Interest rate		4.40%			4.40%			4.40%				4.40%	4.40%
Euro Member Countries, Euro | 0.174% Notes due June 4, 2021
Debt Instrument [Line Items]
Debt instrument, face amount | €											€ 600
Euro Member Countries, Euro | 0.632% Notes due June 4, 2023
Debt Instrument [Line Items]
Debt instrument, face amount | €											800
Euro Member Countries, Euro | 1.208% Notes due June 4, 2026
Debt Instrument [Line Items]
Debt instrument, face amount | €											600
Euro Member Countries, Euro | Notes 0.368% due June 6, 2019
Debt Instrument [Line Items]
Debt Instrument, Repurchased Face Amount | €											€ 1,000
United States of America, Dollars | 0.174% Notes due June 4, 2021
Debt Instrument [Line Items]
Debt instrument, face amount			$ 672,000,000
United States of America, Dollars | 0.632% Notes due June 4, 2023
Debt Instrument [Line Items]
Debt instrument, face amount			896,000,000
United States of America, Dollars | 1.208% Notes due June 4, 2026
Debt Instrument [Line Items]
Debt instrument, face amount			672,000,000
United States of America, Dollars | Notes 0.368% due June 6, 2019
Debt Instrument [Line Items]
Debt Instrument, Repurchased Face Amount			1,120,000,000
Long-term Debt
Debt Instrument [Line Items]
Long-Term Debt			$ 1,112,000,000
Short-term Debt | 2.675% Notes due December 15, 2019
Debt Instrument [Line Items]
Long-Term Debt		$ 825,000,000						$ 825,000,000

Debt - Summary of Long-Term Deb

Debt - Summary of Long-Term Debt (Detail) - USD ($) $ in Millions	Sep. 30, 2019	Jun. 30, 2019	Sep. 30, 2018	Jun. 30, 2018
Debt Instrument [Line Items]
Long-Term Debt	$ 18,081		$ 18,894
2.675% Notes due December 15, 2019
Debt Instrument [Line Items]
Interest rate	2.675%
Long-Term Debt	$ 0		1,123
2.404% Notes due June 5, 2020
Debt Instrument [Line Items]
Interest rate	2.404%
Long-Term Debt	$ 0		998
3.250% Notes due November 12, 2020
Debt Instrument [Line Items]
Interest rate	3.25%
Long-Term Debt	$ 699		699
Floating Rate Notes due December 29, 2020
Debt Instrument [Line Items]
Long-Term Debt	$ 748		996
0.174% Notes due June 4, 2021
Debt Instrument [Line Items]
Interest rate	0.174%	0.174%
Long-Term Debt	$ 651		0
3.125% Notes due November 8, 2021
Debt Instrument [Line Items]
Interest rate	3.125%
Long-Term Debt	$ 1,004		990
2.894% Notes due June 6, 2022
Debt Instrument [Line Items]
Interest rate	2.894%
Long-Term Debt	$ 1,795		1,793
Floating Rate Notes due June 6, 2022
Debt Instrument [Line Items]
Long-Term Debt	$ 498		498
1.000% Notes due December 15, 2022
Debt Instrument [Line Items]
Interest rate	1.00%
Long-Term Debt	$ 542		576
Revolving Credit Facility
Debt Instrument [Line Items]
Long-Term Debt	$ 480		0
3.300% Notes due March 1, 2023
Debt Instrument [Line Items]
Interest rate	3.30%
Long-Term Debt	$ 295		296
1.401% Notes due May 24, 2023
Debt Instrument [Line Items]
Interest rate	1.401%			1.401%
Long-Term Debt	$ 325		346
0.632% Notes due June 4, 2023
Debt Instrument [Line Items]
Interest rate	0.632%	0.632%
Long-Term Debt	$ 867		0
3.875% Notes due May 15, 2024
Debt Instrument [Line Items]
Interest rate	3.875%
Long-Term Debt	$ 181		182
3.363% Notes due June 6, 2024
Debt Instrument [Line Items]
Interest rate	3.363%
Long-Term Debt	$ 1,740		1,738
3.734% Notes due December 15, 2024
Debt Instrument [Line Items]
Interest rate	3.734%
Long-Term Debt	$ 1,369		1,368
3.020% Notes due May 24, 2025
Debt Instrument [Line Items]
Interest rate	3.02%			3.02%
Long-Term Debt	$ 306		324
1.208% Notes due June 4, 2026
Debt Instrument [Line Items]
Interest rate	1.208%	1.208%
Long-Term Debt	$ 649		0
6.700% Notes due December 1, 2026
Debt Instrument [Line Items]
Interest rate	6.70%
Long-Term Debt	$ 174		177
1.900% Notes due December 15, 2026
Debt Instrument [Line Items]
Interest rate	1.90%
Long-Term Debt	$ 541		575
3.700% Notes due June 6, 2027
Debt Instrument [Line Items]
Interest rate	3.70%	3.70%
Long-Term Debt	$ 1,714		2,383
7.000% Debentures due August 1, 2027
Debt Instrument [Line Items]
Interest rate	7.00%
Long-Term Debt	$ 175		156
6.700% Debentures due August 1, 2028
Debt Instrument [Line Items]
Interest rate	6.70%
Long-Term Debt	$ 175		154
6.000% Notes due May 15, 2039
Debt Instrument [Line Items]
Interest rate	6.00%
Long-Term Debt	$ 246		246
5.000% Notes due November 12, 2040
Debt Instrument [Line Items]
Interest rate	5.00%
Long-Term Debt	$ 124		296
4.875% Notes due May 15, 2044
Debt Instrument [Line Items]
Interest rate	4.875%	4.875%
Long-Term Debt	$ 248		331
4.685% Notes due December 15, 2044
Debt Instrument [Line Items]
Interest rate	4.685%	4.685%
Long-Term Debt	$ 1,045		1,159
4.669% Notes due June 6, 2047
Debt Instrument [Line Items]
Interest rate	4.669%
Long-Term Debt	$ 1,485		1,484
Other long-term debt
Debt Instrument [Line Items]
Long-Term Debt	$ 5		$ 8

Debt - Extinguishments of Debt

Debt - Extinguishments of Debt (Details) - USD ($) $ in Millions	Sep. 30, 2019	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2018
Extinguishment of Debt [Line Items]
Debt Instrument, Repurchased Face Amount		$ 1,100	$ 539	$ 461
3.700% Notes due June 6, 2027
Extinguishment of Debt [Line Items]
Interest rate	3.70%	3.70%
Debt Instrument, Repurchased Face Amount		$ 675
Notes 5.000% due November 12, 2040
Extinguishment of Debt [Line Items]
Interest rate		5.00%
Debt Instrument, Repurchased Face Amount		$ 175
4.875% Notes due May 15, 2044
Extinguishment of Debt [Line Items]
Interest rate	4.875%	4.875%
Debt Instrument, Repurchased Face Amount		$ 75
4.685% Notes due December 15, 2044
Extinguishment of Debt [Line Items]
Interest rate	4.685%	4.685%
Debt Instrument, Repurchased Face Amount		$ 175

Debt - Debt Exchange (Detail)

Debt - Debt Exchange (Detail) - USD ($) $ in Millions	Dec. 29, 2017	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Debt Instrument [Line Items]
Long-Term Debt		$ 18,081	$ 18,894
Notes 3.000% due May 15, 2026
Debt Instrument [Line Items]
Long-Term Debt					$ 452
6.700% Notes due December 1, 2026
Debt Instrument [Line Items]
Interest rate		6.70%
Long-Term Debt		$ 174	$ 177
CR Bard Inc | Exchanged Notes
Debt Instrument [Line Items]
Long-Term Debt	$ 1,150
Principal Amount Accepted for Exchange	1,039
CR Bard Inc | Exchanged Notes | Notes 4.400% due January 15, 2021
Debt Instrument [Line Items]
Interest rate		4.40%		4.40%
Long-Term Debt	500
Principal Amount Accepted for Exchange	432
CR Bard Inc | Exchanged Notes | Notes 3.000% due May 15, 2026
Debt Instrument [Line Items]
Interest rate		3.00%		3.00%	3.00%
Long-Term Debt	500
Principal Amount Accepted for Exchange	470
CR Bard Inc | Exchanged Notes | 6.700% Notes due December 1, 2026
Debt Instrument [Line Items]
Interest rate		6.70%
Long-Term Debt	150
Principal Amount Accepted for Exchange	$ 137

Debt - Summary of Interest Cost

Debt - Summary of Interest Costs and Payments (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Debt Disclosure [Abstract]
Charged to operations	$ 639	$ 706	$ 521
Capitalized	44	42	32
Total interest costs	683	748	553
Interest paid, net of amounts capitalized	$ 658	$ 674	$ 435

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes from Continuing Operations (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Federal	$ 235	$ 665	$ (230)
State and local, including Puerto Rico	41	73	(20)
Foreign	300	387	200
Total, Current	576	1,124	(50)
Domestic	(566)	(201)	(64)
Foreign	(67)	(61)	(10)
Total, Deferred	(633)	(262)	(74)
Income tax provision	$ (57)	$ 862	$ (124)

Income Taxes - Components of In

Income Taxes - Components of Income from Continuing Operations Before Income Taxes (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Domestic, including Puerto Rico	$ 1,340	$ (135)	$ (386)
Foreign	(164)	1,308	1,362
Income Before Income Taxes	$ 1,176	$ 1,173	$ 976

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Income Tax [Line Items]
Federal statutory tax rate			21.00%	24.50%	35.00%
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateNew			21.00%
Tax Cuts and Jobs Act, Income Tax Expense (Benefit)			$ 50	$ (640)
OtherTaxExpenseBenefitRelatedtoHistoricUnremittedForeignEarnings	$ 138	$ 67		138
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	624		624	632	$ 415
Unrecognized tax benefits interest and penalties reflected in current year			26	20	57
Tax reductions related to tax holidays			$ 157	$ 107	$ 146
Income Tax Holiday, Income Tax Benefits Per Share			$ 0.57	$ 0.40	$ 0.65
Income taxes paid, net			$ 536	$ 235	$ 265
Deferred Income Taxes and Other
Income Tax [Line Items]
Indemnification liability, non-current	$ 156		$ 156

Income Taxes - Summary of Gross

Income Taxes - Summary of Gross Amounts of Unrecognized Tax Benefits (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at October 1	$ 543	$ 349	$ 469
Increase due to acquisitions	3	140	0
Increase due to current year tax positions	11	43	41
Increase due to prior year tax positions	6	43	19
Decreases due to prior year tax positions	(39)	0	(30)
Decrease due to settlements with tax authorities	0	(29)	(145)
Decrease due to lapse of statute of limitations	(5)	(3)	(5)
Balance at September 30	$ 519	$ 543	$ 349

Income Taxes - Deferred Income

Income Taxes - Deferred Income Taxes (Detail) - USD ($) $ in Millions	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Compensation and benefits, assets	$ 513	$ 458
Loss and credit carryforwards, assets	1,327	1,290
Other, assets	634	707
Deferred income taxes, assets, gross	2,474	2,455
Valuation allowance, assets	(1,240)	(1,181)
Deferred income taxes, assets	1,234	1,275
Property and equipment, liabilities	255	253
Deferred Tax Liabilities, Other Finite-Lived Assets	2,624	2,948
Other, liabilities	189	384
Deferred income taxes, liabilities, gross	3,068	3,585
Deferred income taxes, liabilities	$ 3,068	$ 3,585

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Federal Statutory Tax Rate to Company's Effective Tax Rate (Detail)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Federal statutory tax rate	21.00%	24.50%	35.00%
New U.S. tax legislation (see discussion above)	(0.043)	0.546	0
State and local income taxes, net of federal tax benefit	0.10%	0.80%	(2.60%)
Effect of foreign and Puerto Rico earnings and foreign tax credits	(12.20%)	7.30%	(40.80%)
Effect of Research Credits and FDII/Domestic Production Activities	(3.30%)	(2.80%)	(2.70%)
Effect of change in accounting for excess tax benefit relating to share-based compensation (see Note 2)	(4.70%)	(6.70%)	(7.90%)
Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent	(2.00%)	1.30%	0.00%
Effective Income Tax Rate Reconciliation, Uncertain Tax Position, Percent	0.00%	3.30%	0.00%
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	0.00%	(4.80%)	0.00%
Effective Income Tax Rate Reconciliation, Change in Accounting Method, Percent	0.00%	(4.50%)	0.00%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent	0.00%	1.60%	0.00%
Other, net	0.60%	(1.10%)	6.30%
Total	(4.80%)	73.50%	(12.70%)

Sale-Type Leases and Financin_2

Sale-Type Leases and Financing Receivables Sales-Type Leases and Financing Receivables - Additional Information (Detail) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Jun. 30, 2017	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Receivables [Abstract]
Lessor, Sales-Type Lease, Contract Term	5 years
Lease Contract Modification Related Charge		$ 0	$ 0	$ 748

Supplemental Financial Inform_3

Supplemental Financial Information - Other Income (Expense), Net (Detail) - USD ($) $ in Millions	3 Months Ended			12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Royalty Income, Nonoperating				$ 64	$ 51	$ 0
Insurance Recoveries				35	0	0
Income (Loss) from Equity Method Investments				18	8	3
Foreign Currency Transaction Gain (Loss), Realized				(23)	(14)	(11)
Losses on debt extinguishment	$ (57)	$ (3)	$ (13)	(59)	(16)	(73)
Gains on previously held investments				0	0	24
Other Nonoperating Income				4	0	3
Other Nonoperating Income (Expense)				43	305	(101)
Other Nonoperating Income (Expense)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)				(2)	(13)	(44)
Vyaire Medical
Income (Loss) from Equity Method Investments				$ 6	$ 288	$ (3)

Supplemental Financial Inform_4

Supplemental Financial Information - Trade Receivables, Allowances for Doubtful Accounts and Cash Discounts (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	$ 86	$ 58	$ 67
Additions charged to costs and expenses	125	89	68
Deductions and other	(123)	(61)	(76)
Ending Balance	88	86	58
Allowance for Doubtful Accounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	75	54	61
Additions charged to costs and expenses	31	31	25
Deductions and other	(31)	(11)	(32)
Ending Balance	75	75	54
Allowance for Cash Discounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	12	4	6
Additions charged to costs and expenses	94	58	43
Deductions and other	(92)	(50)	(45)
Ending Balance	$ 13	$ 12	$ 4

Supplemental Financial Inform_5

Supplemental Financial Information - Inventories (Detail) - USD ($) $ in Millions	Sep. 30, 2019	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Materials	$ 544	$ 510
Work in process	318	297
Finished products	1,717	1,644
Inventories	$ 2,579	$ 2,451

Supplemental Financial Inform_6

Supplemental Financial Information - Property, Plant and Equipment, Net (Detail) - USD ($) $ in Millions	Sep. 30, 2019	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Land	$ 164	$ 173
Buildings	2,842	2,724
Machinery, equipment and fixtures	7,932	7,405
Leasehold improvements	190	182
Property, Plant and Equipment, gross	11,128	10,485
Less accumulated depreciation and amortization	5,469	5,111
Property, Plant and Equipment, Net	$ 5,659	$ 5,375

Supplementary Data (Unaudited_2

Supplementary Data (Unaudited) - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Quarterly Financial Information Disclosure [Abstract]
Revenues	$ 4,584	$ 4,350	$ 4,195	$ 4,160	$ 4,402	$ 4,278	$ 4,222	$ 3,080	$ 17,290	$ 15,983	$ 12,093
Gross Profit	2,266	2,074	1,974	1,974	2,094	2,017	1,606	1,553	8,288	7,269
Net Income	$ 163	$ 451	$ 20	$ 599	$ (135)	$ 594	$ (12)	$ (136)	$ 1,233	$ 311	$ 1,100
(Loss) earnings per Share: (a)
Basic Earnings per Share (USD per share)	$ 0.46	$ 1.53	$ (0.07)	$ 2.09	$ (0.64)	$ 2.08	$ (0.19)	$ (0.76)	$ 4.01	$ 0.62	$ 4.70
Diluted Earnings per Share (USD per share)	$ 0.45	$ 1.51	$ (0.07)	$ 2.05	$ (0.64)	$ 2.03	$ (0.19)	$ (0.76)	$ 3.94	$ 0.60	$ 4.60